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1 Abbreviations	  
4E-­‐BP	   	   eukaryotic	  translation	  initiation	  factor	  4E	  binding	  protein	  AMPK	   	   AMP	  activated	  protein	  kinase	  Ax	   	   anoxia	  CNS	   	   central	  nervous	  system	  DIV	   	   days	  in	  vitro	  eIF2α	   	   eukaryotic	  translation	  initiation	  factor	  2	  subunit	  α	  eIF4E	   	   eukaryotic	  translation	  initiation	  factor	  4E	  eIF4F	   	   eukaryotic	  translation	  initiation	  factor	  4F	  eIF4G	   	   eukaryotic	  translation	  initiation	  factor	  4G	  GSK3	   	   glycogen	  synthase	  kinase	  3	  HIF	   	   hypoxia-­‐inducible	  factors	  HRE	   	   hypoxia	  response	  elements	  Hx	   	   hypoxia	  IGF1	   	   insulin	  growth	  factor	  1	  IRS1	   	   insulin	  receptor	  substrate	  1	  mTOR	  	   mammalian	  target	  of	  rapamycin	  mTORC	   mammalian	  target	  of	  rapamycin	  complex	  Nx	   	   normoxia	  PDK	   	   phosphoinositide-­‐dependent	  kinase	  PI3K	   	   phosphatidylinositol	  3-­‐	  kinase	  PIP2	   	   phosphatidylinositol-­‐4,5-­‐phosphate	  PIP3	   	   phosphatidylinositol-­‐3,4,5-­‐	  phosphate	  PTEN	   	   phosphatase	  and	  tensin	  homolog	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pVHL	   	   von	  Hippel-­‐Lindau	  tumor	  suppressor	  Raptor	  	   regulatory-­‐associated	  protein	  of	  mTOR	  REDD1	   regulated	  in	  development	  and	  DNA	  damage	  response	  1	  Rheb	  	   	   Ras	  homologue	  enriched	  in	  brain	  Rictor	   	   rapamycin	  insensitive	  component	  of	  mTOR	  TOP	   	   terminal	  oligopyrimidine	  TSC	   	   tuberous	  sclerosis	  complex	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2 	  Summary	  
Neurons	   are	   fundamental	   for	   brain	   activity	   and	   tightly	   collaborate	   with	  astrocytes	   to	   guarantee	   proper	   functions	   of	   the	   CNS.	   However,	   they	   show	  extremely	   different	   sensitivity	   towards	   hypoxia,	   a	   deleterious	   factor	   of	   many	  neuropathologies	  such	  as	  stroke,	  cancer	  and	  Alzheimer’s	  disease.	  While	  hypoxic	  insult	   triggers	   neuronal	   damage,	   sustained	   oxygen	   deprivation	   can	   activate	  astrocytic	   cells,	  promoting	   their	  proliferation	  and	   inducing	  gliosis,	  mechanisms	  that	   to	  a	   large	  extent	  can	   lead	   to	  brain	   injury.	  During	  oxygen	  deprivation	  most	  cells	   undergo	   decreased	   protein	   synthesis	   via	   mTORC1	   inhibition	   to	   reduce	  energy	   consumption	   and	   modulate	   transcription	   regulation	   via	   HIF-­‐1.	   The	  mTORC1	   pathway	   controls	   the	   synthesis	   of	   the	   majority	   of	   proteins	   and	  ribosomal	   subunits	   by	   regulating	   cap-­‐	   and	   TOP-­‐dependent	   mRNA	   translation.	  This	   cascade	   has	   been	   extensively	   studied	   in	   cancer	   cells,	   however	   recently	  unbalanced	  mTORC1	  signaling	  was	  also	  implicated	  in	  neurological	  diseases.	  The	  main	   focus	   of	   this	   study	   was	   to	   elucidate	   the	   role	   of	   mTORC1	   pathway	   in	  astrocyte	  and	  neuronal	   response	   to	  oxygen	  deprivation.	   In	  particular,	  we	  were	  interested	   in	   understanding	   how	  mTORC1	   signaling	  modulates	   overall	   protein	  synthesis	  and	  energy	  levels	  in	  brain	  cells	  with	  different	  sensitivity	  to	  hypoxia.	  In	  neurons	  mTORC1	   activity	   is	   partially	   inhibited	   already	   at	   baseline	   (normoxic)	  conditions	  and	  inhibition	  of	  cap-­‐dependent	  translation	  does	  not	  affect	  the	  overall	  protein	   synthesis	   rate.	   On	   the	   other	   hand,	   astrocytic	   mTORC1	   pathway	   is	  insensitive	   to	   low	   oxygen	   levels	   but	   is	   completely	   inhibited	   during	   ischemia	  (oxygen	  and	  glucose	  deprivation).	  Although	   ischemic	  dephosphorylation	  of	  4E-­‐BP1	  prevents	   the	   interaction	   of	   eIF4E	  with	   eIF4G	   and	   impedes	   cap-­‐dependent	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translation	   in	   astrocytes,	   it	   has	   no	   added	   inhibitory	   effect	   on	   global	   protein	  synthesis	   rate	   and	   results	   in	   a	   marked	   fall	   of	   cellular	   ATP.	   Overall	  pharmacological	   inhibition	  of	  mTORC1	  via	   rapamycin	   treatment	  does	  not	   alter	  global	  protein	  synthesis	  regulation	  or	  ATP	  levels	  in	  either	  astrocytes	  or	  neurons,	  but	  does	  slow	  HIF-­‐1α	  accumulation	  in	  either	  cell	  type.	  In	   direct	   relation	   to	   this	   we	   showed	   in	   astrocytes	   that	   knockdown	   of	   4E-­‐BP1	  during	   normoxia,	   when	   the	   protein	   is	   hyper-­‐phosphorylated	   by	   mTORC1,	  reduced	   protein	   synthesis	   rate	   and	   cell	   proliferation,	   while	   during	   oxygen	  deprivation	  did	  not	  affect	  either	  mRNA	  translation	  or	  cell	  cycle.	  Taken	   together	   the	   present	   work	   reveals	   that	   neurons	   and	   astrocytes	  differentially	   inhibit	   mTORC1	   signaling	   during	   stress	   conditions	   and	   that	   this	  signaling	   cascade	   is	   not	   implicated	   in	   overall	   protein	   synthesis	   and	  ATP	   levels	  regulation	   in	  either	  cell	   type.	  Moreover,	   in	  astrocytes	   the	  mTORC1	  effector	  4E-­‐BP1	  not	  only	  acts	  as	  brake	  of	  cap-­‐dependent	  translation	  during	  ischemia	  but	  also	  as	  stimulator	  of	  cell	  growth	  and	  proliferation	  in	  normoxic	  conditions.	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3 Zusammenfassung	  
Nervenzellen	   sind	   die	   Grundlage	   jeglicher	   Hirnfunktion.	   Ihre	   Zusammenarbeit	  mit	   den	   Hauptkomponenten	   der	   Glia,	   Astrozyten,	   stellt	   sicher	   dass	   die	  Aktivitäten	  des	  ZNS	  im	  physiologischen	  Rahmen	  bleiben	  und	  im	  engen	  Einklang	  mit	   der	   Umwelt	   stehen.	   Allerdings	   zeigen	   beiden	   Zelltypen	   eine	   stark	  unterschiedliche	   Sensitivität	   gegenüber	   Hypoxie	   (Mangelversorgung	   an	  Sauerstoff),	  einem	  Faktor	  also,	  der	  die	  Pathogenese	  bei	  vielen	  Erkrankungen	  des	  Nervensystems	  wie	   Schlaganfall,	  Hirntumoren	  und	  Alzheimer	  Demenz	   antreibt	  und	  die	  Prognose	  verschlechtert.	  Während	  andauernde	  oder	  strenge	  Hypoxie	  zu	  irreversiblen	  neuronalen	  Defiziten	  durch	  Zelltod	  führt,	  werden	  Astrozyten	  durch	  dieses	   Signal	   und	   die	   absterbenden	   benachbarten	   Neurone	   zu	   hypertrophem,	  bisweilen	   auch	   hyperplastischem,	   Wachstum	   angeregt.	   Mit	   dieser	   reaktiven	  Astrogliose	   geht	   eine	   Vernarbung	   des	   betroffenen	   Hirnareals	   einher,	   die	   Zell-­‐Zell-­‐Kommunikationen	   und	   Signalausbreitung	   massiv	   beeinträchtigen	   kann,	  gleichermaßen	  aber	  auch	  eine	  Abgrenzung	  des	  geschädigten	  Gewebes	  bedeutet	  (Barrikadenfunktion).	   Die	   meisten	   Zellen	   reagieren	   auf	   starke	   Gewebshypoxie	  mit	   der	   Hemmung	   des	   mTORC1	   Kinase	   Komplexes	   und,	   infolge	   dessen,	   einer	  verlangsamten	  Proteinsyntheserate.	  Diese	  Maßnahme	  soll	  den	  Energieverbrauch	  in	   Zeiten	   mangelhafter	   ATP	   Produktion	   reduzieren,	   sowie	   vielfache	  Genexpressionen	   durch	   den	   Transkriptionsfaktor	   HIF-­‐1	   modulieren.	   Es	   ist	  bekannt	   dass	   der	   mTORC1	   Signalweg,	   je	   nach	   Umweltsignal	   (z.B.	   O2	   Normal-­‐	  oder	  Mangelversorgung),	   die	   Synthese	   der	  Mehrheit	   an	   Zellproteinen	   und	   von	  ribosomalen	   Untereinheiten	   durch	   Abstimmung	   der	   Translationsrate	   von	   cap-­‐	  bzw.	  TOP-­‐abhängigen	  mRNAs	  koordiniert.	  Bislang	  wurde	  die	  Kaskade	  vor	  allem	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in	   Krebszellen	   untersucht,	   kann	   jedoch	   auch	   in	   Neuropathien	   dereguliert	  vorliegen.	  	  	  Das	   zentrale	   Anliegen	   dieser	   Doktorarbeit	   war	   es	   die	   Rolle	   des	   mTORC1	  Signalweges	   in	   der	   astrozytären	   und	   neuronalen	   Reaktion	   auf	   eine	  Mangelversorgung	   an	   Sauerstoff	   (inkl.	   Mangelversorgung:	   Hypoxie;	  ausbleibende	   Versorgung:	   Anoxie)	   bzw.	   einen	   unterbrochenen	   Zufluss	   an	  biochemischen	   Substraten	   (z.B.	   Glukose)	   und	   Sauerstoff	   (Ischämie)	   zu	  untersuchen.	   Dabei	   wollten	   wir	   vor	   allem	   verstehen	   wie	   sich	   die	   mTORC1	  Kaskade	   unter	   diesen	   verschiedenen	   Stressbedingungen	   auf	   die	   globale	   (i.e.	  Translationstypus	  übergreifende)	  Proteinsynthese	  und	  ATP	  Fließgleichgewichte	  in	   Hypoxie	   sensitiven	   (Neuronen)	   und	   toleranten	   (Astrozyten)	   Hirnzellen	  auswirkt.	  Wir	   fanden	   dass	   der	   neuronale	   mTORC1	   Signalweg	   bereits	   unter	  Basisbedingungen	   (Normoxie)	   partiell	   gehemmt	   vorlag,	   möglicherweise	   in	  Korrelation	   mit	   dem	   post-­‐mitotischen	   Zustand	   von	   Nervenzellen	   des	  Säugerhirns.	   Dementsprechend	   war	   die	   Stress-­‐induzierte	   (Hypoxie,	   Anoxie)	  Steigerung	   der	   Hemmung	   von	   cap-­‐abhängiger	   Translation	   moderat	   und	   hatte	  keine	   Auswirkungen	   auf	   die	   globale	   Proteinsynthese.	   Die	   Gliazell-­‐Kaskade,	   vor	  allem	   von	  mTORC1	   zu	   Effektor	   4E-­‐BP1,	   war	   hingegen	   in	   normoxischen	   Zellen	  maximal	  aktiv,	  jedoch	  refraktär	  gegenüber	  Hypoxie	  oder	  Anoxie,	  und	  wurde	  erst	  durch	  Ischämie	  komplett	   inaktiviert.	  Dieser	  Totalverlust	  von	  mTORC1	  Aktivität	  in	  ischämischen	  Astrozyten	  bedingte	  eine	  quantitative	  Dephosphorylierung	  von	  4E-­‐BP1	   und	   maximale	   kompetitive	   Interferenz	   mit	   der	   für	   die	   Translation	  unerlässlichen	  eIF4E-­‐eIF4G	  Interaktion.	  Aber,	  selbst	  diese	  strikt	  gehemmte	  cap-­‐Translation	  korrelierte	  auch	  in	  Gliazellen	  nicht	  mit	  einer	  maximal	  verlangsamten	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globalen	   Proteinsyntheserate,	   weshalb	   ein	   massiver	   Schwund	   an	   ATP	   in	  ischämischen	   Gliazellen	   zu	   beobachten	  war.	   Desgleichen	   beeinflusste	   auch	   die	  pharmakologische	   Inaktivierung	   von	   mTORC1	   durch	   Gabe	   von	   Rapamyzin	  (Sirolimus),	   über	  das	   jeweilige	  hypoxische,	   anoxische	  oder	   ischämische	  Niveau	  hinaus,	  weder	  die	  globale	  Proteinsynthese	  noch	  das	  ATP	  Fließgleichgewicht	  von	  Glia-­‐	  und	  Nervenzellen.	  Allerdings	  wurde	  die	  Akkumulation	  von	  HIF-­‐1α	   infolge	  dieser	   Stresssignale	   durch	   Rapamyzin	   in	   beiden	   Hirnzelltypen	   deutlich	  verringert.	  	  Zu	  guter	  Letzt	  untermauerte	  diese	  Arbeit	  dass	  Vorhandensein	  einer	  neuartigen,	  weniger	   gut	   verstandenen	   Funktion	   von	   4E-­‐BP1	   in	   oxygenierten	   Astrozyten.	  Hier	  wird	  der	  Faktor	  durch	  aktiven	  mTORC1	  Komplex	  hyper-­‐phosphoryliert.	  Der	  siRNA-­‐bedingte	  knockdown	  von	  4E-­‐BP1	  ging	  nur	  in	  normoxischen	  Gliazellen	  (i.e.	  Funktionsverlust	   von	   	   hyper-­‐phosphoryliertem	  4E-­‐BP1),	   nicht	   aber	   anoxischen	  oder	   ischämischen	   Pendants,	   mit	   einer	   Reduktion	   von	   Proteinsynthese-­‐	   und	  Zellproliferationsrate	  einher.	  Zusammenfassend	   erarbeitete	   diese	   Studie	   wesentliche	   Aspekte	   zu	   der	  unterschiedlichen	   Stress	   Reaktion	   des	   mTORC1	   Signalweges	   in	   Hypoxie-­‐sensitiven	   Neuronen	   und	   Hypoxie-­‐toleranten	   Astrozyten.	   Allerdings	   hat	   dieser	  Signalweg	  in	  beiden	  Zelltypen	  keinen	  merklichen	  Einfluss	  auf	  die	  Regulation	  der	  globalen	   Proteinsynthese	   und	   des	   Energiehaushaltes.	   Die	   pharmakologische	  Hemmung	   des	  mTORC1	   Signalweges	   bedingt	   hingegen	   auch	   in	   ZNS	   Zellen	   ein	  verändertes	   HIF-­‐abhängiges	   Stress	   Transkriptom.	   Bezüglich	   der	  Translationskontrolle	   durch	   mTORC1-­‐4E-­‐BP1	   ist	   anzunehmen	   dass	   die	  Produktion	   einiger	  weniger,	   für	   das	   Zellüberleben	  wesentlicher,	  mRNAs	   durch	  diesen	   Signalweg	   reguliert	  wird.	   Um	  welche	   Transkripte	   es	   sich	   dabei	   handelt	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müssen	   künftige	   Studien	   ergeben.	   Schließlich	   konnte	   für	   primäre	   Astrozyten	  gezeigt	   werden	   das	   4E-­‐BP1	   eine	   Ying-­‐Yang-­‐artige	   Doppelfunktion	   innewohnt:	  eIF4E-­‐bindende	   Translationsbremse	   im	   dephosporylierten	   Zustand,	   also	   unter	  ischämischen	   Kinase-­‐hemmenden	   Bedingungen,	   und	   Synthese-­‐/Wachstum-­‐fördernder	  Faktor	  sobald	  die	  Zellen	  den	  Stress	  überwunden	  haben	  und	  wieder	  mit	  Sauerstoff	  und	  Energiesubstraten	  versorgt	  werden.	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4 Introduction	  
4.1 Brain	  physiology	  	  The	  brain	  represents	  the	  fundamental	  link	  between	  organism	  and	  environmental	  stimuli,	  generating	  patterns	  of	  muscle	  activity	  and	  driving	  secretion	  of	  molecules	  called	   hormones,	   it	   carries	   out	   disparate	   functions	   such	   as	   behavior	   control,	  comprehension,	  memory,	  motor	  commands,	  signals	  interpretation	  and	  decoding.	  Brain	  is	  highly	  dependent	  on	  the	  supply	  of	  nutrients	  and	  oxygen,	  and	  it	  requires	  a	  correct	  homeostasis	  to	  ensure	  coordination	  of	  both	  cognitive	  and	  non-­‐cognitive	  processes.	   Impaired	  developmental	  mechanisms	  as	  well	  as	  external	   factors	  can	  cause	   structural,	   biochemical	   or	   electrical	   alterations	   and	   negatively	   influence	  normal	  brain	  activity.	  Although	  it	  constitutes	  only	  2-­‐3%	  of	  the	  total	  body	  weight,	  the	   brain	   utilizes	   approximately	   20%	   of	   the	   body	   oxygen	   consumption	   (1).	  Decreased	   oxygen	   delivery,	   as	   a	   result	   of	   impaired	   blood	   flow,	   cardiovascular	  and/or	   respiratory	   disease	   as	   well	   as	   hemorrhage,	   can	   lead	   to	   critical	   oxygen	  tension	  (in	  adult	  mammals	   is	  between	  25	  and	  40	  mmHg)	  and	  cause	  up	  to	  90%	  decline	   of	   energy	   in	   as	   little	   as	   5	   min	   (2).	   Since	   oxygen	   metabolism	   provides	  energy	  for	  normal	  functions	  of	  the	  central	  nervous	  system	  (CNS),	  limited	  oxygen	  supply	   is	   an	   important	   and	   frequent	   pathological	   component	   of	   many	   brain	  diseases	  and	  pathologies	  such	  as	  stroke,	  cancer	  and	  Alzheimer’s	  disease	  (3).	  Of	   the	   many	   different	   cell	   types	   found	   in	   the	   brain	   (e.g.	   neurons,	   astrocytes,	  pericytes,	   endothelial	   cells)	   that	   contribute	   to	   the	   correct	   activity	   of	   the	   CNS,	  neurons	   and	   astrocytes	   seem	   to	   play	   major	   roles,	   thus	   different	   in	   both	  physiological	  and	  pathological	  events.	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4.1.1 Neurons	  and	  stress	  sensitivity	  Neuronal	  cells	  are	  fundamental	  for	  brain	  activity.	  They	  are	  electrically	  excitable	  cells	  that	  process	  and	  transmit	  information	  via	  electrical	  and	  chemical	  signals	  to	  the	  whole	  body.	  Although	  various	  types	  of	  neurons	  are	  characterized	  by	  different	  morphology,	   they	   all	   consist	   of	   four	   regions:	   1)	   dendrites,	   the	   projections	  receiving	   electrochemical	   stimulation	   from	   other	   neural	   cells,	   2)	   cell	   body	  (soma),	   containing	  nucleus	  and	   cytoplasm,	  3)	   axon,	   the	  output	   fiber	   conducing	  electric	   impulses	  and	  4)	  axon	   terminals,	   the	  projections	   transmitting	  signals	   to	  the	  other	  cells	   (Fig.	  1,	  micrograph	  of	   cultured	  murine	  6	  DIV	  neurons	   that	  have	  been	  used	  in	  this	  project).	  Communication	  between	  neurons	  and	  other	  cells	  takes	  place	  at	  specialized	  sites	  called	  synapses,	  where	  the	  information	  flows	  from	  one	  cell	  to	  another	  by	  release	  of	  molecules	  known	  as	  neurotransmitters.	  Once	  the	  signal	  reaches	  the	  dendrites,	  the	   propagation	   of	   the	   impulse	   occurs	   in	   only	   one	   direction	   and	   involves	   the	  opening	  and	  closing	  of	  ATP-­‐driven	  ion	  channels	  along	  the	  axon.	  Action	  potentials	  and	   excitatory	   postsynaptic	   currents	   generated	   by	   ion	   fluxes	   through	   the	  channels	   represent	   the	   major	   energy	   expenditure	   for	   the	   brain	   (1)	   and	   are	  fundamental	  for	  the	  correct	  transmission	  of	  signals.	  Maintenance	  of	  functional	  neurons	  is	  essential	  through	  life	  to	  guarantee	  normal	  brain	   activity.	   Disturbance	   of	   brain	   homeostasis	   due	   to	   alteration	   of	   different	  factors,	  e.g.	  oxygen	  supply	  and	  energy	  metabolism,	  not	  only	  affects	  the	  brain	  but	  can	  influence	  the	  whole	  body.	  Memory,	  learning,	  locomotion	  and	  senses	  are	  only	  few	  of	  the	  aspects	  that	  can	  be	  altered	  by	  neuronal	  loss	  during	  CNS	  injury	  (4–6).	  Neurons	   use	   most	   of	   the	   energy	   consumed	   by	   the	   brain	   to	   generate	   action	  potentials	  and	  restore	  ionic	  concentrations	  after	  synaptic	  transmission	  (7).	  	  




Fig.	  1	  Neurons	  in	  culture.	  Micrograph	  of	  primary	  murine	  neurons	  (6	  DIV)	  that	  have	  been	  used	  in	  this	  project.	  Cells	  were	  stained	  with	  TUJ-­‐1	  (neuronal-­‐specific	  tubulin).	  Picture	  provided	  by	  Dr.	  O.	  Ogunshola.
100µM 
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  A	   drop	   in	   cerebral	   perfusion,	   hypoxia,	   hypoglycemia,	   and	   severe	   anemia	   can	  cause	  a	   critical	   energy	  decrease	  and	   trigger	  neuronal	  damage.	   Indeed,	  neurons	  are	   considered	   to	   be	   the	   most	   sensitive	   cells	   of	   the	   CNS	   and	   there	   is	   large	  evidence	   that	   oxygen	   deprivation	   can	   induce	   neuronal	   cell	   injury,	  neurodegeneration	   and	   cell	   death	   within	   minutes	   (8).	   Mammalian	   neurons	  exposed	  to	  acute	  hypoxia	  undergo	  neurophysiological	  changes	  as	  a	  consequence	  of	   loss	   of	   ionic	   homeostasis	   and	   abnormal	   release	   of	   excitatory	  neurotransmitters	   (9).	   The	   early	   neuronal	   response	   to	   oxygen	   deprivation	  involves	   inhibition	   of	   the	   electrochemical	   gradient	   regulator	   Na+-­‐K+-­‐ATPase,	  cellular	   edema	   and	   subsequent	   neurodegeneration	   (10).	  Moreover,	   energy	   fall	  may	  induce	  glycolysis	  (11),	  increase	  free	  radical	  formation	  and	  cytosolic	  calcium	  levels	  (12),	  leading	  to	  cell	  death.	  Indeed,	  in	  a	  neonatal	  model	  of	  hypoxic-­‐ischemic	  injury	  apoptotic	  and	  necrotic	  neuronal	  death	  contributed	  to	  brain	  damage	  (13).	  Moreover,	   acute	   exposure	   to	  high	  altitude,	  where	   reduced	   air	  pressure	   creates	  low	   partial	   pressure	   of	   oxygen,	   has	   been	   shown	   to	   lead	   neuronal	   loss,	   alter	  neuro-­‐transmitter	  metabolism	  and	  cellular	  energy	  crisis	  in	  old	  rats	  (14).	  Although	   it	   is	   known	   that	   hypoxia	   characterizes	   many	   neurological	   diseases,	  such	   as	   stroke,	   Alzheimer’s	   and	   Parkinson’s	   diseases	   (15,	   16),	   the	   pathways	  contributing	   to	  hypoxic-­‐driven	  neurodegeneration	  are	   still	  not	   fully	   elucidated.	  Notably,	   neurons	   alone	   cannot	   perform	   all	   sophisticated	   brain	   functions,	  therefore	   other	   cells	   (e.g.	   astrocytes,	   oligodendrocytes,	   pericytes,	   endothelial	  cells)	   support	   and	   cooperate	   with	   them	   to	   allow	   proper	   CNS	   activities.	   In	   the	  complex	  network	  of	  cellular	  brain	  connections,	  astrocytes	  play	  a	  significant	  role	  in	   maintaining	   the	   neuronal	   environment	   and	   providing	   nutrients	   (Fig.	   2,	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schematic	  representation	  of	  substances	  released	  from	  astrocytes	  at	  the	  synapsis	  to	  provide	  local	  metabolic	  support	  to	  neurons).	  	  
	  
Fig.	   2	   Schematic	   representation	   of	   an	   astrocyte	   interacting	  with	   neurons	   at	   the	  
synapse.	   At	   the	   synapse,	   astrocytes	   interact	   with	   neurons	   through	   their	   processes.	  Astrocytic	  and	  neuronal	  cells	  both	  express	  many	  common	  receptors.	  Therefore	  release	  of	  neurotransmitters	  from	  the	  neuronal	  presynaptic	  terminal	  also	  stimulates	  astrocytes.	  Activation	   of	   astrocytic	   receptors	   triggers	   the	   increase	   of	   intracellular	   calcium	  and,	   in	  turn,	  the	  release	  of	  active	  substances,	  which	  provide	  local	  metabolic	  support	  to	  neuronal	  cells	  and	  participate	  to	  synaptic	  transmission.	  Figure	  taken	  from	  (17).	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4.1.2 Astrocytes	  and	  their	  responses	  to	  CNS	  injury	  Astrocytes	   are	   the	   most	   abundant	   cells	   in	   the	   mammalian	   brain	   (Fig.	   3,	  micrograph	   of	   primary	   rat	   astrocytic	   cultures	   that	   have	   been	   used	   in	   this	  project).	   The	   proportion	   of	   astrocytes	   to	   neuronal	   cells	   seems	   to	   increase	  dramatically	   during	   the	   course	   of	   evolution,	   ranging	   from	   a	   1:6	   ratio	   in	  
Caenorabditis	   elegans,	   where	   neurons	   exceed	   astrocytes,	   to	   a	   3:1	   ratio	   in	   the	  cortex	   of	   lower	   mammals.	   Astrocytes	   are	   specialized	   glia	   cells	   performing	   a	  broad	  number	  of	  functions:	  maintenance	  of	  the	  homeostasis,	  metabolic	  and	  anti-­‐oxidant	  support	  and	  neuroprotection	  (18).	  Therefore	  they	  not	  only	  contribute	  to	  normal	  performance	  of	   the	  healthy	  CNS,	  but	  also	   respond	   to	  all	   forms	  of	  brain	  injury.	  Astrocytes	  are	  essential	  for	  synaptic	  transmission	  (18)	  and	  provide	  local	  metabolic	   support	   to	   neurons.	   Being	   the	   exclusive	   holder	   of	   glycogen	   energy	  stores	  in	  the	  brain,	  they	  are	  fundamental	  for	  neuronal	  survival	  and	  function	  (19)	  even	  during	  hypoglycemia	  and	  during	  periods	  of	  high	  neuronal	  activity.	  Indeed,	  glycogen	  breakdown	  leads	  to	  the	  production	  of	  lactate,	  which	  is	  then	  exported	  to	  neurons	  as	  a	  major	  energy	  source,	  thus	  conferring	  to	  astrocytes	  the	  critical	  role	  in	   supporting	   neuronal	   metabolism	   by	   the	   “lactate	   shuttle”	   (19).	   Additionally,	  astrocytes	  show	  high	  resistance	  to	  oxidative	  stress	  due	  to	  their	  elevated	  levels	  of	  antioxidants	  such	  as	  glutathione	  and	  the	  ability	   to	  overexpress	  reactive	  oxygen	  species	   (ROS)	   scavengers	   metallothionein	   and	   superoxide	   dismutase	   (SOD)	  enzymes	  during	  cerebral	  ischemia	  (20,	  21).	  





Fig.	  3	  Astrocytes	  in	  culture.	  Micrograph	  of	  primary	  rat	  astrocytic	  cultures	  that	  have	  been	  used	  in	  this	  project.	  Cells	  were	  stained	  with	  GFAP	  (glial	  acidic	  protein;	  green)	  and	  DAPI	  (blue).	  Picture	  provided	  by	  S.	  Engelhardt.	  	  
100	  µM 
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  Notably,	  astrocytes	  can	  withstand	  extreme	  insults	  for	  a	  prolonged	  period	  of	  time	  (22,	  23).	  During	  oxygen/glucose	  deprivation	  these	  cells	  are	  able	  to	  switch	  from	  an	   aerobic	   to	   anaerobic	   metabolism	   (24,	   25),	   contribute	   to	   injury	   response	  mechanisms	   and	   preserve	   the	   host	   tissue	   integrity	   (26).	   Astrocytes	   are	   also	  considered	  the	  main	  source	  of	  erythropoietin	  (EPO)	  in	  the	  brain	  (27,	  28),	  which	  protects	   neurons	   from	   ischemic	   insults	   in	   vitro	   (29,	   30)	   and	   in	   in	   vivo	   stroke	  models	   (31–33).	   Moreover,	   astrocytes	   can	   induce	   and	   secrete	   vascular	  endothelial	   growth	   factor	   (VEGF)	   (23,	   34),	   activating	   angiogenic	   and	  neuroprotective	  mechanisms	   (35).	   However	   during	   stress	   or	   injury	   astrocytes	  may	   become	   highly	   activated	   and	   undergo	   gliosis,	   a	   process	   involving	  proliferation,	  hypertrophy	  of	  cellular	  processes	  and	  altered	  expression	  of	  many	  proteins	  (36),	  that	  to	   large	  extent	  can	  be	  less	  desirable	  and	  perpetuate	  damage	  (37).	  Therefore,	  following	  CNS	  injury	  astrocytic	  response	  can	  include	  changes	  in	  gene	  expression,	  hypertrophy	  and	  cell	  growth	  (38,	  39).	  Particularly,	  hypoxic	  and	  ischemic	   insults	   can	   activate	   and	   promote	   proliferation	   of	   resident	   astrocytes	  both	   in	  vitro	   (23),	  and	   in	  vivo	   (26,	  40).	  Although	  gliosis	   is	  believed	  to	  provide	  a	  permissive	  environment	  to	  preserve	  neuronal	  functions	  (41),	  hyperproliferation	  and	   formation	   of	   a	   glial	   scar	   may	   also	   be	   detrimental	   and	   impede	   axon	  regeneration	  (42,	  43).	  To	  date	  despite	  being	  clear	  that	  astrocytes	  play	  a	  fundamental	  role	  in	  supporting	  normal	   brain	   functions	   and	   maintaining	   CNS	   homeostasis	   during	   insults,	  molecular	  changes	  during	  O2	  deprivation	  are	  only	  poorly	  understood.	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4.2 Physiological	  response	  to	  hypoxia	  O2	  is	  fundamental	  for	  life	  since	  it	  is	  part	  of	  proteins,	  nucleic	  acids,	  carbohydrates,	  fats	   and	   water,	   the	   main	   constituents	   of	   cells.	   Moreover,	   O2	   is	   essential	   to	  synthetize	  the	  ATP	  that	  is	  used	  as	  a	  fuel	  to	  perform	  many	  activities.	  The	  ability	  to	  maintain	  O2	  homeostasis	  is	  essential	  for	  the	  development,	  growth	  and	  survival	  of	  multicellular	  organisms.	  Thanks	   to	   the	  evolution	  of	  complex	  structures	  such	  as	  respiratory	  and	  cardiovascular	  systems,	  O2	   is	  properly	  distributed	   from	  organs	  to	   tissues	   to	   cells	   and	   functions	   as	   the	   terminal	   electron	   acceptor	   during	  mitochondrial	   oxidative	   phosphorylation	   ensuring	   ATP	   production.	   A	   switch	  from	   aerobic	   to	   anaerobic	   metabolism	   during	   decreased	   O2	   supply	   reduces	  energy	  levels	  (44)	  and	  challenges	  organisms,	  although	  tolerance	  to	  O2	  depletion	  varies	   considerably	   among	   species	   (45).	   Sensitivity	   to	   O2	   availability	   is	   also	  markedly	  different	  among	  organs	  in	  the	  same	  organism.	  Inside	  the	  human	  body	  normal	  O2	   levels	  are	  considerably	   lower	   than	  the	  20.9%	  O2	  we	  breathe,	  e.	  g.	   in	  lung	  parenchyma,	  liver,	  kidneys	  and	  heart	  O2	  varies	  from	  14	  to	  4%,	  while	  in	  the	  eye	  from	  1	  to	  5%	  and	  in	  the	  brain	  from	  0.5	  to	  7%	  (46).	  	  Hypoxia	   is	   best	  defined	  as	   the	   condition	  where	  oxygen	  partial	   pressures	   (pO2)	  have	   fallen	   to,	   or	   below,	   a	   tissue	   (cell)-­‐specific	   critical	   value	   that	   separates	  oxidative	  from	  anaerobe	  metabolism	  (47).	  Tissue	  hypoxia	  can	  occur	  during	  both	  physiological	  and	  pathological	  events.	  In	  the	  human	  body	  different	  processes	  are	  activated	   to	   allow	   acclimatization	   to	   the	   hypobaric	   hypoxia	   at	   high	   altitude,	  where	   hypoxic	   conditions	   may	   occur	   (48).	   Physiological	   adaptations	   such	   as	  increased	   ventilation,	   cardiac	   output,	   vascularization	   of	   tissues	   and	   cellular	  modifications	  aim	  to	  maintain	  the	  oxygen	  carrying	  capacity	  of	  the	  system	  during	  periods	   of	   reduced	   pO2	   and	   ensure	   better	   utilization	   of	   the	   available	   O2	   (49).	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Other	  mechanisms	  such	  as	  development	  of	  the	  mammalian	  embryo	  (50),	  control	  of	  stem	  cell	  differentiation	  and	  angiogenesis	  (46,	  51)	  require	  reduced	  O2	  supply,	  therefore	   indicating	   O2	   deprivation	   as	   regulatory	   mechanism	   during	   normal	  conditions.	  	  	  
4.2.1 Pathophysiological	  response	  to	  hypoxia	  Disturbed	   O2	   homeostasis	   is	   a	   typical	   feature	   of	  many	   pathological	   conditions	  that	   often	   exacerbates	   disease	   progression.	   Impaired	   blood	   flow,	   as	   observed	  during	   myocardial	   and	   cerebral	   ischemia	   and	   other	   diseases,	   can	   cause	  significant	  brain	  hypoxia	  (49).	  In	  these	  injuries	  detrimental	  outcome	  occurs	  not	  only	  as	  a	  direct	  consequence	  of	  hypoxic	  conditions	  but	  also	  due	  to	   the	  burst	  of	  reactive	  oxygen	  species	   (ROS)	   following	   the	  restoration	  of	   the	  blood	   flow	  (49).	  Moreover,	   periods	   of	   chronic	   hypoxia	   can	   predispose	   to	   development	   of	  neurodegeneration.	   Increased	   risk	   of	   Alzheimer’s	   disease	   has	   been	   associated	  with	  hypoxia	  arising	  from	  cardiovascular	  and	  respiratory	  disorders	  (15,	  52)	  and	  impaired	   oxygen	   supply	   can	   also	   contribute	   to	   amyotrophic	   lateral	   sclerosis	  (ALS)	   (53)	   probably	   due	   to	   motor	   neuronal	   death	   (54).	   Solid	   tumors	   are	  characterized	  by	   regions	  of	   low	  oxygen	   tension	   that	   activate	   complex	  pathway	  cascades	  for	  the	  formation	  of	  new	  blood	  vessels,	  a	  pathological	  mechanism	  called	  neoangiogenesis	   (55),	   to	   increase	   O2	   and	   nutrients	   supply	   and	   allow	   tumors	  growth	  and	  survival	  (56).	  Although	   the	   involvement	   of	   reduced	   oxygen	   availability	  was	   demonstrated	   in	  both	   physiological	   and	   pathological	   mechanisms,	   the	   molecular	   pathways	  involved	  still	  need	  to	  be	  fully	  elucidated.	  Low	  oxygen	  levels	  cause	  modulation	  of	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transcriptional	   responses,	   particularly	   via	   the	   hypoxia-­‐inducible	   factors	   (HIF),	  but	   cellular	   adaptation	   is	   primarily	   affected	   by	   regulation	   of	   translational	  mechanisms.	  	  
4.2.2 HIF-­‐mediated	  transcriptional	  regulation	  of	  hypoxic	  responses	  Hypoxia-­‐inducible	  factors	  (HIF)	  are	  mainly	  responsible	  for	  cellular	  adaptation	  to	  oxygen	  deprivation.	  HIF-­‐1	  was	  identified	  about	  two	  decades	  ago	  by	  Semenza	  and	  Wang	   (57,	   58)	   and	   since	   then	   different	   isoforms	   have	   been	   discovered.	   HIF-­‐1	  plays	   and	   essential	   role	   during	   oxygen	   homeostasis	   by	   inducing	  more	   than	   70	  validated,	   and	   perhaps	   several	   hundred	   of	   potential,	   hypoxia-­‐responsive	   gene	  targets	  in	  all	  mammalian	  cell	  types	  examined	  (59,	  60).	  Cellular	  changes	  induced	  by	   HIF-­‐1	   affect	   glucose	   transport,	   glycolytic	   versus	   mitochondrial	   activities,	  survival	   and	   proliferation	   (61),	   and	   ensure	   systemic	   oxygen	   homeostasis	   by	  increasing	  EPO,	  angiogenesis	  and	  dilation	  of	  blood	  vessels	  (62).	  HIF	   is	   a	   heterodimer	   composed	   of	   an	   oxygen-­‐regulated	   HIF-­‐α	   subunit	   and	   a	  constitutively	   expressed	   HIF-­‐β	   subunit	   (also	   known	   as	   aryl	   hydrocarbon	  receptor	   nuclear	   translocator	   or	   ARNT).	   Alpha	   and	   beta	   subunits	   of	   HIF	   are	  members	  of	  the	  basic	  helix-­‐loop-­‐helix	  (bHLH)	  and	  PER-­‐ARNT-­‐SIM	  (PAS)	  domain	  family	  of	  transcription	  factors	  that	  mediate	  their	  dimerization	  via	  the	  HLH/PAS	  motifs	   and	   the	  binding	   to	  DNA	   (63).	   To	  date,	   three	  HIF-­‐α	   (HIF-­‐1α,	  HIF-­‐2α	   and	  HIF-­‐3α)	   and	   HIF-­‐β	   (ARNT,	   ARNT2	   and	   ARNT3)	   isoforms	   have	   been	   described	  among	  which	  HIF-­‐1α	   and	  HIF-­‐2α	   are	   the	   best	   characterized.	  Although	  oxygen-­‐independent	   mechanisms	   can	   also	   promote	   HIF-­‐α	   stabilization	   via	   RACK1	   or	  GSK3β	   (64),	  modulation	  of	  HIF-­‐α	  abundance	  mainly	  depends	  on	  O2	  availability	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and	   occurs	   at	   many	   levels:	   mRNA	   expression,	   protein	   stability,	   nuclear	  translocation	  and	  transcriptional	  activity.	  At	  the	  protein	  level,	  regulation	  of	  HIF-­‐α	  subunits	  is	  mediated	  by	  hydroxylation	  of	  prolyl	  residues,	  followed	  by	  the	  von	  Hippel-­‐Lindau	   tumor	   suppressor	   (pVHL)-­‐dependent	   ubiquitylation	   and	  proteasomal	   degradation	   (Fig.	   4).	   During	   normoxia,	   or	   in	   re-­‐oxygenating	   cells,	  human	  HIF-­‐1α	   is	  hydroxylated	  at	   two	   conserved	  proline	   residues	   (Pro402	  and	  Pro564)	  by	  prolyl	  hydroxylase	  domain	  proteins	   (PHD1,	  2	  and	  3).	  A	   second	  O2-­‐requiring	  hydroxylation	  by	  the	  asparaginyl	  hydroxylase	  FIH-­‐1	  (factor	  inhibiting	  HIF-­‐1)	  modifies	   an	  asparagine	  within	   the	  C-­‐terminal	   transactivation	  domain	  of	  HIF-­‐1α	   or	   -­‐2α,	   thus	   preventing	   recruitment	   of	   the	   coactivator	   proteins	  p300/CBP,	   and	   transactivation	   of	   target	   genes	   under	   high	   oxygen	   partial	  pressure	   (65).	   PHD	   and	   FIH-­‐1	   activity	   decreases	   during	   hypoxia,	  which	   allows	  the	   rapid	   accumulation	   of	   transcriptionally	   active	   HIF-­‐1α/-­‐2α	   isoforms.	  Thereafter	  the	  factors	  translocate	  to	  the	  nucleus	  where	  they	  dimerize	  with	  HIF-­‐β/ARNT	  partner	  proteins.	  HIF-­‐1	  and	  HIF-­‐2	  heterodimers	  work	  as	  transactivators	  i.e.	   they	   induce	  expression	  of	  both	  shared	  and	  specific	   target	  genes	   involved	   in	  important	  processes	  such	  as	  metabolism	  and	  cell	  growth	  by	  binding	  to	  hypoxia	  response	  elements	  (HREs).	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Fig.	  4	  HIF-­‐1α	  regulation	  by	  prolyl-­‐hydroxylation.	  a)	  In	  the	  presence	  of	  O2	  (normoxia),	  Fe2+,	  2-­‐oxoglutarate	  (2-­‐OG)	  and	  ascorbate	  HIF-­‐α	   is	  hydroxylated	  by	  prolyl	  hydroxylase	  domain	  proteins	  (PHD1,	  2	  and	  3).	  Poly-­‐hydroxylated	  HIF-­‐1α	  binds	  to	  von	  Hippel-­‐Lindau	  tumor	   suppressor	   (pVHL),	   is	   poly-­‐ubiquitylated	   and	   therefore	   degraded	   by	   26S	  proteasome	   complex.	   Acetylation	   of	   HIF-­‐1α	   (OAc)	   also	   promotes	   pVHL	   binding	   and	  following	   degradation.	   	   b)	   During	   hypoxia,	   hydroxylation	   is	   inhibited,	   HIF-­‐1α	   is	   no	  longer	  degraded	  but	  translocates	  to	  the	  nucleus	  where	  it	  dimerises	  with	  HIF-­‐1β.	  HIF-­‐1	  complex	   recruits	   the	   co-­‐activators	   p300/CBP	   and	   SRC-­‐1,	   binds	   the	   hypoxia-­‐response	  elements	   (HREs)	   of	   the	   target	   genes	   and	   modulates	   the	   activity	   of	   the	   general	  transcription	  factor	  (GTF)/RNA	  polymerase	  II	  machinery	  in	  a	  hypoxia-­‐responsive	  way.	  Targets	   genes	   regulate	   many	   different	   functions.	   Figure	   from	   (66).
	   25	  
	  Due	  to	  the	  broad	  range	  of	  cellular	  proteins	  they	  activate,	  it	  is	  not	  surprising	  that	  HIF-­‐1/-­‐2	   are	   required	   during	   physiological	   processes,	   such	   as	   embryonic	  survival	  and	  development	  of	  the	  circulatory	  system	  (67–69).	  Messenger	  RNAs	  of	  HIF-­‐1α	   and	   -­‐2α	   are	   constitutively	   expressed	   in	   cultured	   cells	   and	   the	   normal	  adult	   brain.	   However,	   focal	   cerebral	   ischemia	   is	   known	   to	   dramatically	   induce	  HIF-­‐1α	  mRNA	  expression	   in	  peri-­‐infarct	   areas	   (70).	   It	   has	  been	   suggested	   that	  increased	   HIF-­‐1	   activity	   could	   be	   beneficial	   for	   Parkinson’s	   and	   Huntington’s	  diseases,	  although	  the	  mechanisms	  are	  still	  not	  clear	  (71).	  However,	  the	  role	  of	  HIF-­‐1	  during	  hypoxia	  can	  have	  either	  favorable	  or	  detrimental	  effects.	  While,	  on	  the	   one	  hand,	   several	   studies	   have	   confirmed	   a	   pro-­‐survival	   role	   of	  HIF-­‐1	   (72,	  73),	   it	   has	   also	  been	   shown	   that	   in	  neuronal	  model	   of	   ischemic	   injury	  HIF	   can	  promote	  cell	  death	  (74).	  Even	   though	   much	   is	   known	   about	   HIF-­‐1α	   degradation,	   specific	   upstream	  mechanisms	  able	   to	   impinge	  on	   the	   steady	  state	  of	   the	   subunit	   still	  need	   to	  be	  fully	  elucidated.	  Of	  particular	  interest	  for	  this	  study	  is	  the	  widely	  held	  notion	  that	  mammalian	  target	  of	  rapamycin	  (mTOR)	  can	  activate	  HIF-­‐1	  (75).	  It	  was	  recently	  shown	   in	   vivo	   that	   expression	   of	   HIF-­‐1α	   and	   its	   target	   vascular	   endothelial	  growth	  factor	  (VEGF)	  is	  reduced	  upon	  mTOR	  inhibition	  in	  developing	  brain	  (76),	  thus	  supporting	  the	  hypothesis	  of	  such	  pathway	  being	  involved	  in	  the	  regulatory	  mechanism	   of	   HIF-­‐1.	   Moreover,	   in	   non-­‐excitable	   cells	   mRNA	   translation	   uses	  more	   cellular	   energy	   than	  any	  other	  biosynthetic	   activity	   (77)	   and	  accordingly	  translational	   rate	   in	   such	   cells	   is	   extremely	   sensitive	   to	  O2	   availability	   and	   cell	  metabolism	  and	  is	  finely	  regulated	  at	  many	  levels.	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4.2.3 mRNA	  translation	  Gene	   expression	   is	   a	   complex	   process	   regulated	   by	   many	   different	   and	   finely	  tuned	  mechanisms	  that	  counteract	  changes	  in	  the	  microenvironment	  and	  trigger	  cellular	  responses	  to	  stimuli.	  Regulating	  the	  content	  and	  level	  of	  proteins	  in	  cells,	  gene	   expression	   drives	   differentiation,	   proliferation,	   apoptosis,	   transformation	  and	  many	  other	  cellular	  mechanisms.	  It	  is,	  therefore,	  not	  surprising	  that	  protein	  expression	  is	  finely	  controlled	  at	  many	  levels.	  Transcription	  of	  genes	  into	  mRNAs	  exerts	  the	  primary	  control	  on	  protein	  regulation	  occuring	  in	  the	  nucleus	  of	  cells	  and	   depends	   on	   DNA	   sequences	   (e.g.	   promoters	   and	   enhancers)	   and	  modification	   (e.g.	  methylation),	   as	  well	   as	   activity	  of	   transcriptional	   regulatory	  proteins	  (e.	  g.	  HIF;	  see	  section	  4.2.2)	  (78).	  However,	   it	  was	  recently	  shown	  that	  the	  rate	  of	  mRNA	  translation	   is	   intensively	  regulated	  during	  cell	  differentiation	  (79)	  and	  is	  decreased	  under	  stress	  conditions	  as	  first	  line	  of	  defense	  mechanism	  (see	  section	  4.2.4),	  therefore	  underlying	  the	  importance	  of	  the	  protein	  synthesis	  modulation	  in	  response	  to	  different	  stimuli.	  Translation	  of	  mRNAs	  into	  proteins	  occurs	   in	   the	   cell	   cytoplasm	   and,	   is	   tightly	   dependent	   on	   post-­‐transcriptional	  modification	  of	  the	  mRNA,	  such	  as	  addition	  of	  the	  5’	  cap	  (see	  section	  4.3.3.1)	  and	  the	  poly	  (A)	  tail	  structures	  (80),	  and	  the	  recruitment	  of	  protein	  factors	  devoted	  to	  the	  assembly	  of	  the	  translation	  machinery	  	  (see	  section	  4.3.3.1).	  Coordinated	  recruitment	  of	  translational	  factors	  to	  the	  mRNA	  is	  determined	  by	  the	  activity	  of	  different	   kinases	   and	   the	  modulation	   of	   signaling	   cascades	   via	   diverse	   stimuli	  (81).	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4.2.4 Translational	  regulation	  during	  hypoxia	  Due	   to	   the	   strong	   dependence	   of	   ongoing	   mRNA	   translation	   on	   abundant	   O2	  delivery	   to	   the	   cells,	   regulation	   of	   protein	   synthesis	   is	   important	   for	   rapid	  response	  to	  hypoxic	  conditions.	  Hypoxia	  modulates	  cellular	  protein	  synthesis	  at	  least	   at	   two	   levels:	   i)	   through	   the	   inhibition	   of	   the	   overall	   level	   of	   the	   mRNA	  translation	  and	  ii)	   through	  differential	  protein	  expression	  (82).	  Decrease	  of	   the	  overall	  protein	  synthesis	  during	  O2	  deprivation	  requires	  inhibition	  of	  ribosomal	  clustering	  and	  mRNA	  initiation	  (82).	  It	  was	  shown	  that	  within	  minutes	  of	  anoxia	  HeLa	   cells	   reduce	   the	   number	   of	   ribosomes	   per	   translated	   transcript	   (83).	  Similarly,	   loss	   of	   polysomes	   has	   been	   described	   to	   occur	   in	   different	   types	   of	  deoxygenated	  cells	  such	  as	  human	  cancer	  cell	   lines	  as	  well	  as	  primary	  prostate	  adenocarcinoma	   and	   immortalized	   human	   fibroblasts	   (82).	   These	   findings	  suggest	   the	   reversible	   arrest	   of	   protein	   synthesis	   to	   represent	   a	   first	   line	   of	  defense	   mechanism	   that	   is	   common	   among	   primary	   and	   transformed	   cells	  subjected	   to	   acute	   O2	   deprivation.	   Translational	   control	   of	   constituents	   of	   the	  ribosomal	   machinery	   is	   mainly	   conferred	   via	   the	   so-­‐called	   5'	   terminal	  oligopyrimidine	  tract	  (TOP)	  seen	  in	  a	  small	  number	  of	  mRNAs	  (84)	  while	  mRNAs	  encoding	  the	  majority	  of	  cellular	  proteins	  are	  regulated	  by	  a	  different	  path,	   the	  so-­‐called	  5’-­‐cap-­‐dependent	  mRNA	  translation	  (see	  section	  4.3.3).	  Cap-­‐dependent	  translation	   is	   modulated	   by	   a	   complex	   series	   of	   phosphorylation	   events	   in	  response	   to	   diverse	   environmental	   stimuli,	   a	   mechanism	   where	   the	   mTORC1	  complex	  seems	  to	  play	  a	  central	  role	  (85).	  Production	   of	   selective	   “survival”	   transcripts	   and	   polypeptides	   evidently	  requires	   changes	   in	   specific	   transcription	   and	   translation	   processes.	   Indeed,	  selection	   of	   gene	   expression	   during	   O2	   deprivation	   does	   not	   only	   depend	   on	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transcriptional	  regulation,	  mediated	  by	  HIF	  and	  other	  transcription	  factors,	  but	  is	   it	   also	   influenced	   at	   the	   translational	   level	   (86).	   While	   life-­‐threatening	  challenges	   may	   yield	   a	   marked	   slow-­‐down	   of	   global	   protein	   synthesis	   rate,	  translation	   of	   some	   survival	   factors,	   such	   as	   VEGF	   and	   HIF-­‐1α	   itself,	   is	  maintained,	  if	  not	  activated	  (87,	  88).	  Up	  to	  5%	  of	  cellular	  mRNAs	  are	  believed	  to	  be	   translated	   via	   a	   cap-­‐independent	   initiation	   mechanism,	   for	   example	   by	  internal	  ribosome	  entry	  sites	  (IRES)	  (89).	  In	  such	  mechanisms,	  ribosomes	  will	  be	  directly	  recruited	  to	  mRNA	  to	   internal	  entry	  site	  elements,	   therefore	  bypassing	  the	   inhibition	   of	   the	   bulk	   of	   the	   (cap-­‐dependent)	   translation	   initiation	  machinery.	  	  	  
4.3 mTOR	  kinase	  The	   target	   of	   rapamycin	   (TOR)	  kinase	  was	  originally	   isolated	   in	  budding	  yeast	  
Saccharomyces	   cerevisiae	   (90)	   as	   target	   of	   the	   antifungal	   macrocyclic	   lactone	  antibiotic	  rapamycin	  (aka	  sirolimus),	  through	  identification	  of	  mutants	  resistant	  to	   the	  drug.	  Shortly	  after	   this	  discovery,	   the	  mammalian	  TOR	  (mTOR)	  homolog	  was	   characterized	   by	   different	   groups	   (91,	   92).	   Since	   then	  mTOR´s	   impact	   on	  many	   physiological	   and	   pathological	   mechanisms	   became	   more	   and	   more	  evident	  (93,	  94).	  	  mTOR,	   also	   known	   as	   FRAP	   (FKBP12-­‐rapamcyin-­‐associated	   protein),	   RAFT1	  (rapamycin	  and	  FKBP12	  target),	  RAPT	  1	  (rapamycin	  target	  1),	  or	  SEP	  (sirolimus	  effector	   protein),	   is	   a	   serine/threonine	   kinase	   of	   289	   kDa	   (2549	   amino	   acids)	  	  and	  member	   of	   the	   phosphatidylinositol	   3-­‐kinase-­‐related	   kinase	   (PIKK)	   family	  (93).	  Amino	  acid	  sequences	  of	  the	  mTOR	  protein	  of	  human,	  rat	  and	  mouse	  share	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95%	  identity,	  while	  the	  human	  sequence	  of	  mTOR	  displays	  42	  and	  45%	  identity	  with	   those	   of	   yeast	   TOR1	   and	  TOR2,	   respectively	   (95).	   The	   importance	   of	   this	  kinase	   is	   clearly	   highlighted	   by	   its	   genetic	   conservation	   among	   species	   and	   is	  further	   confirmed	   by	   embryonic	   lethality	   in	   mice	   upon	   genetic	   mTOR	   loss-­‐of-­‐function	   (96).	   mTOR	   is	   believed	   to	   be	   the	   central	   regulator	   in	   coordinating	  cellular	   activities	   with	   the	   presence	   and	   abundance	   of	   many	   environmental	  factors	  such	  as	  nutrients,	  growth	  factors,	  energy	  and	  oxygen	  supply.	  Thus	  it	  plays	  a	   fundamental	   role	   in	   modulating	   cell	   growth,	   proliferation,	   survival	   and	  development	   in	   response	   to	   environmental	   changes.	   Dysfunction	   of	   mTOR	  signaling	   has	   been	   associated	   with	   different	   pathologies	   including	   metabolic	  disease,	  neurodegenerative	  disorders	  and	  cancer	  (97).	  	  The	   mTOR	   kinase	   regulates	   cellular	   mechanisms	   within	   the	   context	   of	   two	  protein	   complexes	   commonly	   referred	   as	   mTOR	   complex	   1	   (mTORC1)	   and	  mTOR	  complex	  2	  (mTORC2)	  (98).	  Of	  note,	  mTORC1	  is	  involved	  in	  the	  regulation	  of	   translational	   initiation	   and	   ribosome	   biogenesis,	   while	   mTORC2	   regulates	  cytoskeletal	  organization.	  	  	  
4.3.1 mTOR	  complexes	  Both	   mTORC1	   and	   mTORC2	   are	   structurally	   distinct	   multi-­‐protein	   complexes,	  which	  phosphorylate	  different	  substrates	  and	  regulate	  distinct	  cellular	  cascades.	  	  The	   mTORC1	   is	   the	   master	   controller	   of	   energy	   consumption	   invested	   into	  protein	   synthesis,	   thus	   coordinates	   cell	   growth	  and	  proliferation	   as	  modulated	  by	   mRNA	   translation.	   It	   consists	   of	   mTOR	   kinase,	   G	   protein	   beta	   subunit-­‐like	  (GβL;	   also	   known	   as	   mLST8),	   regulatory-­‐associated	   protein	   of	   mTOR	   (raptor)	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and	   proline-­‐rich	   protein	   40	   (PRAS40).	   GβL,	   present	   in	   both	   mTORC1	   and	  mTORC2	   complexes,	   constitutively	   binds	   the	   catalytic	   domain	   of	   the	   mTOR	  kinase	  and	  enhances	  its	  activity	  (99).	  The	  subunit	  raptor	  functions	  as	  scaffold	  for	  recruiting	   substrates,	   therefore	   controls	   specificity	   of	   the	   complex	   and	   brings	  proteins	   such	   as	   ribosomal	   protein	   S6	   kinase	   70kDa	   (S6K)	   and	   eukaryotic	  translation	   initiation	   factor	   4E	   (eIF4E)-­‐binding	   protein	   1	   (4E-­‐BP1)	   in	   the	  proximity	  of	  the	  kinase	  (100).	  The	  last	  partner	  of	  mTORC1,	  PRAS40,	  functions	  as	  direct	   inhibitor	  of	   the	  binding	  of	   the	  different	  proteins	  with	  the	  enzyme	  during	  nutrient	   deprivation	   (101,	   102).	   The	   binding	   partners	   of	  mTORC2	   are:	  mTOR,	  GβL,	   rapamycin	   insensitive	   component	   of	   mTOR	   (rictor)	   and	   the	   recently	  identified	  proteins	  SIN1	  and	  proline-­‐rich	  protein	  5	  (PRR5)	  (103,	  104).	  Similar	  to	  raptor	   subunit	   in	   mTORC1,	   rictor	   is	   responsible	   to	   recruit	   substrate	   to	   the	  mTORC2	   complex	   (105)	   while	   the	   last	   identified	   SIN1	   and	   PRR5	   have	   been	  shown	  to	  be	  important	  in	  maintaining	  mTORC2	  stability	  and	  regulate	  its	  kinase	  activity	  (104,	  106).	  However,	  beyond	  the	  modulation	  of	  mass	  accumulation	  and	  cell	  size	  via	  cytoskeletal	  organization	  by	  mTORC2,	  other	  functions	  and	  principles	  of	  the	  regulation	  of	  this	  complex	  are	  far	  less	  known	  (98).	  Of	  the	  two	  mTOR	  complexes	  only	  mTORC1	  is	  sensitive	  to	  the	  allosteric	  inhibition	  by	   rapamycin.	   This	   selective	   effect	   is	   due	   to	   the	   binding	   of	   the	   drug	   to	   the	  intracellular	   receptor	  FK506	  binding	  protein	  12	   (FKBP12),	  which	   then	  directly	  interacts	   with	   the	   FKBP-­‐rapamycin-­‐binding	   (FRB)	   domain	   of	   mTOR	   (107).	  However,	   although	   mTORC2	   is	   not	   inhibited	   by	   FKBP12/rapamycin	   complex,	  long-­‐term	  drug	  exposure	  is	  known	  to	  reduce	  its	  activity	  (108)	  and	  this	  has	  been	  shown	  to	  be	  responsible	  for	  the	  side	  effects	  of	  rapamycin	  in	  vivo	  (109).	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4.3.2 Upstream	  of	  mTORC1	  The	   regulation	   of	   translational	   rate	   plays	   a	   fundamental	   role	   in	  many	   cellular	  activities;	  therefore	  a	  complex	  orchestra	  of	  proteins	  finely	  tunes	  this	  process	  at	  many	   levels	  (Fig.	  5).	  As	  stated	  above,	  mTORC1	  coordinates	   the	   initiation	  of	   the	  translational	  mechanism	  with	   the	   presence	   and	   abundance	   of	   stimuli	   such	   as:	  growth	  factors,	  nutrients,	  energy	  and	  stress	  signals.	  	  	  
4.3.2.1 Regulation	  of	  mTORC1	  by	  growth	  factors	  and	  nutrients	  Growth	   factors	   such	   as	   insulin	   initiate	  mTORC1	   signaling	   via	   activation	   of	   the	  kinases	  phosphatidylinositol	  3-­‐	  kinase	   (PI3K)	  and	  AKT.	  The	  PI3K/AKT	  cascade	  relays	   signals	   coming	   from	   active	   receptor	   tyrosine	   kinases	   (RTKs)	   including	  epidermal	   growth	   factor	   receptor	   (EGFR),	   insulin-­‐like	   growth	   factor	   receptor	  (IGFR),	  platelet-­‐derived	  growth	  factor	  receptor	  (PDGFR)	  via	  the	  insulin	  receptor	  substrate	  1	  (IRS1)	  (Fig.	  5).	  One	  of	  the	  best	  characterized	  cascades	  is	  activated	  by	  insulin	  growth	  factor	  1	  (IGF1)	  (110).	  The	  binding	  of	  IGF1	  or	  insulin	  to	  the	  IGFR	  triggers	   autophosphorylation	   of	   the	   receptor	   on	   different	   tyrosines	   and	  subsequent	   recruitment	  of	   IRS1	  and	  PI3K,	  which	   is	   then	  activated	   (110).	  Next,	  PI3K	   catalyzes	   the	   conversion	   of	   phosphatidylinositol-­‐4,5-­‐phosphate	   (PIP2)	   to	  phosphatidylinositol-­‐3,4,5-­‐	   phosphate	   (PIP3)	   that	   allows	   the	   recruitment	   of	  phosphoinositide-­‐dependent	  kinase	  1	  (PDK1)	  to	  the	  cell	  membrane,	  which	  then	  phosphorylates	  AKT	  at	  Thr308	   (111).	  A	   second	  phosphorylation	  at	   the	  Ser473	  triggered	   by	   mTORC2	   complex	   fully	   activates	   AKT	   (112),	   which	   then	  phosphorylates	  the	  tuberous	  sclerosis	  complex	  2	  (TSC2)	  subunit	  of	   the	  TSC1/2	  complex,	   blocking	   its	   inhibitory	   role	   and,	   in	   turn,	   activates	   mTORC1	   via	   GTP-­‐
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bound	  Ras	   homologue	   enriched	   in	   brain	   (Rheb)	   (113).	   In	   its	   GTP-­‐bound	   form,	  Rheb	   functions	   as	   indispensable	   activator	   of	   mTORC1	   and	   TSC1/2	   complex	  exerts	   its	   inhibitory	   role	   by	   converting	  Rheb	   into	   its	   GDP-­‐bound	   inactive	   state	  (114).	  Although	  the	  mechanism	  is	  not	  completely	  elucidated,	  it	   is	  well	  accepted	  that	  GTP-­‐bound	  Rheb	  activates	  mTORC1,	  hence	  allowing	  the	  phosphorylation	  of	  its	  effectors	  S6K1	  and	  4E-­‐BP1.	  	  The	   PI3K/AKT/mTORC1	   pathway	   can	   be	   regulated	   at	   many	   levels.	   The	   best	  known	   antagonists	   of	   this	   cascade	   are	   the	   TSC1/TSC2	   complex	   (previously	  described	   in	   this	   section),	   AMP-­‐activated	   protein	   kinase	   (AMPK)	   (see	   section	  4.3.2.2)	   and	   the	   phosphatase	   and	   tensin	   homolog	   (PTEN)	   phosphatase.	   PTEN	  acts	  upstream	  of	  the	  pathway	  and	  specifically	  catalyzes	  the	  dephosphorylation	  of	  PIP3	   back	   to	   PIP2,	   thus	   resulting	   in	   inhibition	   of	   the	   AKT/mTORC1	   cascade	  downstream	  of	  PI3K	  (Fig.	  5).	  Since	  mTORC1	  controls	  processes	  in	  which	  amino	  acids	  play	  a	  fundamental	  role,	  such	  as	  ribosome	  biogenesis	  and	  mRNA	  translation,	  it	  is	  favorable	  for	  the	  cells	  to	  be	   able	   to	   respond	   to	   variations	   of	   the	   levels	   of	   essential	   amino	   acids	   that	  mammalian	   cells	   are	   unable	   to	   synthesize	   themselves.	   Leucine	   is	   a	   strong	  activator	   of	  mTORC1.	   The	  mechanisms	   by	  which	   leucine	   and	   the	   other	   amino	  acids	   activate	   the	   pathway	   are	   still	   not	   clear	   but	   the	   downstream	   effects	   of	  mTORC1	   activation	   are	  well	   studied	   and	   include	   phosphorylation	   of	   S6K1	   and	  4E-­‐BP1	   (115).	   Proteins	   such	   as	   class	   III	   phosphoinositide	   3-­‐kinase	   (human	  vacuolar	  protein	  sorting	  34),	  Rag-­‐GTPases	  and	  MAP	  kinase	  kinase	  kinase	  kinase	  3	   (MAP4K3)	   have	   been	   proposed	   to	   act	   as	   intracellular	   sensors	   of	   these	  molecules	  (116).	  






Fig.	   5	  Mammalian	   target	   of	   rapamycin	   complex	   1	   (mTORC1)	   signaling	   pathway.	  Growth	   factors,	   nutrients,	   oxygen	   availability	   promote	   mTORC1	   signaling	   via	  phosphorylation	   cascade.	   Activation	   of	   the	   PI3K/AKT	   signaling	   converges	   on	   TSC1/2	  complex	   inhibition,	   leading	   to	   Rheb	   activation.	   Subsiquently	   phosphorylated	  mTORC1	  promotes	   cap	   and	   TOP-­‐dependent	   translation,	   via	   4E-­‐BP1	   and	   S6K1	   phosphorylation	  respectively.	   Stimulating	   (white	   P	   in	   black	   circle)	   and	   inactivating	   (black	   P	   in	   white	  
circle)	   phosphorylations	   are	   indicated.	  mTORC1	   is	   illustrated	   in	   a	   green	   square	  while	  blue	  circles	  indicate	  proteins	  analyzed	  in	  this	  thesis	  work.	  Figure	  modified	  from	  (47).	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4.3.2.2 Regulation	  of	  mTORC1	  by	  cellular	  energy	  and	  oxygen	  Translation	   and	   ribosome	   biogenesis	   are	   the	   most	   energy-­‐costly	   biosynthetic	  processes	   in	   the	   cells	   (117),	   therefore	   these	   mechanisms	   must	   be	   finely	  regulated	   during	   periods	   of	   reduced	   energy	   charge	   (i.e.	   rise	   in	   [AMP]/[ATP]	  	  ratio)	  or	  O2	  availability.	  Energy	   depletion	   inhibits	   mTORC1	   via	   AMPK	   and	   involves	   the	   activation	   of	  TSC1/2	  complex	  (118).	  High	  levels	  of	  AMP	  (low	  cellular	  energy	  charge)	  trigger,	  through	  direct	  binding,	  the	  activating	  phosphorylation	  of	  AMPK	  by	  LKB1	  (119).	  Activated	   of	   AMPK	   then	   phosphorylates	   and	   stimulates	   TSC1/TSC2	   inhibitory	  function	   towards	   Rheb	   and	   mTORC1	   (118),	   in	   contrast	   to	   the	   inactivating	  phosphorylation	   triggered	   by	   AKT	   in	   response	   to	   growth	   factors	   (Fig.	   5).	  Inhibition	  of	  mTORC1	  via	  TSC1/TSC2	  complex	  during	  low	  energy	  charge	  reduces	  the	  rate	  of	  protein	  synthesis	  to	  rematch	  declining	  ATP	  supplies	  with	  decreasing	  ATP	  demand.	  Multiple	   pathways	   converge	   on	   mTORC1	   during	   hypoxia.	   However	   since	   O2	  availability	  ultimately	  regulates	  ATP	  in	  the	  cells,	  it	  is	  not	  surprising	  that	  effect	  of	  O2	  deprivation,	  to	  some	  extent,	  are	  similar	  to	  those	  caused	  by	  energy	  depletion.	  Under	  conditions	  of	  mild	  hypoxia	  elevated	  [AMP]/[ATP]	  ratios	   inhibit	  mTORC1	  signaling	   via	   AMPK-­‐driven	   TSC1/2	   activation	   (120,	   121),	   as	   previously	  described.	  Yet,	  O2	  deprivation	   itself	   is	  also	  able	   to	  negatively	  regulate	  mTORC1	  activity	  by	  promoting	  the	  TSC1/2	  interference	  of	  the	  kinase	  through	  the	  HIF-­‐1-­‐driven	   induction	   of	   the	   REDD1	   (regulated	   in	   development	   and	   DNA	   damage	  responses	  1)	  gene	  product	  (122).	  Indeed,	  REDD1	  (aka	  DDIT4,	  RTP801)	  releases	  the	  subunit	  TSC2	  from	  its	  growth	  factor-­‐induced	  association	  with	  inhibitory	  14-­‐
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3-­‐3	  proteins	   (123)	   therefore	  activating	  TSC1/2	  complex	  and	  blocking	  mTORC1	  signaling.	  Additionally,	  it	  was	  recently	  shown	  that	  during	  hypoxic	  conditions	  Bcl-­‐2/adenovirusE1B19-­‐kDa	   interacting	  protein	  3	   (BNIP3)	  disrupts	   the	   interaction	  between	   the	   kinase	   subunit	   mTOR	   and	   its	   positive	   regulator	   Rheb,	   thus	  inhibiting	  mTORC1	  (Fig.	  5).	  	  	  
4.3.3 Downstream	  of	  mTORC1	  Notably,	   active	   mTORC1	   triggers	   mRNA	   translation	   by	   directly	   stimulating	  phosphorylation	   of	   S6K1	   and	   inactivating	   phosphorylation	   of	   4E-­‐BP1	   to	  ultimately	   stimulate	   5-­‐TOP-­‐	   and	   5’-­‐cap-­‐dependent	   mRNA	   translation,	  respectively	  (Fig.	  6).	  The	  entire	  mRNA	  translation	  process	  consists	  of	  initiation,	  elongation	  and	  termination	  stages,	  of	  which	  4E-­‐BP1	  and	  S6K1	  regulate	  the	  first	  stage	   (initiation),	  which	   is	   considered	   to	  be	   the	   rate-­‐limiting	   step	  of	   the	  whole	  mechanism	  (124).	  Each	  of	  these	  effectors	  and	  corresponding	  mechanisms	  will	  be	  discussed	  in	  more	  detail	  below.	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Fig.	   6	   Regulation	   of	   translation	   by	   mTORC1.	  Nutrients	   and	  O2	   availability	   activate	  mammalian	  target	  of	  rapamycin	  (mTOR)	  complex	  1	  (mTORC1),	  which	   	  phosphorylates	  eukaryotic	   translation	   initiation	   factor	   4E	   (eIF4E)-­‐binding	   protein	   1	   (4E-­‐BP1)	   and	  ribosomal	  protein	  S6	  kinase	  70kDa	  (S6K),	  therefore	  activating	  cap	  and	  TOP-­‐dependent	  translation.	   Full	   4E-­‐BP1	   hyper-­‐phosphorylation	   results	   in	   the	   release	   of	   eIF4E,	   which	  recruits	  eIF4G	  and	  eIF4A	  to	  constitute	  eIF4F	  complex.	  The	  eIF4F	  interacts	  with	  the	  cap	  structure	  at	  the	  5’	  terminus	  of	  the	  mRNA	  and	  facilitates	  recruitment	  of	  other	  factors	  to	  initiate	  the	  cap-­‐dependent	  translation.	  During	  nutrient	  starvation	  and/or	  hypoxia,	  hypo-­‐phosphorylated	  4E-­‐BP1	  interacts	  with	  eIF4E	  and	  impedes	  the	  formation	  of	  eIF4F,	  while	  eIF4E-­‐T	   triggers	   the	   translocation	   of	   eIF4E,	   triggering	   cap-­‐dependent	   translation	  inhibition.	  Figure	  modified	  from	  (47).	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4.3.3.1 5’-­‐cap-­‐dependent	  protein	  synthesis	  Most	  eukaryotic	  mRNAs	  possess	  a	  m7GpppN	  (where	  m:	  methyl	  group;	  G:	  guanine	  base;	   ppp:	   triphosphate	   group;	   N:	   any	   nucleotide)	   “cap”	   structure	   at	   their	   5’	  terminus.	  This	  modification	  is	  essential	  in	  determining	  the	  life	  span	  of	  the	  mRNA	  as	   it	   affects	   splicing,	   transport,	   stabilization	   and	   translation	   of	   the	   transcript	  (125).	   The	   cap	   structure	   facilitates	   recruitment	   of	   the	   nascent	   mRNA	   to	   the	  eukaryotic	   initiation	   translation	   factor	   4F	   (eIF4F)	   complex	   and	   40S	   ribosomal	  subunits	  (126,	  127).	  The	  eIF4F	  complex	  consist	  of	  eIF4E,	  eIF4G	  and	  eIF4A	  (126).	  eIF4E	   directly	   binds	   the	   5’	   cap	   structure	   of	   the	   mRNA	   and	   coordinate	  recruitment	   of	   eIF4G	   and	   eIF4A	   onto	   the	   nascent	   transcript	   (128).	   The	  eIF4E/cap	   interaction	   is	   the	  most	   controlled	   target	  of	   the	  process	   (126)	  and	   is	  considered	  to	  be	  the	  first	  rate	  limiting	  step	  of	  translation.	  eIF4A,	  a	  member	  of	  the	  DEAD	   box	   helicase	   family,	   unwinds	   secondary	   structures	   of	   the	   mRNA	   to	  facilitate	  the	  scanning	  of	  the	  40S	  ribosomal	  subunit	  for	  the	  initiation	  codon.	  The	  eIF4Gs	   (i.e.	   eIF4G1,	   eIF4G2)	   are	   scaffolding	   proteins	   that	   interact	   with	   eIF4E.	  Through	   this	   direct	   association	   with	   eIF4E,	   the	   eIF4G	   factors	   co-­‐localize	   the	  proteins	   implicated	   in	   the	   translation	   initiation	   mechanism	   with	   43S	   pre-­‐initiation	   complex,	   which	   consists	   of	   the	   small	   40S	   ribosomal	   subunit,	   the	  initiation	  factor	  eIF3,	  and	  the	  ternary	  complex	  eIF2-­‐GTP-­‐tRNAMet	  (129).	  The	   second	   most	   important	   check	   point	   for	   the	   initiation	   of	   the	   mRNA	  translation	  is	  the	  assembly	  of	  the	  eIF2-­‐GTP-­‐tRNAMet	  complex,	  catalyzed	  by	  eIF2B.	  Phosphorylation	  of	   the	   eIF2α	   subunit	   at	   serine-­‐51	   (S51A)	   residue	  by	   the	  PKR-­‐like	   ER-­‐associated	   kinase	   (PERK)	   (130)	   inhibits	   eIF2B	   and	   blocks	   initiation	   of	  protein	   synthesis	   upon	   accumulation	   of	   unfolded	   or	  misfolded	   proteins	  within	  the	  endoplasmic	  reticulum	  (i.e.	  unfolded	  protein	  response)	  (131).	  Regulation	  of	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mRNA	  translation	  either	  via	  eIF4F	  assembly	  or	  eIF2α	  phosphorylation	  seems	  to	  be	   coordinated.	   Indeed,	   a	   recent	   study	   on	   HeLa	   cells	   has	   shown	   that	   hypoxic	  inhibition	  of	  mRNA	  translation	   is	  a	  biphasic	  process	  characterized	  by	  very	  fast,	  yet	   transient	   phosphorylation	   of	   eIF2α,	   which	   is	   followed	   at	   later	   times	   by	   a	  more	  persistent	  suppression	  of	  the	  eIF4F	  assembly	  (83).	  This	  biphasic	  regulation	  of	  the	  translation	  initiation	  is	  of	  particular	  interest	  for	  our	  study	  as	  we	  wanted	  to	  investigate	   the	   translational	   response	   of	   brain	   cells	   exposed	   to	   prolonged	   O2	  deprivation,	  i.e.	  at	  times	  when	  the	  mechanism	  presumably	  is	  interfered	  with	  via	  eIF4F	  dissociation.	  Availability	  of	  eIF4E,	  and	  of	   the	  translation-­‐promoting	  eIF4E/eIF4G	  partnering,	  depends	  on	  finely	  regulated	  mechanisms	  of	  interaction	  of	  the	  eIF4E	  subunit	  with	  inhibitory	   binding	   partners.	   Over	   the	   last	   years	   proteins	   such	   as	  Maskin,	   Cup,	  Neuroguidin	   and	   CYFIPI	   have	   been	   shown	   to	   be	   inhibitory	   partners	   of	   eIF4E	  (129),	  however	  the	  three	  members	  of	   the	  4E-­‐BP	  family	  seem	  to	  play	  the	  major	  role	  in	  antagonizing	  cap-­‐dependent	  translation	  via	  their	  scavenging	  of	  eIF4E.	  	  	  
4.3.3.1.1 4E-­‐BP	  mediated	  inhibition	  of	  5’	  cap-­‐dependent	  translation	  The	  eIF4E	  binding	  proteins	   (4E-­‐BPs)	  are	  a	  group	  of	  proteins	  encoded	  by	   three	  paralogous	   genes:	   4E-­‐BP1,	   4E-­‐BP2,	   4E-­‐BP3	   (132).	   The	   4E-­‐BPs	   show	   similar	  inhibitory	   activity	   on	   mRNA	   translation	   (133),	   however	   4E-­‐BP1	   has	   been	  characterized	   the	   most.	   Interaction	   of	   4E-­‐BP1	   with	   eIF4E	   is	   a	   reversible	  mechanism	  dependent	  on	  the	  phosphorylation	  state	  of	  the	  binding	  protein	  (Fig.	  6).	   Hypo-­‐phosphorylated	   4E-­‐BP1	   competes	   with	   eIF4G	   for	   an	   overlapping	  binding	   site	   in	   eIF4E.	   Thus,	   the	   interaction	   of	   4E-­‐BP1	   with	   eIF4E	   impede	   the	  
	   39	  
formation	   of	   eIF4F	   complex	   and	   the	   recruitment	   of	   the	   40S	   ribosome	   for	   the	  translation	  initiation	  (134).	  A	  hierarchical	  cascade	  of	  phosphorylation	  reactions	  at	   multiple	   sites	   regulates	   4E-­‐BP1	   capacity	   to	   interact	   with	   eIF4E.	   Fully	  phosphorylated	   (hyper-­‐phosphorylated)	   4E-­‐BP1	   can	   no	   longer	   retain	   the	  binding	  of	   the	  cap-­‐binding	   factor,	  which	  results	   in	   the	  release	  of	  eIF4E	  and	  the	  initiation	   of	   the	   cap-­‐dependent	   translation.	   Different	   pathways	   such	   as	   PI3K,	  AKT	   and	   mTORC1	   regulate	   4E-­‐BP1	   phosphorylation	   (135).	   Indeed,	   hyper-­‐phosphorylation	  of	  4E-­‐BP1	  has	  been	  shown	  to	  be	  triggered	  by	  stimulated	  PI3K	  and	  AKT/PKB	   (protein	   kinase	  B)	   signaling	   (136).	  mTORC1	   itself	   has	   also	  been	  shown	  to	  directly	  phosphorylate	  4E-­‐BP1	  (135).	  	  Human	   4E-­‐BP1	   contains	   seven	   phosphorylation	   sites:	   Thr37,	   Thr46,	   Ser65,	  Thr70,	   Ser83,	   Ser101	   and	   Ser112.	   However,	   not	   all	   the	   sites	   are	   equally	  responsible	   for	   4E-­‐BP1	   regulation.	   Recent	   data	   by	  Gingras	   et	   al.	   demonstrated	  that	   phosphorylation	   of	   Thr37	   and	   Thr46	   via	   mTORC1	   are	   priming	   events	  necessary	   to	   trigger	   the	   final	   phosphorylation	   reactions	   of	   Thr70	   and	   Ser65	  (137).	  Moreover,	  the	  authors	  showed	  that	  phosphorylation	  of	  Ser65,	  alone	  or	  in	  combination	   with	   Thr70,	   does	   not	   interfere	   with	   4E-­‐BP1/eIF4E	   binding,	  therefore	   suggesting	   that	   phosphorylation	   at	  multiple	   sites	   is	   required	   for	   the	  disruption	  of	  such	  binding.	  	  	  
4.3.3.1.2 4E-­‐BP	  mediated	  physiological	  and	  pathophysiological	  functions	  Since	  4E-­‐BPs	  directly	  control	  the	  initiation	  of	  cap-­‐dependent	  translation,	  it	  is	  not	  surprising	   that	   they	   play	   a	   fundamental	   role	   in	   many	   physiological	   and	  pathophysiological	  mechanisms.	  4E-­‐BP2	  is	  mainly	  expressed	   in	  the	  brain	  (138)	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where	  is	  required	  for	  synaptic	  plasticity,	  spatial	   learning	  and	  memory	  (139).	  In	  keeping	   with	   this,	   4E-­‐BP2	   knockout	   mice	   exhibit	   an	   autistic-­‐like	   phenotype	  (140),	   thereby	   indicating	   a	   fundamental	   role	   of	   this	   binding	   protein	   in	  establishing	   correct	   cell-­‐cell	   connections	   in	   the	   brain.	   Regarding	   4E-­‐BP1,	   it	   is	  clear	  to	  date	  that	  this	  isoform	  is	  critical	  in	  numerous	  physiological	  mechanisms,	  including	   regulation	   of	   adipogenesis	   and	  metabolism	   (138),	   as	  well	   as	   control	  and	  synchrony	  of	  the	  circadian	  clock	  (141).	  Whereas	   insulin	  stimulates	  4E-­‐BP1	  phosphorylation	  in	  proximal	  tubular	  epithelial	  cells	  (142),	  low	  sulfur	  amino	  acid	  intake	   is	  known	  to	   increase	  4E-­‐BP1	  expression	   in	   liver	  of	   rats	   (143).	  However,	  4E-­‐BP1	   is	   also	   described	   as	   key	   effector	   in	   many	   cancer	   entities	   (144–146).	  Activation	  of	  cap-­‐dependent	  protein	  synthesis	  by	  chronic	  hyper-­‐phosphorylation	  of	   4E-­‐BP1	   is	   associated	   with	   increased	   cancer	   progression	   and	   decreased	  survival	   in	   astrocytoma	   (146).	   Similarly,	   it	  was	   shown	   that	   constitutive	  hyper-­‐phosphorylation	  of	  4E-­‐BP1	  results	  in	  increased	  active	  eIF4E,	  therefore	  aberrant	  translational	  control,	  in	  human	  breast	  carcinoma	  cell	  lines	  (147).	  Even	  decreased	  levels	   of	   the	   binding	   protein	   have	   been	   associated	  with	   cellular	   abnormalities	  due	   to	   hyper-­‐activation	   of	   eIF4E.	   Indeed,	   silenced	   expression	   of	   4E-­‐BP1	   was	  found	   to	   i)	   increase	   resistance	   to	   Enzastaurin	   (acyclic	   bisindolylmaleimide)-­‐induced	   apoptosis	   in	   human	   glioma	   and	   colon	   cancer	   cell	   lines	   (148),	   ii)	   to	  sensitize	   U87	   glioblastoma	   xenograft	   tumors	   to	   experimental	   irradiation	   by	  decreasing	  hypoxia	  tolerance	  (149).	  Moreover,	  4E-­‐BP1	  levels	  have	  been	  found	  to	  inversely	  correlate	  with	  the	  progression	  of	  gastrointestinal	  cancer	  (150).	  	  	  It	   thus	   emerges	   that	   4E-­‐BP	   proteins	   play	   a	   fundamental	   role	   in	   many	  physiological	   mechanisms,	   and	   that	   alteration	   in	   expression	   levels	   or	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phosphorylation	   state	  may	   affect	   activities	   of	   normal	   cells	   as	   they	   do	   for	   cells	  with	  malignant	  background.	  	  
	  
4.3.3.2 S6K1	  and	  TOP-­‐dependent	  translation	  S6Ks	   (S6K1	   and	   S6K2)	   are	   members	   of	   the	   AGC	   family	   of	   serine/threonine	  kinases	   and	   control	   translation	   of	   mRNA	   containing	   a	   5’	   terminal	  oligopyrimidine	  (TOP)	  region.	  S6K1	  is	  expressed	  as	  two	  isoforms	  (p85	  and	  p70)	  that	   derive	   from	   the	   same	   transcript	   through	   alternative	   translation	   initiation	  and	   are	   primarily	   localized	   in	   the	   cytoplasm	   (151).	   In	   contrast,	   the	   two	   S6K2	  isoforms	  (p54	  and	  p56)	  are	  mainly	  nuclear	  (152).	  Although	  the	  specific	  roles	  of	  S6K1	  and	  S6K2	  are	  still	  poorly	  understood,	  a	  recent	  study	  indicates	  S6K1	  to	  be	  ubiquitously	  present,	  while	  S6K2	  levels	  vary	  among	  different	  tissues	  (153).	  With	  regard	   to	   the	   better	   known	   S6K1	   isoform,	   it	   is	   clear	   that,	   Thr389	   and	   Thr229	  function	   as	   essential	   sites	   for	   the	   activation	  of	   the	  kinase,	   despite	   the	   fact	   that	  several	   additional	   sites	  may	   also	   be	   phosphorylated	   (154).	   mTORC1	  mediates	  phosphorylation	   of	   Thr389,	   followed	   by	   the	   PDK1-­‐driven	   phosphorylation	   at	  Thr229	  (154).	  Active	  S6K1	  eventually	  phosphorylates	  the	  S6	  protein	  of	  the	  40S	  small	   ribosomal	   subunit,	   which,	   in	   turn,	   initiates	   the	   translation	   of	   TOP-­‐dependent	   mRNAs.	   This	   mRNA	   category	   mainly	   encodes	   components	   of	   the	  translational	   machinery,	   e.g.	   ribosomal	   protein	   S6	   and	   eukaryotic	   initiation	  factor	   4B	   (eIF4B).	   Other	   phosphorylation	   targets	   of	   active	   S6K1	   are	   IRS1,	  glycogen	  synthase	  kinase	  3	  (GSK3),	  eIF4B,	  translation	  elongation	  factor	  2	  (eEF2),	  and	  Bcl-­‐2-­‐associated	  death	  promoter	  (Bad)	  (155).	  So	  far,	  regulation	  of	   IRS1	  via	  S6K1	   broadly	   attracts	   research	   due	   to	   its	   influences	   on	   the	   insulin	   cascade.	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Indeed,	  phosphorylation	  of	   IRS1	  via	  S6K1	   interferes	  with	   the	   interaction	  of	   the	  substrate	   with	   the	   insulin	   receptor,	   thus	   inhibiting	   insulin	   signaling	   (156).	  Although	  this	  negative	  feedback	  loop	  serves	  to	  down-­‐regulate	  insulin	  stimulation	  of	  the	  PI3K	  cascade,	  its	  chronic	  activation	  may	  contribute	  to	  diabetes	  (157).	  	  
4.3.4 Upstream	  and	  downstream	  of	  mTORC2	  In	  addition	  to	  the	  activation	  of	  mTORC1,	  growth	  factors	  such	  as	  insulin	  and	  IGF1	  also	  stimulate	  mTORC2	  activity.	  Although	  the	  mechanisms	  still	  remain	  unclear,	  it	  was	  recently	  suggested	  by	  Huang	  et	  al.	  that	  the	  TSC1/TSC2	  complex,	  inhibitor	  of	  mTORC1,	  mediates	  the	  activation	  of	  mTORC2	  via	  direct	  binding	  (158).	  However,	  the	   GTPase	   Rheb,	   downstream	   effector	   of	   TSC1/TSC2	   complex	   and	   direct	  activator	   of	   mTORC1	   (see	   section	   4.3.2.1),	   does	   not	   appear	   to	   play	   a	   role	  upstream	  of	  mTORC2	  (158).	  Although	  little	  is	  known	  about	  mTORC2’s	  upstream	  regulation,	   upon	   activation	   the	   complex	   phosphorylates	   members	   of	   the	   AGC	  kinase	  family	  including	  SGK1	  (serum	  and	  glucocorticoid	  induces	  protein	  kinas	  1)	  (159),	  PKC	  (protein	  kinase	  C)	  (160)	  and	  AKT	  (161),	  therefore	  triggering	  different	  cellular	  mechanisms.	  The	  mTORC2	  mediated	  phosphorylation	  of	  SGK1	  at	  Ser422	  contributes	   to	   the	  maintenance	   of	   sodium	   homeostasis	   via	   stabilization	   of	   the	  ENaC	  (epithelial	  sodium	  channel)	  (162),	  while	  PKC	  phosphorylation	  is	  involved	  in	   the	   regulation	   of	   the	   actin	   cytoskeleton	   (163).	   AKT	   phosphorylation	   (112,	  161)	  is	  considered	  to	  be	  one	  of	  the	  most	  critical	  functions	  of	  mTORC2	  complex.	  Indeed,	  phosphorylation	  of	  AKT	  at	  the	  Thr450	  and	  Ser473,	  mTORC2	  contributes	  to	   stability	   and	   activation	   of	   this	   important	   cell	   signaling	   kinase.	   It	   is	   widely	  accepted	   that	   mTORC2	   mediated	   phosphorylation	   of	   AKT	   at	   Ser473	   fully	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activates	   the	   kinase	   in	   the	   PI3K/	   AKT	   cascade	   (see	   section	   4.3.2.1)(112).	  However,	   it	  was	  recently	  shown	  by	  Facchinetti	  et	  al	   that	   the	  mTORC2	  complex	  also	   controls	   the	   phosphorylation	   of	   AKT	   at	   the	   Thr450,	   thereby	   regulating	  folding	   and	   stability	   of	   this	   kinase	   (160).	   The	   importance	   of	   the	   mTORC2	  complex	   is	   revealed	  by	   the	   lethal	  phenotype	  during	  embryonic	  development	  of	  mice	  lacking	  rictor	  or	  SNI1	  (see	  section	  4.3.1)	  (104,	  164).	  A	  recent	  in	  vivo	  study	  provides	   evidence	   that	   the	   mTORC2	   complex	   affects	   hepatic	   gene	   expression,	  transcriptional	   regulation	   and	   metabolism	   (165),	   therefore	   playing	   diverse	  biological	   roles.	   Indeed	   it	   was	   shown	   by	   Urbanska	   et	   al	   that	   together	   with	  mTORC1	  the	  mTORC2	  complex	  is	  needed	  for	  the	  correct	  dendritic	  morphology	  of	  
in	   vitro	   neurons	   (166).	   Interestingly,	   mTORC2	   seems	   to	   play	   a	   role	   also	   in	  pathophysiological	  processes	  as	  mTORC2	  activity	  was	  recently	  discovered	  to	  be	  crucial	   in	   ischemic	   preconditioning-­‐induced	   cardioprotection	   (167).	   Moreover,	  due	  to	  the	  role	  of	  this	  kinase	  in	  regulating	  cytoskeleton	  rearrangement,	  it	  is	  not	  surprising	  that	  mTORC2	  plays	  a	  role	   in	  different	  aspects	  of	  cancer	  progression.	  Gene	  silencing	  of	  Rictor,	  a	  fundamental	  component	  of	  the	  mTORC2	  complex	  (see	  section	  4.3.1),	  decreased	  cell	  migration	  and	  invasion	  of	  in	  vitro	  and	  ex	  vivo	  model	  of	   human	  bladder	   cancer	   cells	   (168),	  while	   tumor	   cells	   lacking	  Rictor	   failed	   to	  form	  tumor	  xenograft	  (169).	  Specific	  pharmacological	  inhibition	  of	  the	  complex	  also	  prevented	  breast	  tumor	  growth	  in	  nude	  mice	  (170).	  It	  is	  therefore	  clear	  that	  although	  mTORC1	  is	  the	  most	  studied	  mTOR	  dependent	  complex,	  also	  mTORC2	  plays	  a	  fundamental	  role	  in	  many	  different	  cellular	  mechanisms.	  	  	  Regulation	   of	   protein	   synthesis	   is	   fundamental	   for	   the	   adaptation	   to	   O2	  deprivation.	   Adjusting	   mTORC1	   signaling	   to	   the	   altered	   environment	   clearly	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plays	  a	  major	   role	   for	   this	   adaptation.	  With	   this	   study	  we	  aimed	   to	   investigate	  how	  mTORC1	  pathway	   is	  modulated	   in	  primary	  O2	   sensitive	   (i.e.	  neurons)	  and	  tolerant	   (i.e.	   astrocytes)	   brain	   cells	   and	   which	   role	   it	   occupies	   in	   controlling	  overall	  protein	  synthesis	  and	  energy	  steady	  states.	  Identification	  of	  mechanisms	  regulating	  the	  very	  distinct	  O2	  sensitivities	  between	  nerve	  and	  glia	  cells	  could	  be	  beneficial	   for	   the	   discovery	   of	   new	   biological	   targets	   for	   pharmacological	  treatment	  of	  hypoxia-­‐driven	  CNS	  injuries.	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5 Aim	  
Decreased	   protein	   synthesis	   is	   considered	   a	   first	   common	   cellular	  mechanism	  that	   cells	   undergo	   to	   reduce	   energy	   consumption	   during	   hypoxic	   insult	   (82),	  although	  transcriptional	  regulation,	  particularly	  via	  HIFs,	  also	  plays	  a	  major	  role.	  The	  mTORC1	  pathway	   is	   fundamental	   in	   cell	   stress	   responses	   since	   it	   controls	  protein	  synthesis	  via	  ribosomal	  biogenesis	  and	  translation	  of	  most	  mRNAs	  (123,	  171).	  Furthermore	  published	  data	  suggests	  that	  mTORC1	  inhibition	  impacts	  HIF-­‐1α	  signaling	  and	   thus	   transcriptional	  and	   translational	  control	  may	  collaborate	  in	   the	   complex	  mechanisms	   stimulated	   during	   hypoxia.	   Although	  mTORC1	  has	  been	  extensively	  studied	  in	  cancer	  cells,	  only	  recent	  studies	  highlighted	  its	  role	  in	   regulating	   physiological	   brain	   development	   (172),	   and	   synaptic	   plasticity	  (173).	  The	  aim	  of	  this	  thesis	  work	  was	  to	  understand	  the	  role	  of	  mTORC1	  signaling,	  and	  particularly	   4E-­‐BP1,	   in	   astrocytic	   and	   neuronal	   responses	   to	   oxygen	   and/or	  glucose	   deprivation.	   Specifically,	   we	   hypothesized	   that	   the	   mTORC1	   cascade	   is	  
responsible	  for	  differential	  regulation	  of	  overall	  protein	  synthesis	  and	  energy	  levels	  
in	   neurons	   and	   astrocytes	   challenged	   with	   hypoxia	   or	   ischemia,	   respectively.	  Additionally,	   we	   investigated	   whether	   mTORC1	   influences	   transcriptional	   and	  translational	   mechanisms	   during	   hypoxic	   response	   in	   primary	   brain	   cells	   by	  modulating	  HIF-­‐1α	  stabilization.	  To	  this	  aim	  we	  subjected	  primary	  neurons	  and	  astrocytes	   to	   different	   severities	   of	   oxygen	   and/or	   glucose	   deprivation.	  Subsequently	  we	  investigated	  regulation	  of	  the	  mTORC1	  effectors	  S6K1	  and	  4E-­‐BP1,	  HIF-­‐1α	  as	  well	  as	   translational	   responses	   including	  protein	  synthesis	   rate	  and	  cell	  survival.	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6 Materials	  and	  methods	  
Methods	  not	  listed	  below	  are	  described	  in	  section	  10	  (Manuscript).	  	  Primary	  culture	  of	  neurons	  Primary	  neuronal	  cultures	  were	  obtained	  from	  the	  cerebral	  cortex	  of	  C57B1/6J	  mice	   (gestational	   stage	   E14)	   as	   described	   previously	   (174).	   Dissected	   cortices	  were	  dissociated	  in	  Hank’s	  buffered	  salt	  solution	  (HBBS)	  containing	  trypsin	  and	  DNase	   I	   for	   5	  min	   at	   37°C.	   Neurons	  were	   seeded	   in	   poly-­‐L-­‐lysine	   coated	   petri	  dishes	   (3	   x	   106	  cells	   per	   100mm	   dish),	   in	   neurobasal	   medium	   complemented	  with	   B27	   supplement	   (1X),	   AlbuMAXI	   (0.25g/ml),	   streptavidin-­‐penicillin	   (1%),	  sodium-­‐pyruvate	  100U/ml	  and	  L-­‐glutamine	  (0.5	  mM).	  Neurons	  were	  maintained	  in	   culture	   for	  6	  days	   (days	   in	  vitro	   =DIV)	  at	  normal	   atmosphere	   (21%	  O2)	   in	  a	  humidified	  incubator	  at	  37°C.	  For	  analysis	  of	  culture	  purity,	  immunofluorescence	  staining	  was	  performed	  on	  6	  DIV	  neurons	  using	  the	  astrocyte	  marker	  GFAP	  and	  the	   neuronal	   marker	   NeuN	   (neuronal	   nuclear	   antigen).	   6	   DIV	   neurons	   were	  estimated	  to	  be	  98%	  pure.	  	  	  PI	  staining	  Cell	   survival	   was	   determined	   by	   propidium	   iodide	   (PI)	   staining	   using	   an	  automated	   cell	   counter	   (ADAM,	   Digital	   Bio)	   according	   to	   manifacturer’s	  instructions.	   Following	   incubation	   cells	   were	   trypsinized,	   stained	   with	   PI	   and	  counted.	   Percentage	   of	   cell	   death	   was	   determined	   as	   ratio	   of	   the	   number	   of	  positively	  stained	  cells	  compared	  to	  total	  number	  of	  cells.	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LDH	  assay	  Cytotoxicity	  was	  determined	  by	  lactose	  dehydrogenase	  (LDH)	  cytotoxicity	  assay	  kit	   (Roche,	   Penzberg,	   Germany)	   according	   to	   manifacturer’s	   instructions.	  Following	   incubation,	   cell	   culture	  media	   was	   transferred	   to	   a	   96	  wells/	   plate,	  reaction	   mixture	   was	   added	   (1:1	   v/v)	   and	   incubated	   for	   30	   min	   at	   room	  temperature	   in	   the	  dark.	  Absorbance	  was	  measured	   at	   490	  nm	  with	   reference	  filter	  at	  650	  nm.	  	  	  ATP	  measurements	  ATP	  levels	  were	  measure	  by	  an	  ATP	  biomiluminescent	  assay	  kit	  (Sigma,	  Buchs,	  Swizterland)	   and	   used	   according	   to	   manifacturer’s	   instructions.	   Following	  incubation	  cell	  lysates	  were	  generated	  using	  cell	  lysis	  buffer	  supplemented	  with	  protease	  inhibitor	  cocktail	  and	  sodium	  orthovanadate	  (1	  mM),	  incubated	  10	  min	  on	   ice	   and	   then	   cleared	  by	   centrifugation	   for	  10	  min	  at	  16,000	  x	   g	   at	  4°C.	  The	  supernatant	  was	  mixed	  with	  5%	  TCA	  (1:1	  v/v)	  to	  block	  residual	  ATPase	  activity	  and	  luminescence	  was	  measured	  using	  Berthold	  luminometer	  (Detection	  system	  GmbH,	   Pforzheim,	   Germany).	   ATP	   amount	   were	   determined	   from	   a	   standard	  curve.	  	  MTT	  	  Mitochondrial	   activity	   was	   measured	   by	   MTT	   (Sigma-­‐Aldrich,	   St.	   Louis,	   MO)	  assay.	   After	   exposure	   a	   solution	   of	   yellow	   3-­‐(4,5-­‐dimethythiazol-­‐	   2-­‐yl)-­‐2,5-­‐diphenyl	   tetrazolium	   bromide	   (MTT)	   was	   added	   to	   the	   medium	   (final	  concentration	  0.5	  mg/ml)	  and	  cells	  were	  incubated	  for	  1	  hour	  at	  37°C.	  The	  MTT-­‐containing	  medium	  was	   then	   removed	   and	  purple	   formazan	   crystals	   dissolved	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by	  adding	  DMSO	  (Dimethyl	  Sulfoxide).	  Optical	  density	  was	  measured	  at	  560	  nm	  with	  reference	  filter	  at	  670	  nm.	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7 Own	  research	  
7.1 	  ASTROCYTIC	  RESPONSE	  TO	  ACUTE	  (16	  HOURS)	  OXYGEN	  
DEPRIVATION	  The	  following	  research	  represents	  the	  basis	  of	  a	  submitted	  manuscript	  (see	  section	  10,	  accompanying	  manuscript).	  
7.1.1 	  4E-­‐BP1	  and	  S6K1	  have	  different	  sensitivity	  to	  mTORC1	  inhibition	  Immunoblot	   analysis	   shows	   that	   4E-­‐BP1	   and	   S6K1,	   the	   two	   downstream	  effectors	   of	   the	   mTORC1	   kinase,	   are	   differently	   sensitive	   to	   inhibition	   of	   the	  pathway.	  Despite	  the	  fact	  that	  ischemia	  completely	  dephosphorylated	  both	  S6K1	  and	   4E-­‐BP1,	   treatment	   with	   rapamycin	   and	   16h	   anoxia	   were	   effective	   in	  abrogating	   S6K1	  phosphorylation	  while	   these	   applications	  only	  partially	   hypo-­‐phosphorylated	  4E-­‐BP1.	  Different	   studies	  have	   shown	   that	   the	  kinase	  AKT	  can	  be	   activated	  by	   rapamycin-­‐driven	   S6K1	  dephosphorylation	   (175)	   and	   that	   this	  signaling	   cascade	   can	  mediate	   4E-­‐BP1	   regulation	   (136).	   Under	   our	   conditions	  rapamycin	  treatment	  increased	  AKT	  phosphorylation,	  thus	  activated	  AKT	  may	  in	  turn	  sustain	  4E-­‐BP1	  phosphorylation	  at	  times	  when	  mTORC1	  is	  inhibited.	  	  
7.1.2 	  Hypo-­‐phosphorylated	  4EBP1	  scavenges	  eIF4E	  but	  does	  not	  affect	  overall	  
protein	  synthesis	  Since	   partial	   hypo-­‐phosphorylation	   of	   4E-­‐BP1	   by	   rapamycin	   treatment	   barely	  affected	  the	  assembly	  of	  the	  initiation	  complex,	  incomplete	  dephosphorylation	  of	  the	  binding	  protein	  appears	  inadequate	  to	  inhibit	  cap-­‐dependent	  translation.	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It	  was	  shown	  that	  4E-­‐BP1	  in	  immortalized	  breast	  epithelial	  cells	  at	  least	  partially	  contributes	   to	   the	   regulation	   of	   overall	   protein	   synthesis	   during	   oxygen	  deprivation	   (176).	   However,	   in	   primary	   astrocytes,	   where	   general	   mRNA	  translation	  decreased	  with	  oxygen	  deprivation,	  the	  hypo-­‐phosphorylation	  of	  4E-­‐BP1	   during	   16h	   ischemic	   challenges	   or	   rapamycin	   application	   did	   not	   further	  intensify	  inhibition	  of	  global	  protein	  synthesis	  compared	  to	  the	  anoxic	  decrease,	  where	  hyper-­‐phosphorylated	  4E-­‐BP1	  prevails.	  	  
7.2 	  ASTROCYTIC	  RESPONSE	  TO	  PROLONGED	  (36	  HOURS)	  OXYGEN	  
DEPRIVATION	  
7.2.1 Astrocytic	  survival	  is	  not	  affected	  by	  prolonged	  oxygen	  and/or	  glucose	  
deprivation	  To	  increase	  the	  challenge	  of	  these	  stress-­‐resistant	  cells,	  we	  prolonged	  the	  oxygen	  deprivation	   and	   drug	   treatment	   to	   36	   hours	   and	   investigated	   cell	   death	   by	  propidium	  iodide	  (PI)	  staining	  (Fig.	  1).	  As	  expected,	  astrocytes	  were	  not	  affected	  by	  mild	  oxygen	  deprivation	  (Hx,	  1%	  O2)	  and	  10	  nM	  rapamycin	  treatment,	  while	  36	  hours	  near-­‐anoxic	  exposure	  showed	  a	  trend	  to	  increase	  cell	  death	  to	  almost	  20%.	   Interestingly,	   however,	   simultaneous	   glucose	   withdrawal	   and	   severe	  oxygen	   deprivation	   did	   not	   further	   affect	   astrocytic	   survival.	   	   Altogether	   these	  data	   indicate	   that	   astrocytes	   are	  highly	   resistant	   to	   stress	   conditions,	   although	  prolonged	   and	   severe	   oxygen	   deprivation	   seem	   to	   marginally	   reduce	   cell	  survival.	  





























Fig.	   1	   Astrocytic	   survival	   is	   not	   affected	   by	   prolonged	   oxygen	   and/or	   glucose	  
deprivation.	   After	   36h	   exposure,	   astrocytes	   show	   a	   trend	   to	   increase	   cell	   death	   only	  under	   near-­‐anoxic	   condition.	   Glucose	   deprivation	   and	   rapamycin	   treatment	   do	   not	  affect	  astrocytic	  survival.	  Values	  are	  means	  ±	  SD	  (n=3;	  36h	  Ax-­‐G	  n=2).	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7.2.2 	  Differential	  effect	  of	  Rapamycin-­‐driven	  mTORC1	  inhibition	  on	  4E-­‐BP1	  and	  
S6K1	  phosphorylation	  To	   investigate	   the	   regulation	   of	  mTORC1	  pathway	  we	   analyzed	   the	   changes	   in	  4E-­‐BP1,	   eIF2α,	   S6K1	   and	   AKT	   phosphorylation	   by	   immunoblot.	   Oxygen	   or	  glucose	   deprivation	   alone	   did	   not	   alter	   astrocytic	   4E-­‐BP1	   phosphorylation	  relative	   to	   the	  Nx±G	  control	   situation	   (Fig.	  2).	  However,	  hypoxia	   together	  with	  glucose	   withdrawal	   moderately	   reduced	   phosphorylated	   4E-­‐BP1	   (stronger	   β	  band)	  and	  ischemia	  completely	  inhibited	  it	  (α	  band;	  Fig.	  2),	  parallel	  to	  increased	  eIF2α	   phosphorylation, as observed in preliminary studies (data not shown).	   As	  previously	   observed	   (see	   section	   7.1.1),	   rapamycin	   treatment	   only	   partially	  hypo-­‐phosphorylated	  4E-­‐BP1	  (γ,	  β,	  α	  bands).	  S6K1	  phosphorylation,	  on	  the	  other	  hand,	   was	   completely	   inhibited	   during	   ischemia	   and	   drug	   treatment,	   while	  oxygen	   or	   glucose	   deprivation	   alone	   was	   less	   effective	   (Fig.	   2).	   AKT	   was	  activated	   during	   36	   hours	   rapamycin	   treatment	   (elevated	   p-­‐AKT	   levels),	  while	  ischemia	   inhibited	   it.	   These	   results	   mimic	   our	   previous	   data	   on	   16	   hours	  exposure,	   indicating	   that	   prolonged	   stress	   has	   no	   additional	   effect	   on	  phosphorylation	  of	  4E-­‐BP1	  and	  S6K1	  and	  that	  AKT	  may	  indeed	  contribute	  to	  the	  phosphorylation	   of	   the	   binding	   protein	   also	   during	   prolonged	   rapamycin	  treatment.	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Fig.	   2	   Rapamycin	   treatment	   partially	   inhibits	   4E-­‐BP1	   phosphorylation	   and	  
completely	   dephosphorylates	   S6K1.	  Representative	  Western	  blot	   analysis	  of	  n=3	  of	  independent	  experiments	  shows	  phosphorylated	  (p-­‐)	  and	  total	   levels	  of	  S6K1	  and	  AKT	  and	  phosphorylation	   states	  of	  4E-­‐BP1	   (γ,	  β	   and	  α	  bands).	  β-­‐actin	  was	  used	  as	   loading	  control.	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7.2.3 	  Rapamycin-­‐dependent	  4E-­‐BP1	  hypo-­‐phosphorylation	  affects	  protein	  
synthesis	  rate	  only	  in	  normoxic	  astrocytes	  exposed	  to	  glucose	  deprivation	  To	  determine	  if	  varying	  degrees	  of	  4E-­‐BP1	  phosphorylation	  impact	  global	  mRNA	  translation	   in	   astrocytes,	   we	   investigated	   overall	   protein	   synthesis	   rates	   after	  16h	  (see	  section	  10,	  accompanying	  manuscript)	  or	  36h	  incubations	  as	  described	  in	   this	   section	   (Fig.	   3).	   Compared	   to	   normoxic	   controls	   (Nx),	   overall	   protein	  synthesis	  rates	  dropped	  progressively	  with	  increasing	  O2	  deprivation.	  36	  hours	  hypoxia	   (Hx)	   reduced	   the	   rate	   of	   protein	   synthesis	   to	   65%	   of	   the	   control	  (p<0.05),	  while	  anoxia	  further	  reduced	  it	  to	  35%	  (p<0.001).	  Glucose	  withdrawal	  had	   no	   additional	   effects	   during	   hypoxic	   exposure,	   yet,	   for	   unknown	   reasons,	  marginally	   stimulated	   protein	   synthesis	   in	   aerobe	   glia	   cells	   (Fig.	   3).	   In	   vitro	  ischemia	   (Ax-­‐G),	   however,	   caused	   the	   expected	   massive	   slowdown	   of	   global	  mRNA	   translation	   (5%	  of	   controls;	   p<0.0001).	   Treating	   astrocytes	  with	   10	  nM	  rapamycin	  in	  combination	  with	  glucose	  deprivation	  reduced	  translational	  rate	  to	  67%	  in	  normoxia	  glia	   (p<0.05),	  but	  did	  not	   further	  attenuate	  protein	  synthesis	  rates	   in	   the	   other	   conditions	   (comparing	   same	   condition,	  with	   versus	  without	  rapamycin).	  These	  data	  suggest	  that	  dephosphorylated	  4E-­‐BP1	  (36h	  Ax-­‐G	  in	  Fig.	  2)	   may	   contribute	   to	   the	   massive	   inhibition	   of	   protein	   synthesis	   rate	   during	  prolonged	  ischemia.	  Yet,	  the	  incomplete	  4E-­‐BP1	  hypo-­‐phosphorylation	  following	  36h	   rapamycin	   application	   (Fig.	   2)	   reduces	   total	   mRNA	   translation	   only	   in	  normoxic	  astrocytes	  challenged	  with	  glucose	  withdrawal,	  while	  it	  does	  not	  affect	  protein	  synthesis	  in	  cells	  exposed	  to	  oxygen	  deprivation.	  


































Fig.	   3	   Rapamycin-­‐dependent	   4E-­‐BP1	   hypo-­‐phosphorylation	   affects	   protein	  
synthesis	  rate	  only	  in	  normoxic	  astrocytes	  exposed	  to	  glucose	  deprivation.	  In	  36h	  incubations	  overall	  protein	  synthesis	  rates	  decrease	  as	  a	  function	  of	  O2	  deprivation	  but	  are	   not	   additionally	   inhibited	   by	   glucose	   deprivation.	   10	   nM	   rapamycin	   treatment	  reduces	  mRNA	  translation	  only	  when	  astrocytes	  are	  exposed	  to	  normoxia	  in	  absence	  of	  glucose.	  Values	  are	  means	  ±	  SD	  (n=3).	  *p<0.05,	  **p<0.01,	  ***p<0.001,	  ****p<0.0001	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7.2.4 Ischemia	  severely	  reduces	  ATP	  but	  does	  not	  affect	  MTT	  levels	  We	   have	   shown	   that	   in	   primary	   astrocytes	   global	   translation	   decreases	   with	  oxygen	   deprivation	   but	   rapamycin	   treatment	   does	   not	   further	   reduce	   it	   (see	  section	  10,	  accompanying	  manuscript).	  Since	  ATP	  steady	  state	   is	   closely	   linked	  with	   translational	   regulation,	   we	   investigated	   cellular	   energy	   regulation	   after	  both	  16	  and	  36	  hours	  exposure	  (Fig.	  4).	  16	  hours	  oxygen	  and	  glucose	  deprivation	  alone	  did	  not	   affect	  ATP	   levels,	  while	   ischemia	   resulted	   in	   approximately	   50%	  decrease	   (p<0.05)	   that	  was	  not	   reversed	  by	   rapamycin	   treatment	   (Fig.	  4A).	  36	  hour	  of	  glucose	  withdrawal	  during	  normoxia	  elicited	  a	  surprising	  50%	  (p<0.05)	  increase	   in	   energy	   content,	   while	   ATP	  was	   completely	   depleted	   during	   anoxic	  conditions	   (p<0.0001).	   The	   effects	   of	   oxygen	   ±	   glucose	   deprivation	   during	  prolonged	  exposure	  were	  not	  reversed	  by	  drug	  treatment	  (Fig.	  4B).	  These	  data	  clearly	  highlight	  the	  susceptibility	  of	  ATP	  steady	  state	  levels	  only	  to	  severe	  stress	  conditions	   and	   that	   prolonged	   mTORC1	   inhibition	   and	   4E-­‐BP1	  dephosphorylation	  does	  little	  to	  prevent	  ATP	  depletion.	  Activity	  of	  mitochondrial	  dehydrogenases	  is	  not	  affected	  by	  oxygen	  deprivation	  either	  after	  16	  hours	  (Fig.	  5A)	   or	   36	   hours	   (Fig.	   5B)	   exposure.	   Although	   glucose	   withdrawal	   caused	   a	  general	  trend	  of	  MTT	  concentrations	  to	  fall,	  it	  is	  interesting	  to	  note	  that	  only	  the	  combination	   with	   rapamycin	   treatment	   significantly	   reduced	   its	   levels	   to	   50-­‐60%	  (p<0.05)	  (Fig.	  5A&B),	  suggesting	  a	  possible	  role	  for	  mTORC1	  in	  stimulating	  substrate	  turnover	  in	  mitochondria.	  	  

































































Fig.	  4	  Ischemia	  severely	  reduces	  ATP	  levels.	  	  Oxygen	  and	  glucose	  deprivation	  lead	  to	  a	  dramatic	  drop	   in	  ATP	   levels	  after	  both	  16	  A)	  and	  36	  B)	  hours	   incubation	  and	  10	  nM	  rapamycin	  treatment	  did	  not	  rescue	  it.	  Values	  are	  means	  ±	  SD	  (n=3).	  *p<0.05,	  **p<0.01,	  ****p<0.0001	  	  




































































Fig.	   5	   Ischemia	   does	   not	   affect	   MTT	   levels.	   Oxygen	   and	   glucose	   deprivation	   affect	  MTT	   levels	   only	  when	   cells	   are	   treated	  with	   10	  nM	   rapamycin	   after	   either	   shorter	  A)	  and	   prolonged	   B)	   time	   exposures.	   Values	   are	   means	   ±	   SD	   (n=3).	   *p<0.05,	   **p<0.01,	  ***p<0.001	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7.2.5 Rapamycin	  reduces	  HIF-­‐1α	  stabilization	  during	  oxygen	  deprivation	  In	   agreement	   with	   recent	   evidence	   on	   the	   crosstalk	   of	   HIF-­‐1α	   and	   mTORC1	  signaling	   (177),	   our	   previous	   data	   on	   neuronal	   cells	   indicated	   a	   correlation	  between	  decreased	  HIF-­‐1α	   stabilization	  and	  rapamycin	  exposure.	   In	  astrocytes	  16	   hours	   oxygen	   deprivation	   also	   stabilized	  HIF-­‐1α,	   while	   glucose	  withdrawal	  did	   not	   add	   to	   the	   accumulation	   of	   the	  HIF-­‐1α	   subunit	   (Fig.	   6A).	   Interestingly,	  rapamycin	   treatment	   caused	   an	   attenuation	   of	   HIF-­‐1α	   levels	   (Fig.	   6A).	   Similar	  results	  were	  obtained	  even	  after	  prolonged	  (36h)	  exposure	  although	  total	  levels	  of	  HIF-­‐1α	  were	  reduced	  compared	  to	  16	  hours	  exposure,	  which	  probably	  reflects	  the	  transient	  nature	  of	  HIF-­‐1	  induction	  during	  periods	  of	  O2	  scarcity	  (Fig.	  6A&B).	  Overall,	  we	  provide	  strong	  evidence	  that	  crosstalk	  between	  the	  mTORC1	  cascade	  and	  the	  hypoxic	  response	  regulator	  in	  O2-­‐deprived	  primary	  astrocytes	  occurs.	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Fig.	   6	   Rapamycin	   reduces	   HIF-­‐1α	   stabilization	   during	   oxygen	   deprivation.	  Representative	  Western	   blot	   analysis	   of	   n=3	   independent	   experiments	   shows	   HIF-­‐1α	  levels	  after	  16	   	  (Fig	  6A)	  and	  36	  (Fig	  6B)	  hours	  exposure	  to	  oxygen	  deprivation	  and	  10	  nM	  rapamycin.	  β-­‐actin	  was	  used	  as	  loading	  control.	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7.2.6 	  4E-­‐BP1	  is	  the	  major	  player	  in	  the	  astrocytic	  response	  to	  severe	  stress	  Interestingly,	   in	   primary	   astrocytes	   grown	   in	   vitro	   4E-­‐BP1	   protein	   level	  expression	  clearly	  dominated	  over	  abundance	  of	  4E-­‐BP2	  and	  showed	  sensitivity	  towards	  changes	   in	   the	  supply	  of	  oxygen	  and	  glucose	  (Fig.	  7).	  As	  noted	  before,	  4E-­‐BP1	  was	  completely	  dephosphorylated	  during	   ischemia	   (α	  band),	  while	  4E-­‐BP2	   was	   refractory	   to	   it.	   Moreover,	   rapamycin	   treatment	   reduced	  phosphorylation	  of	  4E-­‐BP1	  (γ,	  β,	  α	  bands)	  but	  not	  of	  4E-­‐BP2.	  In	  section	  7.4.2	  we	  show	   that	   4E-­‐BP2	   is	   the	   isoform	   preferentially	   expressed	   in	   neuronal	   cells,	  although	   we	   could	   not	   detect	   any	   O2-­‐responsive	   regulation	   of	   this	   binding	  protein	   under	   our	   conditions.	   These	   data	   indicate	   that	   4E-­‐BP1	   is	   the	  predominant	  and	  O2/glucose-­‐sensitive	  isoform	  in	  primary	  astrocytes.	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Fig.	   7	   4E-­‐BP1	   is	   the	   major	   player	   in	   the	   astrocytic	   response	   to	   severe	   stress.	  Representative	  Western	  blot	   analyses	  of	  n=2	   independent	   experiments	   reveals	   that	   in	  astrocytes	   4E-­‐BP1	   is	   more	   expressed	   than	   4E-­‐BP2	   and	   is	   regulated	   in	   O2/glucose-­‐sensitive	  manner.	  β-­‐actin	  was	  used	  as	  loading	  control.	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7.3 DISCUSSION	  ON	  ASTROCYTIC	  RESULTS	  Astrocytic	  cells	  are	  capable	  of	  withstanding	  hypoxic	  and	  ischemic	  injury	  for	  long	  periods	   of	   time	   (178).	   Hypoxic	   and	   ischemic	   insults	   stimulate	   proliferation	   of	  resident	  astrocytes	  in	  vivo	  (26,	  40,	  179),	  a	  process	  called	  astrogliosis.	  Although	  it	  was	   shown	   that	   VEGF	   signaling	   plays	   an	   important	   role	   in	   astrocytic	  proliferation	   and	   resistance	   to	   oxygen	   and	   glucose	   deprivation	   in	   vitro	   (23),	  additional	   mechanisms	   endowing	   astrocytes	   with	   this	   remarkable	   degree	   of	  stress	  tolerance	  and	   its	  overall	  meaning	   for	   the	  highly	  susceptible	  neurons	  still	  need	   to	   be	   fully	   elucidated.	   mTORC1	   has	   been	   shown	   to	   orchestrate	   energy	  requiring	  synthetic	  and	  proliferative	  responses	  with	  ambient	  oxygen	  deprivation	  in	   different	   human	   cancer	   cells	   (93)	   and	   to	   play	   a	   role	   in	   astrocytic	   activation	  during	   CNS	   injury	   (180).	   Inhibition	   of	   mTORC1	   in	   developing	   rat	   brain	   is	  associated	  with	   decreased	   accumulation	   of	   HIF-­‐1α	   (76),	   the	  main	   regulator	   of	  cellular	   adaptation	   to	   oxygen	   deprivation.	   Here	   we	   show	   that	   in	   primary	  astrocytes	   ischemic	   conditions,	   but	   not	   oxygen	   deprivation	   alone,	   are	   able	   to	  suppress	  mTORC1	  activity	  and	  that	  inhibition	  via	  rapamycin	  treatment	  reduces	  HIF-­‐1α	   levels.	   Yet,	   rapamycin	   treatment,	   although	   it	   moderately	   inhibits	   cap-­‐dependent	   translation,	   does	   not	   affect	   protein	   synthesis	   rate	   and	   ATP	   steady	  state.	  It	   was	   already	   described	   in	   cancer	   cells	   that	   rapamycin	   mediated	   mTORC1	  inhibition	  evokes	  differential	   sensitivity	   towards	   the	  4E-­‐BP1	  and	  S6K1	  effector	  (175,	   181,	   182).	   For	   primary	   astrocytes	  we	   observed	   a	   similar	   discrepancy	   in	  susceptibility	   thresholds	   of	   mTORC1	   signaling.	   Although	   ischemia	   completely	  dephosphorylated	   4E-­‐BP1	   and	   S6K1,	   rapamycin	   treatment	   abolished	   S6K1	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phosphorylation	   while	   it	   only	   partially	   affected	   the	   phospho-­‐status	   of	   4E-­‐BP1	  independently	  of	  time	  exposure.	  In	  bladder	  cancer	  cells	  rapamycin-­‐driven	  S6K1	  dephosphorylation	   triggered	   the	   loss	   of	   a	   negative	   feedback	   loop	   exerted	   by	  phosphorylated	  S6K1	  onto	  IRS1,	  which	  eventually	  yield	  a	  pronounced	  activatory	  phosphorylation	   of	   AKT	   (175).	   In	   agreement	   with	   this,	   astrocytic	   AKT	   was	  activated	   by	   prolonged	   rapamycin	   treatment.	   Since	   other	   groups	   have	   shown	  that	   AKT	   can	   directly	   mediate	   4E-­‐BP1	   phosphorylation	   in	   cancer	   and	   human	  embryonic	   kidney	   cells	   (136,	   144),	   we	   speculate	   that	   this	   kinase	   might	  contribute	  to	  the	  sustained	  inactivation	  (phosphorylation)	  of	  the	  binding	  protein	  	  during	  rapamycin	  treatment.	  Although	  we	  have	  also	  shown	  analogous	  sensitivity	  of	  4E-­‐BP1	  and	  S6K1	  to	  rapamycin	   treatment	   in	  primary	  neurons,	   in	   these	  cells	  AKT	  activity	  was	  not	  affected	  by	  drug	  treatment,	  thus	  indicating	  cell	  specificity	  of	  the	  S6K1-­‐feedback	  loop	  and	  its	  disruption	  by	  rapamycin.	  It	  was	  recently	  shown	  in	  HeLa	  cells	  that	   inhibition	  of	  mRNA	  translation	  via	  4E-­‐BP1	   dephosphorylation	   occurs	   during	   prolonged	   oxygen	   deprivation	   as	   the	  second	  stage	  of	  a	  biphasic	  process	  that,	  in	  the	  first	  instance,	  is	  regulated	  by	  very 
fast phosphorylation of eIF2α (83).	  However, our preliminary data in astrocytic cells 
indicate that phosphorylation of eIF2α occurs in parallel to 4E-BP1 
dephosphorylation, similar to our observations in primary neurons (see section 7.4.4 
and 7.5). These data suggest a differential kinetic of the mechanisms controlling 
mRNA translation in normal versus tumor cells and highlight distinct regulation of 
the mTORC1 signaling cascade in cells of different origin.	  During	  stress	  conditions	  cancer	  cells	  effectively	  inhibit	  mTORC1	  to	  foster	  4E-­‐BP1	  hypo-­‐phosphorylation,	   which	   is	   known	   to	   contribute	   to	   the	   inhibition	   of	   cap-­‐dependent	   translation,	   the	   reduction	   of	   ATP	   consumption	   and	   to	   improve	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survival	   of	   cells	   (47,	   149).	   Similarly,	   in	   ischemic	   primary	   astrocytes	   hypo-­‐phosphorylation	  of	  4E-­‐BP1	  prevented	  the	  interaction	  of	  eIF4E	  with	  eIF4G	  within	  eIF4F	  complex	  as	  observed	  in	  HeLa	  cells	  (83).	  However,	  short-­‐term	  inhibition	  of	  cap-­‐translation	   during	   oxygen	   and	   glucose	   deprivation	   through	  dephosphorylated	   4E-­‐BP1	   did	   not	   further	   inhibit	   overall	   protein	   synthesis	  compared	   to	   anoxia,	   where	   hyper-­‐phosphorylated	   4E-­‐BP1	   prevails.	   Extended	  period	   of	   oxygen	   deprivation	   caused	   an	   overall	   decrease	   of	   protein	   synthesis	  rate	   compared	   to	   shorter	   exposure,	   although	   4E-­‐BP1	   phosphorylation	   did	   not	  change.	  Moreover,	  prolonged	  ischemia	  showed	  a	  trend	  to	  further	  reduce	  overall	  mRNA	  translation	  compared	  to	  anoxic	  condition.	  These	  results,	  suggest	  that	  4E-­‐BP1	   dephosphorylation	   has	   no	   impact	   on	   global	   protein	   synthesis	   rate	   during	  shorter	  exposure	  to	  severe	  stress	  conditions	  while	  it	  still	  may	  inhibit	  translation	  of	   capped	   mRNAs	   during	   prolonged	   ischemia.	   Studies	   on	   the	   role	   of	   4E-­‐BP1	  phosphorylation	  with	   respect	   to	   the	   regulation	   of	   global	   protein	   synthesis	   are	  controversial.	  While	  the	  state	  of	  4E-­‐BP1	  phosphorylation	  does	  not	  seem	  to	  have	  an	  effect	  on	  overall	  mRNA	  translation	   in	   isolated	  rat	  hepatocytes	   (183),	  on	   the	  other	  hand,	  Connolly	  and	  colleagues	  reported	  that	  4E-­‐BP1	  in	  breast	  cancer	  cells	  partially	  regulates	  global	  translation	  during	  hypoxia	  (176).	  Therefore,	  the	  impact	  of	  dephosphorylated	  4E-­‐BP1	  on	  overall	  protein	  synthesis	  and	  ATP	  steady	  state	  appears	  to	  hinge	  on	  the	  background	  of	  the	  cells	  (normal	  vs	  transformed)	  and/or	  the	   severity	   and	   duration	   of	   stress.	   Clearly,	   this	   issue	   should	   be	   further	  investigated.	  Inhibition	   of	   mRNA	   translation	   is	   part	   of	   a	   cellular	   strategy	   to	   coordinately	  decrease	   energy	   consumption	   along	   with	   the	   reduced	   ATP	   production	   of	   O2-­‐deprived	  cells	   in	  a	   controlled	  and	   fully	   reversible	  manner.	  The	  newly	  balanced	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ATP	  steady	  state,	  termed	  hypometabolism,	  prevents	  lethal	  falls	  in	  cellular	  energy	  levels	  and	  is	  the	  single	  most	  protective	  and	  unifying	  feature	  of	  hypoxia	  tolerant	  tissues	  (47).	  Indeed,	  ATP	  levels	  were	  not	  affected	  by	  oxygen	  deprivation	  alone	  or	  rapamycin	   treatment	   indicating	   that	   the	   degree	   of	   protein	   synthesis	   rate	  reduction	  was	  adequate	  to	  preserve	  ATP	  levels.	  However,	  ischemia,	  particularly	  prolonged	   exposure,	   caused	   a	  massive	   depletion	   of	   cellular	   ATP	  while	   protein	  synthesis	   rate	   was	   maximally	   suppressed	   (to	   5%	   of	   normoxic	   controls),	   thus	  revealing	   the	   inability	  of	   the	  cell	   to	  prevent	  energetic	  depletion	  under	  extreme	  circumstances.	   Since	   ATP	   production	   mainly	   occurs	   via	   oxidative	  phosphorylation	   within	   the	   inner	   membrane	   of	   the	   mitochondrion,	   we	  investigated	  generic	  enzymatic	  activities	  in	  mitochondria	  using	  the	  MTT	  assay	  in	  response	   to	   various	   degrees	   of	   stress.	   Although	   extra-­‐mitochondrial	   redox	  reactions	   (i.e.	   cytosolic	   enzymes)	   have	   been	   suggested	   by	   some	   to	   function	   as	  major	  MTT	   reductase	   systems	  even	   in	   rat	   astroglia	   cells	   (184),	   the	  majority	  of	  publications	   report	   evidence	   for	  mitochondrial	   (succinate)	   dehydrogenases,	   in	  brain	  and	  other	  cells,	  to	  be	  responsible	  for	  the	  reduction	  of	  MTT-­‐like	  tetrazolium	  substrates	   to	   the	   corresponding	  water-­‐insoluble	   formazan	   product	   (185,	   186).	  Contrary	   to	   the	   findings	   of	   the	   Takahashi	   study	   (184),	   we	   too	   observed	   that	  normoxic,	  hypoxic	  or	  anoxic	  cultures	  of	  astrocytes	   in	  glucose-­‐deficient	  medium	  did	   not	   alter	   their	   MTT	   conversion,	   as	   one	   might	   expect	   if	   glycolytic	   redox	  reactions	  would	  account	  for	  the	  turnover	  of	  the	  tetrazolium	  compounds.	  Rather,	  glucose-­‐deprived	  cells,	  relative	  to	  glucose	  proficient	  ones,	  displayed	  a	  moderate	  and	   O2-­‐independent	   decline	   in	   the	   conversion	   rate	   of	   MTT	   over	   time.	   Such	  cellular	   response	   would	   agree	   with	   the	   assumption	   that	   mitochondrial	   redox	  centers,	  whose	  electron	  transport	  is	  not	  (yet)	  limited	  by	  oxygen,	  are	  underlying	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the	   reduction	   of	   tetrazolium	   dyes	   in	   astrocytes	   as	   well.	   However,	   this	  interpretation	   cannot	   explain	   the	  poor	   coupling	  between	  ATP	   steady	   state	   and	  MTT	   conversion	   data,	   especially	   at	   the	   36h	   time	   point.	  While	  MTT	   conversion	  might	  well	  occur	  through	  mitochondrial	  enzymes,	  the	  fact	  that	  their	  activity	  does	  not	  seem	  to	  be	  linked	  to	  ATP	  production	  is	  a	  somewhat	  puzzling	  finding.	  	  Despite	  these	  open	  questions,	  a	  recent	  study	  from	  Liu	  et	  al	  confirmed	  our	  results	  by	  demonstrating	  that	  in	  primary	  astrocytes	  ischemia	  induced	  ATP	  release	  (187)	  suggesting	   that	   this	   mechanism	   could	   also	   affect	   ATP	   levels	   and	   might	   only	  worsen	  energetic	  state	  of	  the	  cells.	  Astrocytic	   responses	   to	   oxygen	   deprivation	   involve	   stabilization	   and	  accumulation	  of	  HIF-­‐1α	  in	  response	  to	  very	  low	  tensions	  of	  oxygen	  (23).	  Here	  we	  show	   that	   rapamycin-­‐dependent	   mTORC1	   inhibition	   yields	   a	   weaker	  accumulation	  of	  HIF-­‐1α	  during	  hypoxic	  or	  anoxic	  challenges	   in	  agreement	  with	  previous	   studies	   on	   cancer	   cells	   (188–190)	   and	   with	   our	   own	   results	   on	  neuronal	   cells	   (see	   section	   7.4.7).	   Moreover,	   we	   observed	   an	   attenuated	  induction	  of	  HIF-­‐1α	  after	  prolonged	  exposure	   to	  oxygen	  deprivation	   compared	  to	  shorter	   incubation	   times	  (36h	  versus	  16h),	  which	  agrees	  well	  with	  previous	  results	   on	   the	   transient	   induction	   of	   HIF-­‐1α	   (peak	   induction	   after	   4	   hrs;	  weakening	   induction	   after	   12	   hrs)	   in	   O2-­‐deprived	   human	   lung	   epithelial	   cells	  (72)	  as	  well	  as	  among	  different	  organs	  (191).	  These	  data,	  therefore,	  indicate	  that	  under	  our	  conditions	  mTORC1-­‐mediated	  translation	  of	  HIF-­‐1α	  contributes	  to	  the	  stabilization	  and	  accumulation	  of	  this	  subunit	  in	  hypoxic	  glia	  cells.	  Although	   4E-­‐BP1	   is	   the	   best	   known	   isoform	   of	   the	   4E-­‐BP	   family,	   4E-­‐BP2	   is	  preferentially	   expressed	   in	   the	   brain	   (138,	   139).	  We	   show	   that	   4E-­‐BP1	   is	   the	  most	  abundant	  isoform	  in	  astrocytic	  cells,	  in	  agreement	  with	  previous	  data	  from	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Roffé	   et	   al.	   (192)	   and	   contrary	   to	   our	   results	   on	  neuronal	   cells,	  where	  4E-­‐BP2	  was	  preferentially	  expressed	  (see	  section	  7.4.2).	  Moreover,	  contrary	  to	  4E-­‐BP1,	  astrocytic	   4E-­‐BP2	   did	   not	   undergo	   detectable	   changes,	   highlighting	   4E-­‐BP1	   as	  the	  isoform	  responsible	  for	  astrocytic	  responses	  under	  our	  conditions.	  In	   conclusion,	  mTORC1	   inhibition	   does	   not	   affect	   overall	  mRNA	   translation	   or	  ATP	   steady	   state	   during	   short-­‐term	   ischemia.	   Despite	   complete	   oxygen	   and	  glucose	   deprivation–mediated	   dephosphorylation	   of	   4E-­‐BP1	   and	   S6K1,	   global	  protein	  synthesis	  rates	  were	  not	   further	   inhibited	  and	  ATP	  depletion	  could	  not	  be	  rescued	  by	  rapamycin	  treatment.	  In	  addition,	  while	  inhibition	  of	  mTORC1	  was	  persistent	  during	  prolonged	  ischemia,	  global	  proteins	  synthesis	  showed	  a	  trend	  to	  decrease,	  which	  anyway	  was	  inadequate	  to	  prevent	  the	  massive	  ATP	  depletion	  under	   such	   extreme	   stress	   conditions.	   The	   reduced	   HIF-­‐1α	   accumulation	   in	  hypoxic/anoxic	   glia	   cells	   subjected	   to	   rapamycin	   suggests	   that	   mTORC1	  inhibition	  may	  indirectly	  alter,	  if	  not	  restrict,	  the	  regulation	  of	  the	  transcriptional	  machinery,	  and	  through	  that,	  the	  adaptation	  of	  astrocytes	  to	  falling	  levels	  of	  O2.	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7.4 NEURONAL	  RESPONSE	  TO	  ACUTE	  (16	  HOURS)	  AND	  PROLONGED	  (36	  
HOURS)	  OXYGEN	  DEPRIVATION	  
7.4.1 	  Rapamycin	  improves	  neuronal	  survival	  during	  prolonged	  oxygen	  
deprivation	  	  We	   investigated	   oxygen	   deprivation-­‐mediated	   neuronal	   cytotoxicity	   by	   LDH	  assay	   (Fig.	   1).	   Although	  16	  hours	   of	  mild	   oxygen	  deprivation	   (16h	  Hx,	   1%	  O2)	  hardly	  diminished	  cell	  viability,	  prolonged	  hypoxia	  (36h	  Hx)	  severely	  increased	  cytotoxicity	   to	   virtually	   100%	   (P<0.0001).	   To	   investigate	   modulation	   of	  mTORC1/4E-­‐BP1	   signaling	   in	   neurons	   challenged	  with	   oxygen	   deprivation	  we	  inhibited	  mTORC1	  directly	  via	  treatment	  with	  non-­‐toxic	  doses	  of	  rapamycin.	  10	  nM	  of	  drug	  exposure	  moderately	   increased	   cell	  death	   to	  almost	  12%	  (P<0.01),	  but	   only	   when	   cells	   were	   exposed	   to	   16	   hours	   near-­‐anoxia	   (Ax,	   0.2%	   O2).	  Interestingly,	   however,	   rapamycin	   significantly	   reduced	   hypoxic	   cytotoxicity	  during	   prolonged	   (36h)	   exposure	   (Fig.	   1B),	   in	   agreement	   with	   a	   recent	   study	  showing	  beneficial	   effect	  of	   the	  drug	   following	  oxygen	  and	  glucose	  deprivation	  (193).	   These	  data	   suggest	   that	   active	  mTORC1	   signaling	   contributes	   to	   sustain	  survival	   of	   neurons	   during	   moderate	   or	   short-­‐term	   oxygen	   scarcity,	   while	  inhibition	   of	   mTORC1	   may	   be	   pivotal	   for	   protection	   from	   detrimental	   effects	  during	  prolonged	  hypoxia.	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Fig.	   1	   Rapamycin	   improves	   neuronal	   survival	   during	   prolonged	   oxygen	  
deprivation.	   Increased	   release	   of	   LDH	   indicates	   an	   increase	   in	   neuronal	   cell	   death	  under	  prolonged	  oxygen	  deprivation.	  After	  36h	  exposure,	  there	  was	  a	  reduction	  of	  LDH	  release	   following	   10	   nM	   rapamycin	   treatment	   in	   line	   with	   a	   decrease	   in	   hypoxic	  cytotoxicity.	  Values	  are	  means	  ±	  SD	  (n=9).	  **p<0.01,	  ****p<0.0001	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7.4.2 	  4E-­‐BP2	  is	  the	  most	  abundant	  species	  in	  neuronal	  cells	  but	  changes	  in	  
regulation	  are	  not	  detectable	  	  Three	   paralogous	   genes	   encode	   for	   the	  members	   of	   the	   eIF4E-­‐binding	   protein	  family:	  4E-­‐BP1,	  4E-­‐BP2	  and	  4E-­‐BP3	  (132).	  While	  the	  role	  and	  regulation	  of	  4E-­‐BP3	  still	  needs	   to	  be	  elucidated,	  4E-­‐BP2	  was	  shown	   to	  predominantly	   regulate	  eIF4F	  in	  the	  brain	  (138).	  Hence,	  we	  examined	  4E-­‐BP2	  versus	  4E-­‐BP1	  abundance	  and	   regulation	   in	   neuronal	   response	   by	   immunoblot	   analysis	   (Fig.	   2).	   In	  agreement	  with	   previous	   reports,	   4E-­‐BP2	  was	   far	  more	   abundantly	   expressed	  than	  4E-­‐BP1	  in	  primary	  neurons,	  yet	  failed	  to	  show	  at	  protein	  level	  any	  response	  to	   oxygen	   deprivation	   or	   10	   nM	   rapamycin	   exposure.	   These	   data	   demonstrate	  that	  4E-­‐BP2	  is	  the	  isoform	  preferentially	  expressed	  in	  primary	  neurons.	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Fig.	   2	   4E-­‐BP2	   is	   the	   most	   abundant	   species	   in	   neuronal	   cells	   but	   changes	   in	  
regulation	   are	   not	   detectable.	   Representative	   Western	   blot	   analysis	   of	   n=3	  independent	  experiments	   shows	   that	  4E-­‐BP2	   is	  more	   strongly	  expressed	   than	  4E-­‐BP1	  but	   lacks	   at	   protein	   level	   any	   sensitivity	   to	   changes	   in	   O2	   supply	   or	   rapamycin	  application.	  β-­‐actin	  was	  used	  as	  loading	  control.	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7.4.3 Rapamycin	  treatment	  partially	  inhibits	  4E-­‐BP1	  phosphorylation	  and	  
completely	  dephosphorylates	  S6K1	  Activity	  of	   the	  mTORC1	  complex	  controls	  cap-­‐	  and	  TOP-­‐dependent	  translations	  via	  direct	  phosphorylation	  of	  4E-­‐BP1	  and	  S6K1,	  respectively,	  a	  phosphorylation	  cascade	   that	   is	   inhibited	   by	   rapamycin.	   To	   study	   changes	   in	   4E-­‐BP1	  phosphorylation,	   we	   performed	   immunoblot	   analysis	   (Fig.	   3A).	   Unlike	  observations	   in	   astrocytes	   (see	   sections	   7.1.1	   and	   7.2.1)	   4E-­‐BP1	   was	   already	  partially	  hypo-­‐phosphorylated	  (γ,	  β	  and	  α	  band)	  even	  under	  normoxic	  conditions	  and	   refractory	   in	   its	   phosphorylation	   status	   to	   16	   or	   36	   hours	   of	   hypoxic	  challenge.	   Surprisingly	   severe	   oxygen	   deprivation	   (Ax)	   and	   10	   nM	   rapamycin	  treatment	  only	  partially	  inhibited	  4E-­‐BP1	  phosphorylation	  (γ,	  β	  and	  α	  band).	  In	  contrast,	   16	   hours	   of	   near-­‐anoxia	   and	   rapamycin	   treatment	   decreased	   total	  levels	   of	   S6K1	   to	   70%	   (P<0.001	   and	   P<0.01,	   respectively)	   of	   normoxia	   (Fig.	  3A&B),	   although	   this	   negative	   impact	   on	   S6K1	   levels	  was	   not	   seen	   in	   hypoxic	  exposure	  and	  prolonged	  (36h)	  drug	  treatment.	  S6K1	  phosphorylation	  showed	  a	  trend	   to	   further	   decrease	   under	   near-­‐anoxia	   (Fig.	   3A&C)	   while	   rapamycin	  treatment	   completely	  abrogated	   it	   independently	  of	   time	  exposure	  and	  oxygen	  deprivation.	   These	   data	   indicate	   differential	   sensitivity	   of	   the	   phosphorylated	  status	  of	  4E-­‐BP1	  and	  S6K1	  to	  mTORC1	  inhibition.	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Fig.	  3	  Rapamycin	  treatment	  partially	  inhibits	  4E-­‐BP1	  phosphorylation	  and	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phosphorylation	  states	  of	  4E-­‐BP1	  (γ,	  β	  and	  α	  bands).	  β-­‐actin	  was	  used	  as	  loading	  control.	  Protein	  levels	  were	  quantified	  by	  densitometry,	  graphs	  represent	  ratio	  of	  S6K1/β-­‐actin	  B)	  and	  p-­‐S6K1/S6K1	  C).	  Values	  are	  means	  ±	  SD	  (n≥3).	  **p<0.01,	  ***p<0.001,	  ****p<0.0001	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7.4.4 	  Rapamycin	  treatment	  does	  not	  affect	  AKT	  signaling	  and	  moderately	  
increases	  eIF2α	  phosphorylation.	  Our	  results	  in	  primary	  astrocytes	  showed	  that	  rapamycin	  treatment	  completely	  inhibited	  S6K1	  phosphorylation	  although	  it	  only	  marginally	  affected	  4E-­‐BP1	  (see	  sections	   7.1.1	   and	   7.2.1).	   In	   glia	   cells	   drug	   treatment	   and	   S6K1	  dephosphorylation	  yielded	   the	   loss	  of	  a	  negative	   feedback	   loop,	   thus	  activating	  AKT,	  which,	   kept	   4E-­‐BP1	   in	   a	   partially	   hypo-­‐phosphorylated	   state.	   In	   neurons	  total	  and	  phosphorylated	  AKT	  levels	  were	  non-­‐responsive	  to	  oxygen	  deprivation	  or	   rapamycin	   treatment	   (Fig.	   4A).	   Therefore,	   AKT	   activity	   is	   not	   modulated	  under	  the	  chosen	  conditions.	  eIF2α	   is	   another	   player	   of	   the	   cap-­‐dependent	   translation,	   important	   for	   the	  assembly	   of	   the	   43S	   pre-­‐initiation	   complex	   (194).	   While	   total	   and	  phosphorylated	  levels	  of	  eIF2α	  did	  not	  change	  during	  either	  oxygen	  deprivation	  or	   rapamycin	   treatment	   alone	   (Fig.	   4A&B),	   the	   phosphorylation	   of	   eIF2α	  significantly	   increased	   by	   almost	   38%	   (P<0.05)	   upon	   exposure	   to	   combined	  near-­‐anoxic	  and	  drug-­‐presenting	  cultivation	  of	  primary	  neurons.	  Although	  eIF2α	  phosphorylation	  is	  not	  altered	  through	  any	  of	  our	  oxygen	  deprivation	  schemes,	  phosphorylation	   of	   this	   initiation	   factor	   is	   elevated	   in	   response	   to	   rapamycin	  treatment	  during	  severe	  stress	  conditions.	  	  




Fig.	   4	   Rapamycin	   treatment	   does	   not	   affect	   AKT	   regulation	   but	   moderately	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7.4.5 Rapamycin-­‐dependent	  4E-­‐BP1	  hypo-­‐phosphorylation	  does	  not	  affect	  
protein	  synthesis	  rate	  or	  cap-­‐dependent	  translation	  Since	   mTORC1	   regulation	   of	   4E-­‐BP1	   and	   S6K1	   pathway	   ultimately	   modulates	  global	  mRNA	  translation,	  we	  analyzed	  overall	  protein	  synthesis	   rate	  under	  our	  experimental	   conditions	   (Fig.	   5A).	   For	   a	   better	   understanding	   of	   the	  mechanisms,	  we	  included	  36	  hours	  near-­‐anoxia	  exposures	  to	  challenge	  the	  cells	  with	  a	  more	  severe	  stress.	  Compared	  to	  normoxic	  controls,	  hypoxia	  surprisingly	  did	   not	   attenuate	   global	   mRNA	   translation,	   while	   16	   hours	   severe	   oxygen	  deprivation	   (Ax)	   decreased	   it	   to	   60.4%±18.8	   (P<0.01).	   As	   expected,	   prolonged	  Ax	  exposure	  	  (36	  hours)	  further	  reduced	  it	  to	  48.2%±22.1	  (P<0.01)	  of	  the	  control	  (Fig.	  6A).	  Moreover,	  10	  nM	  rapamycin	  treatment	  did	  not	  alter	  the	  rate	  of	  protein	  synthesis	  beyond	   the	  degree	  of	   inhibition	  by	  O2-­‐deficiency.	  These	  data	   suggest	  that	  incomplete	  4E-­‐BP1	  hypo-­‐phosphorylation,	  as	  demonstrated	  for	  a	  16h	  Ax	  or	  rapamycin	  challenge	  (Fig.	  3A),	  is	  not	  sufficient	  to	  modify	  total	  mRNA	  translation	  in	  primary	  neurons.	  Since	  4E-­‐BP1	  is	  usually	  regarded	  as	  direct	  modulator	  of	  cap-­‐dependent	  translation,	  we	  investigated	  its	  ability	  to	  interact	  with	  eIF4E	  using	  an	  
in	  vitro	   cap-­‐capture	   assay	   (Fig.	   6B).	   4E-­‐BP1	   phosphorylation	   of	   Thr46	   triggers	  the	  phosphorylation	  cascade	  that	  results	  in	  its	  release	  from	  eIF4E	  (137).	  Hence	  we	  used	  non-­‐phospho-­‐4E-­‐BP1	  (Thr46)	  antibody	  to	  specifically	  detect	  the	  active	  species	   that	   bind	   eIF4E.	   Interestingly,	   4E-­‐BP1	   interaction	  with	   eIF4E	   occurred	  even	   under	   non-­‐stress	   conditions	   (36hNx),	   while	   16	   and	   36	   hours	   hypoxia	  actually	   decreased	   the	   association	   (Fig.	   6B;	   lanes	   36hNx	   versus	   16hHx,	   36hHx	  and	   36hAx).	  Moreover,	   16	   hours	   near-­‐anoxia	   and	   rapamycin	   exposure	   did	   not	  affect	   the	   interaction	   of	   4E-­‐BP1	  with	   eIF4E	   compared	   to	   the	   normoxic	   control	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(Fig.	  6B;	   lanes	  36hNx	  versus	  16hAx	  and	  36hNx+Rapamycin).	  Since	  near-­‐anoxic	  condition	  and	  drug	  treatment	  partially	  hypo-­‐phosphorylated	  4E-­‐BP1	  (Fig.	  2A;	  α	  band),	   these	  data	   indicate	   that	  4E-­‐BP1/eIF4E	  binding	   is	  not	  directly	  correlated	  with	   levels	   of	   4E-­‐BP1	   phosphorylation.	   In	   neurons,	   the	   rate	   of	   cap-­‐dependent	  translation	  appears	  to	  primarily	  depend	  on	  the	  assembly	  of	  eIF4E	  with	  eIF4G	  to	  initiate	   the	   eIF4F	   complex.	   This	   interaction,	   although	   refractory	   to	   16	   hours	  hypoxic	   or	   rapamycin	   exposure	   	   (Fig.	   6B;	   lanes	   36hNx	   versus	   16hHx	   and	  16hNx+Rapamycin),	  was	  clearly	  and	  sensitively	  antagonized	  by	  16	  hours	  anoxia	  and	   36	   hours	   of	   hypoxic	   or	   anoxic	   oxygen	   deprivation.	   These	   results	   indicate	  that	   primary	   neurons	   facing	   chronic	   hypoxic	   or	   anoxic	   stresses	   regulate	   the	  initiation	  of	   cap-­‐dependent	  protein	   synthesis	  most	   probably	   via	   the	  binding	  of	  eIF4E	  with	  eIF4G,	  and	  rather	  not	  via	  eIF4E	  scavenging	  by	  4E-­‐BP1.	  































Fig.	   5	   Rapamycin-­‐dependent	   4E-­‐BP1	   hypo-­‐phosphorylation	   does	   not	   affect	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7.4.6 	  Rapamycin	  treatment	  does	  not	  alter	  ATP	  levels	  or	  mitochondrial	  activity	  	  We	  analyzed	  steady	  state	  levels	  of	  cellular	  energy	  by	  ATP	  bioluminescence	  assay,	  to	   assess	   if	   dwindling	  protein	   synthesis	   rates	   seen	   in	   anoxic	   neurons	   (Fig.	   6A)	  might	  aid	  in	  steading	  ATP	  levels	  during	  periods	  of	  O2	  scarcity.	  16	  hours	  hypoxic	  exposure	  and	   rapamycin	   treatment	  hardly	  affected	   the	  ATP	  steady	   state,	  while	  anoxic	  conditions	  reduced	  ATP	  to	  62.2%±18.7	  (P<0.01)	  of	  the	  control	  (Fig.	  6A).	  Unexpectedly,	   during	   prolonged	   oxygen	   deprivation	   and	   drug	   treatment	   ATP	  levels	  were	  more	  or	   less	   stable	   (Fig.	   6A).	  We	   currently	   cannot	   explain	  why	  36	  hours	   of	   rapamycin-­‐treated	   normoxic	   neuronal	   cells	   displayed	   a,	   though	  variable,	  measurable	  increase	  in	  ATP	  levels.	  Since	   ATP	   is	   mainly	   produced	   through	   oxidative	   phosphorylation	   in	  mitochondria,	   we	   investigated	   neuronal	   mitochondrial	   activity	   by	   using	   MTT	  assays.	   While	   16	   h	   hypoxia	   was,	   surprisingly	   enough,	   insufficient	   to	   trigger	   a	  significant	   fall	   in	  oxidative	  enzymatic	  activities,	  16h	  anoxia	  reduced,	   relative	   to	  control	  values,	  MTT	  turnover	  by	  30%	  (P<0.01).	  Beyond	  this	  O2-­‐dependent	  MTT	  activity,	  rapamycin	  application	  did	  not	  add	  any	  further	  impact	  on	  the	  substrate	  turnover	   by	   mitochondria	   (Fig.	   6B).	   However,	   prolonged	   hypoxic	   and	   anoxic	  exposure	  inhibited	  mitochondrial	  activity	  by	  30%	  (P<0.01)	  and	  55%	  (P<0.0001),	  respectively	  (Fig.	  6B).	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Fig.	   6	   Energy	   levels	   and	   mitochondrial	   activity	   decrease	   during	   severe	   oxygen	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7.4.7 	  Rapamycin	  decreases	  HIF-­‐1α	  stabilization	  during	  prolonged	  mild	  oxygen	  
deprivation	  	  Since	   recent	   studies	   indicate	   a	   direct	   control	   of	   HIF-­‐1α	   expression	   by	   the	  mTORC1/4E-­‐BP1	   pathway	   in	   transformed	   cells	   (188)	   we	   hypothesized	   that	  rapamycin	  treatment	  may	  similarly	  modulate	  neuronal	  HIF-­‐1α	  .	  As	  expected,	  Hif-­‐1α	  was	  detectably	  stabilized	  during	  mild	  and	  severe	  oxygen	  deprivation	  (Fig.	  7).	  Rapamycin	   treatment	   reduced	   HIF-­‐1α	   levels	   under	   prolonged	   (36	   hours)	  hypoxia	   (Fig.	   7).	   These	   data	   suggest	   that	   in	   primary	   neuronal	   cells	   HIF-­‐1α	  accumulation	  may	  positively	  correlates	  with	  mTORC1	  signaling	  during	  extended	  oxygen	  deprivation.	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Fig.	   7	   Rapamycin	   decreases	   Hif-­‐1α	   stabilization	   during	   prolonged	   mild	   oxygen	  
deprivation.	   Representative	   Western	   blot	   analysis	   (n	   =6	   independent	   experiments)	  shows	   stabilization	   of	   HIF-­‐1α	   following	   oxygen	   deprivation.	   Exposure	   with	   10	   nM	  rapamycin	  decreased	  HIF-­‐1α	  levels,	  particularly	  during	  prolonged	  hypoxia.	  β-­‐actin	  was	  used	  as	  loading	  control.	  
	   85	  
7.5 DISCUSSION	  ON	  NEURONAL	  RESULTS	  Oxygen	   and/or	   substrate	   deprivation	   disturbs	   homeostasis	   of	   the	   brain	   and	  results	  in	  deleterious	  effects	  (8).	  Due	  to	  the	  brains	  high	  energy	  consumption	  and	  strict	   dependence	   on	   oxygen	   and	   glucose	   as	   biochemical	   fuel	   (1),	   hypoxic	   or	  ischemic	   insults	   have	   long	   been	   known	   to	   trigger	   neuronal	   cell	   death	   within	  minutes	   (195,	   196).	   More	   recently,	   several	   reports	   emphasized	   the	   fact	   that	  neurons	  are	  more	  sensitive	  to	  hypoxic	  insults	  than	  other	  cells	  (178,	  197).	  Yet,	  the	  mechanisms	  behind	  this	  exceptional	  sensitivity	  of	  neuronal	  cells	  still	  need	  to	  be	  fully	   elucidated.	   A	   number	   of	   in	   vitro	   and	   in	   vivo	   studies	   have	   shown	   that	  mTORC1	   signaling	  plays	   an	   important	   role	   in	  neuronal	   response	   to	  CNS	   injury	  (172,	  173,	  198,	  199)	  and	  that	  its	  activity	  correlates	  with	  HIF-­‐1α	  stabilization	  in	  developing	   rat	   brains	   (76).	   Our	   results	   are	   in	   agreement	  with	   others,	   showing	  that	   mTORC1	   inhibition	   via	   rapamycin	   treatment	   improves	   neuronal	   survival	  during	  oxygen	  deprivation	  and	  decreases	  HIF-­‐1α	  stabilization.	  However,	  as	   long	  as	  glucose	   is	  not	   limiting,	  a	  recent	  study	  found	  neurons	  to	  be	  surprisingly	  resistant	  to	  hypoxic	  injury	  even	  for	  prolonged	  periods	  (200).	  In	  line	  with	   that	   study,	   we	   also	   observed	   cytotoxicity	   to	   only	   increase	   once	   neuronal	  cells	  were	  exposed	  to	  prolonged	  hypoxia.	  Moreover,	  similar	  to	  previous	  data	  in	  an	   in	   vitro	   model	   of	   stroke	   (193),	   rapamycin	   treatment	   rescued	   neuronal	  survival,	   suggesting	   that	   sustained	   activation	   of	   mTORC1	   pathway	   in	   neurons	  during	  hypoxia	  partially	  mediates	  neuronal	  death.	  mTORC1	   is	   known	   to	   confer	   its	   signaling	   onto	   protein	   synthesis,	   and	   through	  that	   cell	   viability,	   via	   the	   phosphorylation	   targets	   S6K1	   and	   4E-­‐BP1.	   Although	  4E-­‐BP1	  is	  the	  most	  studied	  isoform	  of	  the	  4E-­‐BP	  family,	  4E-­‐BP2	  was	  shown	  to	  be	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preferentially	  expressed	   in	   the	  brain	  (138,	  139).	   In	  agreement	  with	   these	  data,	  4E-­‐BP2	  protein	  was	  also	  more	  abundant	  than	  4E-­‐BP1	  in	  primary	  neurons.	  In	  vivo	  studies	   demonstrated	   the	   critical	   role	   of	   4E-­‐BP2	   in	   synaptic	   plasticity	   and	  memory	   (139)	   and	   its	   association	   with	   autistic-­‐like	   behavior	   (140),	   thus	  suggesting	  a	  major	  role	  of	  this	  protein	  in	  modulating	  brain	  activities.	  Moreover,	  a	  recent	  report	  indicated	  a	  correlation	  between	  increased	  association	  of	  4E-­‐BP2	  to	  eIF4E	   and	   delayed	   neuronal	   death	   during	   ischemia	   reperfusion	   in	   the	  hippocampus	  (201).	  We	  could	  not	  detect	  changes	  of	  4E-­‐BP2	  protein	   in	  hypoxic	  neurons	  and	  thus	  suggest	  that	  the	  modulation	  seen	  in	  the	  study	  from	  Ayus	  et	  al.	  could	  be	  either	  due	  to	  additional	  substrate	  deprivation	  during	  ischemic	  insult	  or	  caused	   by	   reperfusion-­‐triggered	   effects	   (e.g.	   generation	   of	   reactive	   oxygen	  species,	   ROS).	   Therefore	   it	   may	   be	   possible	   that	   in	   primary	   neurons	   the	   two	  binding	  proteins	  are	  differentially	  regulated	  depending	  on	   the	  stimuli	   to	  which	  cells	  respond.	  Moreover,	  Grolleau	  et	  al	  showed	  that	  granulocytic	  differentiation	  causes	  a	  switch	  from	  4E-­‐BP1	  to	  4E-­‐BP2	  isoform	  and	  suggested	  the	  existence	  of	  specific	  genes	  whose	   translation	  may	  be	  regulated	  by	  one	  or	   the	  other	  binding	  protein	  (202).	  Synapses	  of	   in	  vitro	  neurons	  increase	  with	  culture	  time,	  showing	  morphological	   maturation	   from	   7	   DIV	   to	   20	   DIV	   (203,	   204).	   Therefore,	   it	   is	  possible	   that	  also	   in	  primary	  neurons	  4E-­‐BP1	  and	  4E-­‐BP2	  occur	  at	  different	   in	  
vitro	   differentiation	   stages.	   However,	   we	   require	   more	   studies	   for	   a	   better	  elucidation	   of	   the	   mechanisms	   undergoing	   the	   regulation	   of	   the	   two	   cap-­‐dependent	  translation	  regulators.	  It	   is	   well	   known	   that	   hypo-­‐phosphorylation	   of	   4E-­‐BP1,	   triggered	   by	   the	  inactivation	  of	  mTORC1	  during	   stressful	   environmental	   conditions,	   inhibits	   the	  initiation	  of	   cap-­‐dependent	  protein	  synthesis	   (205).	  However,	  neurons	  showed	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elevated	   basal	   levels	   of	   hypo-­‐phosphorylated	   4E-­‐BP1	   already	   during	   normal	  circumstances.	   It	   is	   tempting	   to	   speculate	   that	   these	   cells	   slow	   down	   mRNA	  translation	   initiation	   because	   of	   the	   reduced	   necessity	   of	   non-­‐dividing	   cells	   to	  produce	   proteins.	   This	   hypothesis	   was	   further	   supported	   by	   eIF2α	  phosphorylation	   data.	   Indeed,	   together	  with	   4E-­‐BP1,	   eIF2α	   is	   known	   to	   be	   an	  important	   player	   in	   cap-­‐dependent	   mRNA	   mechanisms.	   Phosphorylation	   of	  eIF2α	  inhibits	  the	  assembly	  of	  43S	  pre-­‐initiation	  complex,	  thus	  blocking	  protein	  synthesis	  in	  cancer	  (206)	  and	  normal	  cells	  (207)	  exposed	  to	  oxygen	  deprivation.	  However,	   in	  neuronal	  cells	  eIF2α	  was	  already	  phosphorylated	  during	  normoxic	  condition.	  Indeed	  reduced	  cap-­‐dependent	  protein	  synthesis	  levels	  already	  under	  normal	   circumstances	   is	   in	   agreement	   with	   the	   dogma	   that	   post-­‐mitotic	   cells	  require	  lower	  rate	  of	  protein	  synthesis	  compared	  to	  rapidly	  growing	  cells	  (208).	  Moreover,	   since	   4E-­‐BP1	   hypo-­‐phosphorylation	   only	   partially	   increased	   during	  anoxia	   and	   eIF2α	   regulation	   was	   not	   affected,	   it	   is	   probable	   that	   in	   neurons	  subjected	  to	  our	  conditions	  these	  effectors	  of	  cap-­‐dependent	  translation	  are	  not	  as	  important	  as	  in	  cancer	  cells.	  	  mTORC1	   is	   critically	   involved	   in	   tuning	   cellular	   resistance	   to	   environmental	  changes	   due	   to	   its	   role	   in	   the	   cap-­‐	   and	  TOP-­‐	   translational	   regulation.	  mTORC1	  inhibition	   via	   rapamycin	   treatment	   differentially	   affected	   4E-­‐BP1	   and	   S6K1	  regulation	  in	  various	  cancer	  cells	  and	  myoblasts	  (175,	  181,	  182).	  A	  recent	  in	  vivo	  report	   showed	   that	   reduction	   in	   the	   abundance	   of	   total	   and	   phosphorylated	  myocardial	   S6K1	   correlated	  with	   rapamycin	  administration	   (209).	   Similarly,	   in	  primary	   neurons	   rapamycin	   treatment	   reduced	   total	   levels	   and	   completely	  inhibited	   S6K1	   phosphorylation	   but	   only	   moderately	   reduced	   4E-­‐BP1	  phosphorylation.	   We	   have	   shown	   comparable	   response	   also	   in	   primary	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astrocytes	   and	   suggested	   a	   rapamycin-­‐driven	   AKT	   activation	   mechanism	   to	  sustain	   4E-­‐BP1	   phosphorylation	   (see	   section	   7.3).	   In	   agreement,	   previous	  studies	   on	   cancer	   cells	   demonstrated	   that	   prolonged	   rapamycin	   treatment	  caused	  the	  loss	  of	  the	  S6K1/IRS1	  negative	  feedback	  (210),	  which,	  in	  turn,	  yields	  AKT	   activation	   (175)	   and	   4E-­‐BP1	   phosphorylation	   (136,	   144).	   However,	  neuronal	   AKT	   activity	   was	   not	   raised	   by	   drug	   treatment,	   thus	   suggesting	   that	  other	   kinases	  may	   be	   responsible	   for	   the	   sustained	   partial	   phosphorylation	   of	  neuronal	  4E-­‐BP1	  during	  rapamycin	  exposure.	  Although	  4E-­‐BP1	  phosphorylation	  ultimately	   releases	   eIF4E,	   hence,	   resulting	   in	   active	   cap-­‐dependent	   mRNA	  translation,	   its	   binding	   with	   eIF4E	   did	   not	   directly	   correlate	   with	   its	   hypo-­‐phosphorylation	   state.	   Our	   data	   suggest	   that	   neuronal	   inhibition	   of	   cap-­‐dependent	   translation	   during	   oxygen	   deprivation	   is	   probably	  more	   dependent	  on	   decreased	   eIF4E/eIF4G	   binding	   rather	   than	   sequestration	   of	   eIF4E	   by	   4E-­‐BP1.	  However,	  since	  in	  the	  last	  decade	  other	  inhibitory	  eIF4E	  partners	  have	  been	  identified	  (211),	  other	  binding	  proteins	  (e.g.	  4E-­‐BP2,	  masked,	  Neuroguidin,	  Cup)	  may	  regulate	  cap-­‐dependent	   translation	  under	  our	  conditions.	  Nevertheless,	   so	  far	   due	   to	   lack	   of	   time	   we	   could	   not	   investigate	   alternative	   mechanisms.	  Although	  regulation	  of	  cap-­‐dependent	  protein	  synthesis	  is	  believed	  to	  be	  mainly	  regulated	  by	   inhibitory	  proteins	   (126),	   cleavage	  of	   eIF4G	  or	   shuttling	   of	   eIF4E	  (by	  eIF4E-­‐transporter;	  eIF4E-­‐T)	  was	  also	  shown	  to	  modulate	  mRNA	  translation	  inhibition.	  Cells	  infected	  by	  poliovirus	  (212)	  or	  calcivirus	  (213),	  and	  cancer	  cells	  undergoing	   apoptosis	   (214,	   215),	   shut-­‐off	   protein	   synthesis	   via	   eIF4G	  inactivation.	   Since	   it	   was	   previously	   shown	   that	   hypoxia	   induces	   apoptotic	  neuronal	  death	  (216),	  it	  appears	  probable	  that	  under	  our	  conditions	  cleavage	  of	  eIF4G	   plays	   the	   major	   role	   in	   cap-­‐dependent	   mRNA	   translation	   inhibition.	   In	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addition,	   in	   HeLa	   cells	   interaction	   of	   eIF4E	   with	   eIF4E-­‐T	   triggers	   the	  translocation	   of	   the	   complex	   to	   the	   nucleus	   (217),	   a	  mechanism	   that,	   together	  with	  4E-­‐BP1	  hypo-­‐phosphorylation,	  have	  been	  shown	  to	   inhibit	  cap-­‐dependent	  translation	  in	  anoxic	  HeLa	  cells	  (83).	  In	  this	  regard,	  mores	  studies	  are	  required	  to	  address	  the	  role	  of	  eIF4E-­‐T	  under	  our	  conditions.	  Nevertheless,	  dissociation	  of	  eIF4E	  and	  eIF4G	  did	  not	  always	  diminish	  overall	  protein	  synthesis	  rate.	  Indeed,	  eIF4F	  disruption	  and	  decreased	  global	  mRNA	  translation	  correlated	  only	  during	  near	   anoxic	   condition	   (16h	   and	  36h	  Ax).	   These	   results	   agree	  with	  our	  data	   on	  primary	  astrocytes	  where	   inhibition	  of	  eIF4F	  complex	  via	  binding	  of	  4E-­‐BP1	  to	  eIF4E	  also	  failed	  to	  reduce	  global	  protein	  synthesis	  (see	  section	  7.1.2).	  This	  is	  in	  contrast	   to	   observations	   in	   breast	   cancer	   (176)	   and	   PC12	   cells	   (205)	   where	  modulation	   of	   the	   4E-­‐BP1	   phosphorylation	   state	   was	   tightly	   associated	   with	  changes	  in	  global	  translation	  during	  oxygen	  deprivation.	  We	  thus	  conclude	  that	  the	  comparatively	  low	  protein	  and	  RNA	  synthesis	  rate	  of	  slow-­‐growing	  and	  post-­‐mitotic	  cells	  (208)	  probably	  renders	  the	  assembly	  and	  disassembly	  of	  the	  eIF4F	  far	  less	  responsive	  to	  environmental	  signals	  or	  pharmaceutical	  compounds.	  Inhibition	   of	   mRNA	   translation	   is	   a	   mechanism	   activated	   by	   stressed	   cells	   to	  steady	  ATP	  turnover	  at	  times	  when	  little	  ATP	  can	  be	  produced	  (47).	  Indeed,	  ATP	  levels	  showed	  no	  sign	  of	  reduction,	  or	  even	  depletion,	  during	  16	  and	  36	  hours	  of	  hypoxia,	   in	   correlation	   with	   ongoing	   overall	   protein	   synthesis.	   Our	   studies,	   in	  agreement	  with	  previous	  reports	  showing	  high	  resistance	  of	  immature	  neurons	  to	   reductions	   of	   ATP	   levels	   during	   oxygen	   deprivation	   (218),	   showed	   falling	  energy	   levels	   (relative	   to	   controls	   by	   ~40%)	   only	   during	   severe	   stress	  conditions.	   At	   16	   hours	   anoxia,	   energy	   savings	   from	   moderately	   decreased	  protein	  synthesis	  rates	  (down	  to	  ~60%	  of	  controls)	  were	  obviously	  inadequate	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to	  balance	  the	  decreased	  ATP	  production	  of	  the	  cells,	  thus	  causing	  a	  drop	  in	  ATP	  concentration.	   At	   36	   hours	   anoxia,	   however,	   the	   equally	   suppressed	   protein	  synthesis	  was	  surprisingly	  able	  to	  stabilize	  ATP	  levels	  at	  control	  niveau,	  despite	  the	  dramatically	   increased	   incidence	  of	   cell	  death	  as	  measured	  by	  LDH	  release	  assays.	  According	  to	  these	  data,	  a	  steady	  ATP	  turnover	  does,	  in	  neurons	  at	  least,	  not	  seem	  to	  prevent	  or	  delay	  high	  cell	  mortality.	  Currently,	  we	  can	  not	  explain	  the	   disparity	   of	   reduced	   cell	   survival	   and	   protein	   synthesis	   rate	   versus	  maintained	  neuronal	  energy	  levels.	  Nevertheless,	  since	  the	  mitochondrion	  is	  the	  main	  producer	  of	  ATP	  in	  eukaryotic	  cell	  types,	  general	  evaluation	  of	  its	  function	  could	  help	  to	  clarify	  such	  a	  response.	  Under	  our	  conditions,	  oxygen	  deprivation	  reduced	   MTT	   levels	   in	   a	   graded	   fashion	   (i.e.	   Ax	   >	   Hx	   >	   Nx	   and	   36h	   (O2	  deprivation)	   >	   16h	   (O2	   deprivation),	   thus	   illustrating	   the	   progressive	  mitochondrial	   impairment	   in	   O2-­‐limited	   nerve	   cells.	   Reduction	   of	   proteins	  synthesis	   rate,	   ATP	   and	  MTT	   levels	  were	   synchronized	   as	   expected	   at	   shorter	  time	   points.	   Maintained	   ATP	   levels	   during	   36	   hours	   challenges,	   however,	   can	  only	   result	   from	   the	   apparent	   coordination	   in	   the	   reduced	   energy	   production	  (mitochondrial	   activity)	   and	   consumption	   (e.g.	   protein	   synthesis	   rates),	   hence	  reflecting	  the	  completely	  unexpected	  prevention	  of	  any	  measurable	  energy	  loss	  in	   chronically	   hypoxic	   or	   anoxic	   immature	   neurons.	   The	   reason	   for	   this	  discrepancy	  at	   the	   late	   time,	   and	  particularly	   the	   finding	   that	   this	   excellent	   re-­‐programming	   of	   ATP	   production/consumption	   cannot	   prevent	   a	   major	   kill	   of	  cells,	   remains	   entirely	   unclear	   but	   would	   seem	   most	   likely	   to	   be	   a	   technical	  problem.	   However	   an	   unknown	   biological	   response	   cannot	   be	   excluded	   and	  should	  be	  further	  investigated.	  
	   91	  
Notably,	   HIF-­‐1α	   largely	   contributes	   to	   the	   mechanisms	   activated	   by	   neuronal	  cells	   during	   hypoxia	   (64,	   219).	   In	   cancer	   cells,	   rapamycin-­‐driven	   mTORC1	  inhibition	   correlated	   with	   decreased	   HIF-­‐1α	   stabilization	   due	   to	   the	   impaired	  translation	  of	  the	  subunit	  (188–190).	  For	  neurons,	  we	  also	  show	  that	  inhibition	  of	  mTORC1	  via	  rapamycin	  decreases	  HIF-­‐1α	  stabilization	  when	  cells	  are	  exposed	  to	  hypoxic	  stress.	  Thus,	  some	  parallels	  do	  exist	  between	  mitotic	  and	  post-­‐mitotic	  cells	  in	  response	  to	  mTORC1	  inhibition	  during	  O2	  deprivation.	  Altogether	   we	   can	   conclude	   that	   mTORC1	   pathway	   is	   involved	   in	   the	  mechanisms	   of	   cell	   death	   activated	   in	   neuronal	   cells	   during	   prolonged	   oxygen	  deprivation.	   However,	   since	   4E-­‐BP1	   phosphorylation	   state	   and	   eIF4E	   binding	  capacity	   are	   hardly	   affected	   by	   varying	   degrees	   of	   O2-­‐deprivation,	   it	   seems	  unlikely	  that	  this	  binding	  protein	  isoform	  plays	  a	  major	  role	  in	  adjusting	  protein	  synthesis	  to	  external	  stimuli.	  Perhaps,	  other	  factors	  may	  be	  more	  relevant	  in	  this	  regard	  for	  neurons	  (i.e.	  4E-­‐BP2,	  eIF4E-­‐T).	  It	   also	   seems	   that	   4E-­‐BP1	   hypo-­‐phosphorylation	   has	   little	   effect	   on	   protein	  synthesis	   rate	   or	   ATP	   levels	   reduction	   during	   near-­‐anoxia.	   Indeed,	   although	  rapamycin	   and	   near-­‐anoxic	   exposure	   caused	   a	   similar	   decrease	   of	   4E-­‐BP1	  phosphorylation,	  during	  drug	   treatment	  no	  additional	  effects	  were	  detected	  on	  global	  mRNA	  translation	  and	  energy	  levels.	  Also	  S6K1	  activity	  does	  not	  seem	  to	  play	   a	   fundamental	   role	   in	   such	  mechanisms	  under	  our	   conditions.	   Indeed,	  we	  could	  not	  detect	  any	  change	  on	  protein	  synthesis	  rate	  or	  cellular	  energy	  during	  drug	   treatment,	   although	   the	   complete	   inhibition	   of	   S6K1	  phosphorylation.	  On	  the	  other	  hand,	  exposure	   to	   rapamycin	   rescued	  neuronal	  viability	  and	  reduced	  HIF-­‐1α	  accumulation	  during	  long-­‐term	  challenges,	  thus	  suggesting	  a	  role	  of	  this	  transcriptional	  factor	  as	  potential	  player	  in	  promoting	  cell	  death	  mechanisms	  in	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neurons	   subjected	   to	   prolonged	   hypoxia.	   In	   agreement,	   recent	   in	   vivo	   studies	  revealed	  the	  association	  of	  HIF-­‐1α	  and	  neuronal	  apoptosis	  after	  brain	  injury	  and	  indicated	   p53	   and	   BNIP3	   (HIF	   target	   genes)	   as	   probable	   regulators	   of	   such	  mechanism	  (220,	  221).	  However,	  due	  to	   the	  broad	  range	  of	  genes	  regulated	  by	  HIF-­‐1,	  it	  can	  not	  be	  excluded	  that	  other	  proteins	  may	  be	  involved	  in	  the	  neuronal	  cell	  death	  mechanism	  under	  our	  conditions.	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8 Conclusions	  
The	  main	  focus	  of	  this	  thesis	  work	  was	  to	  understand	  how	  mechanisms	  involved	  in	   astrocyte	   and	   neuronal	   responses	   to	   oxygen	   deprivation	   trigger	   their	  differential	  sensitivity	  and	  might	  underlie	  the	  enhanced	  astrocytic	  resistance	  to	  hypoxia	   or	   anoxia.	   Since	   mTORC1	   pathway	   has	   been	   shown	   to	   be	   a	   central	  regulator	  of	  hypoxic	  responses,	  we	  investigated	  the	  role	  of	  this	  signaling	  cascade,	  and	  particularly	  of	  the	  mTORC1	  effector	  4E-­‐BP1,	  in	  neuronal	  and	  astrocytic	  cells	  after	  oxygen	  deprivation.	  Even	   though	   the	   original	   question	   directed	   at	   understanding	   the	   mechanisms	  behind	  the	  differential	  stress	  susceptibility	  remains	  open,	  a	  number	  of	  additional	  issues	  also	  arise	  from	  this	  work.	  In	  primary	  brain	  cells,	  the	  role	  of	  mTORC1	  and	  its	   effectors	   does	   not	   seem	   to	   fit	   with	   the	   current	   knowledge	   that	   is	   mainly	  gained	  from	  cells	  with	  cancer	  background.	  Notably,	  in	  cancer	  cells	  alterations	  of	  many	   signaling	   cascades,	   including	  mTORC1	  pathway,	   are	   required	   to	   increase	  protein	  synthesis	  and	  proliferation	  rates.	  Along	  similar	  lines,	  putative	  alternative	  mTORC1	   functions,	   while	   occurring	   at	   minimal	   activity	   or	   in	   a	   latent	   state	   in	  neoplastic	   backgrounds,	   might	   actually	   play	   more	   important	   roles	   in	   normal	  growing	   or	   post-­‐mitotic	   primary	   cells.	   Current	   evidence	   proposes	   hypo-­‐phosphorylated	  4E-­‐BP1	  to	  act	  as	  translational	  brake	  as	  well	  as	  being	  a	  regulator	  of	   mitosis.	   We	   now	   show	   for	   primary	   astrocytes	   that	   4E-­‐BP1	   functions	   as	   a	  delimiting	   factor	   of	   cap-­‐dependent	   initiation	   of	   translation	   when	   hypo-­‐phosphorylated	   during	   ischemia	   (in	   vitro:	   anoxia	   and	   glucose	   withdrawal).	  Beyond	   its	   canonical	   role,	   however,	   we	   provide	   evidence	   that	   hyper-­‐phosphorylated	  4E-­‐BP1	  in	  oxygenated	  glia	  cells	  stimulates	  protein	  synthesis	  rate	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and	  cell	  cycle	  progression,	  rather	  than	  occupying	  the	  widely	  believed	  role	  of	  an	  inactive	  bystander.	  The	  mechanisms	  and	  partner	  proteins	  for	  this	  non-­‐canonical	  behavior	   have	   yet	   to	   be	   uncovered.	   Therefore,	   it	   would	   be	   interesting	   to	  investigate	   the	   role	   of	   hyper-­‐phosphorylated	   4E-­‐BP1	   in	   other	   rapidly	   dividing	  cells	  as	  well	  as	  post-­‐mitotic	  neuronal	  cells.	  Moreover,	  since	  neuronal	  4E-­‐BP1	  is	  already	   hypo-­‐phosphorylated	   under	   normal	   conditions	   (i.e.	   normoxia),	   stress-­‐induced	   additional	   hypo-­‐phosphorylation	   is	   minimal,	   and	   it	   seems	   to	   play	   a	  marginal	  role	  in	  controlling	  cap-­‐translation	  during	  O2	  scarcity.	  Thus,	  it	  would	  not	  be	   unrealistic	   to	   perceive	   astrocytic	   4E-­‐BP1	   as	   a	   highly	   selective	   factor	   that	  controls	   only	   a	   small	   group	   of	   mRNAs,	   maybe	   those	   involved	   in	   synaptic	  plasticity	  or	  neurotransmission	  of	  nerve	  cells.	  	  The	  question	  of	  which	  mechanisms	  drive	  differential	  sensitivity	  of	  neurons	  and	  astrocytes	   still	   has	   no	   definitive	   answer	   but	   remains	   crucial.	   A	   better	  understanding	  of	   these	  processes	  would	  be	  beneficial	   to	  extend	  our	  knowledge	  of	  mechanisms	  activated	  during	  normal	   conditions	  as	  well	   as	   those	   that	  define	  outcome	  after	  injury	  in	  brain	  cells.	  Undoubtedly,	  such	  insight	  would	  potentially	  identify	   novel	   therapeutic	   targets	   for	   pharmacological	   treatment	   of	   hypoxic	  dependent	  CNS	  injury.	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ABSTRACT	  	  Protein	   synthesis	   and	   cell	   division	   can	   be	   compromised	   in	   CNS	   pathologies	  including	   stroke,	   an	   injury	   leading	   to	   gliosis	   via	   astrocyte	   activation	   and	  hypertrophy,	   and	   malignant	   gliomas,	   often	   characterized	   by	   pronounced	  deregulation	  of	  mRNA	   translation	   and	   cell	   proliferation.	  Eukaryotic	   translation	  initiation	   factor	  4E	   (eIF4E)	   triggers	   the	  binding	  of	   eIF4F	  complex	   to	   the	  5’	   cap	  structure	   of	   mRNAs	   and	   initiates	   transcript	   recruitment	   to	   ribosomes.	   Hypo-­‐phosphorylated	   eIF4E	   binding	   protein	   1	   (4E-­‐BP1)	   sequestrates	   eIF4E,	   thus	  inhibiting	  translational	   initiation.	   In	  contrast,	  hyper-­‐phosphorylation	  of	  4E-­‐BP1	  via	   mammalian	   target	   of	   rapamycin	   complex	   1	   (mTORC1)	   inactivates	   the	  protein.	  As	  most	  of	  our	  knowledge	  on	  4E-­‐BP1	  come	  from	  pathological	  contexts,	  we	  investigated	  modulation	  and	  function	  of	  4E-­‐BP1	  in	  normal	  or	  oxygen	  and/or	  glucose	   deprived	   primary	   astrocytes	   exposed	   to	   mTORC1	   inhibitors	   or	   small	  interfering	   RNA-­‐mediated	   gene	   silencing.	   During	   oxygen	   and	   glucose	  deprivation,	   4E-­‐BP1	   dephosphorylation	   inhibited	   cap-­‐dependent	   protein	  synthesis	   but	  did	  not	   affect	   global	   translation.	   Interestingly,	   knockdown	  of	   4E-­‐BP1	   reduced	   cell	   proliferation	   and	   overall	   protein	   synthesis	   in	   normoxic	  astrocytes,	   i.e.	   when	   4E-­‐BP1	   is	   hyper-­‐phosphorylated,	   while	   no	   effects	   were	  observed	   during	   oxygen	   deprivation.	   Our	   in	   vitro	   experiments	   confirm	   hypo-­‐phosphorylated	   4E-­‐BP1	   as	   translational	   brake	   in	   severely	   stressed	   astrocytes	  but	   also	   reveal	   hyper-­‐phosphorylated	   4E-­‐BP1	   as	   stimulator	   of	   cell	   growth	   and	  proliferation	  in	  oxygenated	  glia.	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INTRODUCTION	  The	   regulation	   of	   translation	   influences	   many	   cellular	   activities	   including	   cell	  growth,	   proliferation	   and	   responses	   to	   environmental	   stimuli.	   Although	   many	  pathways	   modulate	   protein	   synthesis	   through	   various	   eukaryotic	   initiation	  factors	   (eIFs),	   cap-­‐dependent	   translation	   is	   the	   synthesis	   mechanism	   for	   the	  majority	  of	  polypeptides	  (1–3).	  Most	  mRNAs	  possess	  a	  cap	  structure,	  m7GpppN	  (where	   m:	   methyl	   group;	   G:	   guanine	   base;	   ppp:	   triphosphate	   group;	   N:	   any	  nucleotide),	  at	   the	  5’	   terminus	  to	   facilitate	  recruitment	  of	   the	  eIF4F	  complex	  to	  ribosomal	   subunits	   for	   the	   initiation	   of	   cap-­‐dependent	   translation	   (3,	   4).	  Regulation	   of	   the	   initiation	   of	   protein	   synthesis	   via	   binding	   to	   the	   5’	   cap	   of	  mRNAs	   is	   the	  most	  controlled	  phase	  of	   translation,	  and	   is	  considered	  to	  be	   the	  rate-­‐limiting	   step	   of	   the	   process	   (5).	   The	   complex	   eIF4F	   is	   composed	   of	   three	  eIFs:	   the	   cap-­‐binding	   factor	   (eIF4E),	   the	   scaffolding	   protein	   4G1	   or	   4G2	  (eIF4G1/2)	  and	  the	  helicase	  4A	  (eIF4A)	  (3).	  eIF4E-­‐binding	  proteins	  1-­‐3	  (4E-­‐BPs)	  modulate	  the	  assembly	  of	  eIF4F	  and	  inhibit	  cap-­‐dependent	  translation	  via	  their	  interaction	  and	  sequestration	  of	  cap-­‐binding	  eIF4E	  subunit.	  Although	   the	   three	  members	   of	   the	   4E-­‐BP	   family	   show	   similar	   inhibitory	   activity	   (6),	   4E-­‐BP1	   has	  been	  most	  characterized.	  In	  its	  hypo-­‐phosphorylated	  state	  4E-­‐BP1	  directly	  binds	  eIF4E,	  thus	  competing	  with	  the	  eIF4E/4G	  association	  within	  the	  eIF4F	  complex	  and	  impeding	  activation/initiation	  of	  cap-­‐dependent	  translation	  (7).	  In	  contrast,	  phosphorylation	   on	   serine/threonine	   side	   chains	   of	   4E-­‐BP1	   leads	   to	   its	  dissociation	   from	   eIF4E,	   allowing	   eIF4F	   complex	   assembly	   and	   cap-­‐dependent	  protein	   synthesis	   initiation.	   mTORC1,	   a	   protein	   complex	   composed	   of	  mammalian	  target	  of	  rapamycin	  (mTOR)	  kinase,	  GβL	  and	  regulatory-­‐associated	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protein	  of	  mTOR	  (raptor),	  phosphorylates	  4E-­‐BP1	  and	  also	  ribosomal	  protein	  S6	  kinase	  1	  (S6K1).	  Contrary	  to	  the	  inactivation	  of	  the	  4E	  binding	  protein,	  mTORC-­‐driven	   phosphorylation	   of	   S6K1	   functions	   as	   stimulatory	   signal,	   leading	   to	   the	  activation	  of	  the	  5′-­‐terminal	  oligopyrimidine	  tract	  (TOP)	  -­‐dependent	  translation	  of	  ribosomal	  components	  and	  translation	  elongation	  factors.	  Incoming	  cytokine,	  hormone,	   amino	   acid	   and	   growth	   factor	   signals	   activate	   mTORC1,	   thereby	  positively	  stimulating	  mRNA	  translation	  via	  phosphorylation	  of	   its	  downstream	  substrates	  4E-­‐BP1	  and	  S6K1.	  Stress	  conditions	  such	  as	  hypoxia	  and	  nutrient	  deprivation	  inhibit	  the	  mTORC1	  pathway	   causing	   4E-­‐BP1	   dephosphorylation	   that	   in	   turn	   suppresses	   mRNA	  translation	  and	  fosters	  energy	  conservation	  and	  cell	  survival.	  Such	  translational	  regulation	   has	   been	   shown	   to	   play	   a	   fundamental	   role	   in	   cancer	   development,	  growth	   and	   therapeutic	   resistance	   (8,	   9).	   Activation	   of	   cap-­‐dependent	   protein	  synthesis	   by	   hyper-­‐phosphorylation	   of	   4E-­‐BP1	   is	   associated	   with	   increased	  cancer	  progression	   and	  decreased	   survival	   in	   astrocytoma	   (10),	  while	   reduced	  expression	  was	   found	   to	   increase	   resistance	   to	   drug	   treatment	   in	   glioma	   cells	  (11).	  However,	  loss-­‐of-­‐function	  of	  4E-­‐BP1	  in	  xenografts	  of	  U87	  glioblastoma	  cells	  resulted	   in	   marked	   attenuation	   of	   hypoxia	   tolerance	   and	   increasing	  radiosensitivity	   (8).	   Indeed,	   during	   stress	   conditions	   tumors	   inhibit	   cap-­‐dependent	   translation	   via	   4E-­‐BP1	  hypo-­‐phosphorylation,	   thus	   reducing	   energy	  consumption	   and	   improving	   cell	   survival	   (8,	   12).	   A	   similar	   mechanism	   was	  activated	  during	  oxygen	  deprivation	  in	  isolated	  rat	  hepatocytes	  (13).	  So	  far,	  knowledge	  of	  4E-­‐BP1	  function	  has	  been	  mainly	  derived	  from	  cancer	  cells	  and	  primarily	  focused	  on	  the	  hypo-­‐phoshorylated	  form	  as	  the	  major	  antagonist	  of	   cap-­‐dependent	   translation.	   However,	   the	   factor	   was	   recently	   shown	   to	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regulate	   cell	   cycle	   progression	   in	   embryonic	   fibroblasts	   (14),	   HeLa	   (15)	   and	  HepG2	   cells	   (16).	   Clearly	   the	   potential	   function	   of	   the	   as	   yet	   unstudied	   hyper-­‐phosphorylated	  4E-­‐BP1	  and	  the	  role	  of	  this	  regulator	   in	  normal	  untransformed	  cells	  need	  to	  be	   investigated.	   It	   is	  well	  known	  that	  astrocytes	  are	  highly	  stress-­‐resistant	   brain	   cells	   (17)	   and	  play	   a	   neuroprotective	   role	   during	   brain	   disease	  (18).	   The	   mTORC1	   pathway	   was	   recently	   shown	   to	   be	   involved	   in	   the	  physiological	  response	  of	  astrocytes	  to	  injuries	  of	  the	  CNS	  (19).	  Since	  alterations	  in	  4E-­‐BP1	   total	   levels	  and	  phosphorylation	  state	  are	  associated	  with	  astrocytic	  cancer	  development	  and	  progression	   (8–10),	  we	  hypothesize	   that	   in	   its	  hyper-­‐phosphorylated	   state	   4E-­‐BP1	   may	   play	   a	   role	   in	   regulating	   cell	   growth	   and	  proliferation	  also	  in	  normal	  untransformed	  glia	  cells.	  
	  
MATERIALS	  AND	  METHODS	  Chemicals	  and	  reagents	  Cell	  culture	  media	  and	  reagents	  were	  purchased	  from	  Gibco®	  (Life	  Technologies,	  Zug,	  Switzerland).	  Rapamycin	  was	  obtained	   from	  Sigma-­‐Aldrich	  (St.	  Louis,	  MO)	  and	   NVP-­‐BEZ235	   hydrocloride	   (NVP)	   from	   Chemdea	   (Ridgewood,	   NJ).	  OligofectamineTM	   Reagent	   was	   ordered	   from	   Invitrogen	   (Carlsbad,	   CA)	   and	  ON_TARGETplus	  SMARTpool	  targeting	  4E-­‐BP1	  (L-­‐096117-­‐01),	  S6K1	  (L-­‐099323-­‐02)	   and	   non-­‐targeting	   pool	   (D-­‐001810-­‐10)	   from	   Thermo	   Scientific	   (Waltham,	  MA).	  Protease	  inhibitor	  cocktail	  Set	  III	  was	  purchased	  from	  Calbiochem	  (Merck,	  Darmstadt,	   Germany).	   Pierce	   BCA	   Protein	   Assay	   was	   obtained	   from	   Thermo	  Fisher	  Scientific	   Inc.	   (Rockford,	  USA).	  Antibodies	  directed	  against	  4E-­‐BP1,	  non-­‐phospho-­‐4E-­‐BP1(Thr46),	   S6K1,	   phospho-­‐S6K1	   (Thr389),	   AKT,	   phospho-­‐AKT	  (Ser473),	  eIF2α,	  phospho-­‐	  eIF2α,	  eIF4G	  were	  from	  Cell	  Signaling	  (Danvers,	  MA),	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eIF4E	   from	   BD	   Bioscience	   (San	   Jose,	   CA)	   and	   β-­‐actin	   antibody	   from	   Sigma-­‐Aldrich	   (Buchs,	   Switzerland).	   Secondary	   antibodies	   for	  Western	   blotting	   were	  obtained	  from	  Jackson	  ImmunoResearch	  (Suffolk,	  UK).	  5-­‐bromo-­‐2'-­‐deoxyuridine	  (BrdU)	  incorporation	  kit	  was	  from	  Roche	  (Mannheim,	  GE),	  m7GTP-­‐sepharose	  4B	  from	   GE	   Healthcare	   (Glattbrugg,	   Switzerland)	   and	   7-­‐methylguanosine	   5’-­‐triphosphate	   from	   Sigma-­‐Aldrich	   (Buchs,	   Switzerland).	   [35S]	  methionine/cysteine	  was	  purchased	  from	  American	  Radiolabeled	  Chemicals	  Inc.	  (St.	  Louis,	  MO).	  	  Primary	  culture	  of	  astrocytes	  Primary	   astrocytes	  were	   isolated	   from	  newborn	  Wistar	   rat	   pups	   as	   previously	  described	   (17,	   20).	  Briefly	   neonatal	   rats	  were	  decapitated,	   cerebral	   cortex	   and	  meninges	   removed,	   and	   cortices	  minced	   and	   placed	   in	   ice-­‐cold	   buffer	   	   (Krebs	  solution;	   120mM	   NaCl,	   3	   mM	   KCl,	   1.2	   mM	   MgSO4,	   1.2	   mM	   KH2PO4,	   25	   mM	  NaHCO3,	   11	  mM	   glucose,	   and	   0.6	   g/l	   BSA).	   Tissue	  was	   then	   homogenized	   and	  digested	  with	  7.5	  mg	  trypsin	  for	  15	  min	  at	  37°C.	  Dissociated	  cells	  were	  cultured	  in	   DMEM	   containing	   10%	   FBS	   and	   50	   mg/ml	   gentamicin	   at	   37°C	   the	   culture	  media	  was	  changed	  every	  3	  to	  4	  days.	  Astrocytes	  were	  passaged	  for	  maximum	  of	  three	   times	   and	   exposed	   at	   80-­‐90%	   confluency.	   For	   analysis	   of	   culture	   purity,	  cells	  were	  stained	  with	  microglia	  marker	  Iba-­‐1	  (ionized	  calcium	  binding	  adapted	  molecule	   1),	   pericytes	   markers	   NG-­‐2	   and	   PDGF-­‐Rβ	   (platelet-­‐derived	   growth	  factor	   β	   receptor),	   endothelial	   cells	   markers	   Isolectin-­‐B4	   and	   tyrosine-­‐protein	  kinase	  receptor	  TIE-­‐2	  and	  astrocytic	  marker	  GFAP.	  95%	  of	  the	  cells	  were	  GFAP-­‐positive	  and	  negative	  for	  the	  other	  markers,	  therefore	  considered	  astrocytic.	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  Hypoxic,	  glucose	  deprivation	  and	  drug	  exposure	  experiments	  Primary	  astrocytes	  were	   incubated	   in	  5%	  CO2-­‐containing	  atmospheres	  at	  37ºC	  under	   normoxic	   (room	   air),	   hypoxic	   (1%	   O2)	   and	   near-­‐anoxic	   (0.2%	   O2)	  conditions	   in	   a	   humidified	   glove	   box	   incubator	   (Invivo2	   200;	   Ruskinn	  Technologies)	  for	  16	  or	  36	  hours.	  Glucose	  deprivation	  experiments	  were	  carried	  out	  with	  glucose-­‐free	  media.	  mTOR	  inhibitor	  rapamycin	  or	  PI3K/mTOR	  inhibitor	  NVP	   (NVP-­‐BEZ235	  hydrochloride)	  were	   used	   at	   a	   concentration	   of	   10	   nM	  and	  250	  nM,	  respectively	  to	  inhibit	  4E-­‐BP1	  phosphorylation.	  	  Transfection	  Astrocytes	  were	  plated	  and	  allowed	  to	  reach	  80-­‐90%	  confluency	  (except	  where	  differently	   specified).	   Cells	   were	   transfected	   with	   100	   nM	   siRNA	   using	  	  OligofectamineTM	   Reagent	   according	   to	   manufacturer’s	   instructions.	   Briefly,	  Oligofectamine	   was	   diluted	   in	   Opti-­‐MEM®	   and	   incubated	   5	   min	   at	   room	  temperature	  (RT).	  In	  parallel,	  ON_TARGETplus	  SMARTpool	  siRNA	  or	  siCONTROL	  Non-­‐Targeting	   scrambled	   RNA	   were	   combined	   with	   Opti-­‐MEM®,	   added	   to	   the	  Oligofectamine/Opti-­‐MEM	   mixture	   and	   incubated	   20	   min	   at	   RT.	   Cells	   were	  washed	  once	  with	  PBS,	  medium	  was	   replaced	  with	  DMEM	  Glutamax	   II	   and	   the	  siRNA	   duplexes	   were	   added,	   mixed	   gently	   and	   incubated	   for	   5.5	   hours	   at	  37°C/5%	  CO2	  before	  the	  media	  was	  replaced	  with	  media	  containing	  serum	  and	  antibiotics.	   The	   next	   day	   cells	   were	   exposed	   to	   oxygen	   and/or	   glucose	  deprivation	  and/or	  drug	  for	  16	  hours	  and	  then	  analyzed.	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  Immunoblotting	  Cell	  lysates	  were	  generated	  using	  cell	  lysis	  buffer	  (50	  mM	  Tris,	  150	  mM	  NaCl,	  1%	  Triton,	   1%	   NP-­‐40)	   supplemented	   with	   protease	   inhibitor	   cocktail,	   sodium	  orthovanadate	   (1	   mM),	   dithiothreitol	   (0.5	   mM)	   and	   phenylmethansulfonyl	  fluoride	  (0.5	  mM),	  incubated	  10	  min	  on	  ice	  and	  then	  cleared	  by	  centrifugation	  for	  10	  min	  at	  16,000	  g	  at	  4°C.	  Protein	  concentrations	  were	  quantified	  with	  the	  Bio-­‐Rad	  protein	  assay	  kit.	  30	  μg	  lysates	  were	  generated	  using	  Laemli	  buffer	  (250	  mM	  Tris-­‐HCl	   pH	   6.8,	   10%	   SDS,	   25%	   glycerol,	   0.02%	   bromophenol	   blue,	   25%	   2-­‐mercaptoethanol),	  then	  resolved	  on	  polyacrylamide	  gel	  with	  SDS	  running	  buffer	  (192	   mM	   glycine,	   25	   mM	   Tris,	   0.1%	   SDS)	   and	   transferred	   to	   nitrocellulose	  membrane.	  The	  membrane	  was	  blocked	  for	  1	  h	  at	  RT	  with	  5%	  dry	  milk	  in	  Tris-­‐buffered	   saline	   containing	   0.1%	   Tween-­‐20,	   probed	   with	   primary	   antibodies	  overnight	   at	   4°C.	   Immobilized	   primary	   antibodies	   were	   visualized	   using	   HRP-­‐conjugated	   secondary	  antibodies.	   Image	  analysis	  was	  done	  using	   ImageJ-­‐image	  processing	  and	  analysis	  software	  (National	  Institute	  of	  Health),	  and	  normalized	  to	  β-­‐actin	  or	  total	  protein	  levels.	  	  BrdU	  incorporation	  and	  detection	  in	  vitro	  Cell	  proliferation	  ELISA	  BrdU	  kit	  was	  used	  following	  manufacturer	  instructions.	  Briefly,	   40	   to	   50%	   confluent	   cells	   were	   transfected	   and	   the	   following	   day	  exposed	  to	  BrdU.	  Subsequently,	  cells	  were	  fixed	  for	  30	  minutes,	  then	  incubated	  1.5	   hours	   at	   37°C	  with	   a	   BrdU	   antibody	   conjugated	   to	   peroxidase	   (anti-­‐BrdU-­‐POD).	  Following	  a	  PBS	  wash	  POD	  substrate	  was	  added	  and	  optical	  density	  read	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at	  405	  nm	  with	  reference	  at	  520	  nm.	  The	  measured	  absorbance	  is	  proportional	  to	  the	  cells	  in	  S-­‐phase.	  	  	  Cap-­‐affinity	  assay	  Astrocytes	  were	   lysed	   in	   freeze-­‐thaw	   lysis	   buffer	   (FTLB;	   50	  mM	  Tris-­‐HCl,	   150	  mM	   NaCl,	   50	   mM	   NaF,	   1	   mM	   EDTA,	   10	   mM	   Tetrasodium	   pyrophosphate	  decahydrate)	   containing	   protease	   inhibitor	   cocktail,	   1	   mM	   sodium	  orthovanadate,	  0.5	  mM	  phenylmethansulfonyl	  fluoride.	  Cells	  were	  snap-­‐frozen	  in	  liquid	  nitrogen	  and	  thawn	  three	  times	  and	  then	  centrifuged	  for	  10	  min	  at	  16,000	  g	  at	  4°C.	  170	  μg	  proteins	  were	   incubated	  with	  60	  μl	  of	  m7GTP-­‐sepharose	  while	  mixing	   for	   2	   hours	   at	   4°C.	   The	   sepharose	   was	   then	   washed	   twice	   and	   the	  captured	  proteins	  eluted	  in	  elution	  buffer	  (25	  mM	  Tris-­‐HCl	  pH	  7.5,	  150mM	  KCl)	  containing	  100	  μM	  7-­‐methylguanosine	  5’-­‐triphosphate	  for	  1	  hour	  at	  4°C.	  Eluted	  proteins	  were	  then	  prepared	  for	  immunoblotting.	  	  Protein	   synthesis	   rate	   analysis:	  metabolic	   labeling	  with	   [35S]-­‐methionine	  and	  cysteine	  Cells	  were	  labeled	  for	  30	  minutes	  with	  10	  μCi/ml	  of	  [35S]-­‐methionine/cysteine	  in	  methionine	   and	   cysteine-­‐free	   media	   supplemented	   with	   0.1%	   serum,	   washed	  three	  times	  with	  cold	  PBS	  and	  protein	  precipitated	  with	  cold	  10%	  trichloroacetic	  acid	   twice	   for	   30	   minutes	   on	   ice.	   Precipitated	   proteins	   were	   solubilized	   with	  0.1%	  SDS,	  0.1M	  NaOH	  for	  30	  minutes	  at	  37°C	  shaking	  occasionally,	  neutralized	  with	  1	  M	  acetic	  acid,	  then	  counted	  in	  a	  liquid	  scintillation	  counter	  (Packard,	  Tri-­‐Carb1600	  RT).	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Statistical	  analysis	  All	  data	  were	  analyzed	  using	  Prism	  5	  software.	  After	  having	  confirmed	  normal	  distribution	  of	  respective	  data	  populations	  the	  comparison	  between	  two	  groups	  was	  performed	  using	  Two-­‐way	  ANOVA	  followed	  by	  Bonferroni	  post-­‐hoc	  test.	  P<	  0.05	  was	  considered	  statistically	  significant	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RESULTS	  Astrocytic	  4E-­‐BP1	  and	  S6K1	  have	  different	  sensitivity	  to	  rapamycin	  We	   investigated	   changes	   in	   4E-­‐BP1	   and	   S6K1	  phosphorylation	   by	   immunoblot	  under	   normal	   and	   stress	   conditions	   (Fig.	   1A).	   Under	   normoxic	   conditions	   (Nx,	  room	  air)	  4E-­‐BP1	  was	  hyper-­‐phosphorylated	  (γ	  and	  β	  bands)	  and	  hypoxic	  (Hx,	  1%	  O2)	  or	  near-­‐anoxic	  (Ax,	  0.2%	  O2)	  exposure	  (16	  hours	  each)	  did	  not	  alter	  this	  state.	   In	   contrast	   ischemic	   conditions	   (near-­‐anoxia	   and	   glucose	   deprivation)	  yielded	  considerable	  hypo-­‐phosphorylation	  of	  4E-­‐BP1	  (α	  band).	  It	  is	  well	  known	  that	   in	   cancer	   cells	   4E-­‐BP1	   regulation	  mainly	   depends	   on	  mTORC1	   activity	   (7,	  21,	  22).	  To	  test	  the	  effect	  of	  this	  kinase	  on	  4E-­‐BP1	  phosphorylation,	  we	  treated	  cells	  with	  10	  nM	  rapamycin,	  a	  specific	  mTORC1	   inhibitor.	  The	  10	  nM	  dose	  was	  chosen	   based	   on	   literature	   findings	   (23)	   and	   pilot	   experiments	   revealed	   this	  concentration	  as	  non-­‐toxic	  (data	  not	  shown).	  Surprisingly,	  rapamycin	  treatment	  only	   partially	   dephosphorylated	   4E-­‐BP1	   (γ,	   β	   and	   α	   bands)	   independent	   of	  oxygen	   and	   glucose	   exposure	   (Fig.	   1A).	   In	   contrast	   phosphorylation	   of	   S6K1,	  another	   downstream	   target	   of	  mTORC1,	  was	  moderately	   inhibited	   during	   sole	  oxygen	  deprivation,	  yet	   completely	  abrogated	  during	   ischemia	   	   (Ax-­‐G;	  Fig.	  1A).	  As	   expected,	   rapamycin	   dephosphorylated	   S6K1	   in	   all	   conditions,	   indicating	  differential	   sensitivity	   of	   4E-­‐BP1	   and	   S6K1	   to	   rapamycin	   driven	   mTORC1	  inhibition.	  Since	  AKT	  has	  been	  shown	  to	  directly	  phosphorylate	  4E-­‐BP1	  (24,	  25),	  we	   hypothesized	   a	   role	   for	   this	   kinase	   in	   such	   regulation.	   Particularly	   S6K1	  dephosphorylation	   by	   prolonged	   rapamycin	   application	   is	   known	   to	   activate	   a	  feedback	  loop	  involving	  AKT	  (26).	  Under	  our	  conditions,	  oxygen	  deprivation	  did	  not	  affect	  AKT	  phosphorylation,	  while	  glucose	  withdrawal	  slightly	  decreased	  it.	  Interestingly,	   rapamycin	   triggered	   a	   pronounced	   elevation	   of	   AKT	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phosphorylation	   in	   all	   conditions	   except	   ischemia	   (Fig.	   1A).	   These	   results	  suggest	   that	   in	   primary	   astrocytes	   S6K1	   phosphorylation	   is	   inhibited	  with	   far	  greater	  sensitivity	  to	  oxygen	  reduction	  or	  rapamycin	  exposure,	  while	  only	  severe	  (ischemic)	   conditions	   inactivate	  mTORC1-­‐	   and	   AKT-­‐relayed	   signaling	   onto	   4E-­‐BP1.	  To	   determine	   if	   varying	   degrees	   of	   4E-­‐BP1	   phosphorylation	   impact	   overall	  protein	   synthesis	   in	   astrocytes,	   we	   performed	   protein	   synthesis	   rate	   (PSR)	  assays	   (Fig.	   1B).	   Compared	   to	   the	   respective	   normoxic	   (Nx)	   reference,	   overall	  PSR	  dropped	  as	  a	  function	  of	  oxygen	  deprivation	  (Nx	  >	  Hx	  >	  Ax).	  Unexpectedly,	  simultaneous	   glucose	   withdrawal	   or	   rapamycin	   application	   had	   no	   additional	  effect	   (Fig.	  1B),	  hence	  maximal	  activation	  (hypo-­‐phosphorylation)	  of	  4E-­‐BP1	   in	  Ax-­‐G	  condition	  does	  not	   correlate	  with	  a	  major	   reduction	   in	   the	  global	  protein	  synthesis	   of	   astrocytes.	   We	   next	   assessed	   changes	   induced	   by	   oxygen	   and	  glucose	   deprivation	   on	   the	   activity	   of	   the	   binding	   protein	   using	   in	   vitro	   cap-­‐capture	  assay	  with	  a	  specific	  antibody	  that	  detects	  non-­‐phosphorylated	  (Thr46)	  in	  4E-­‐BP1	  (Fig.	  1C).	  This	  site	   initiates	  the	  hierarchical	  phosphorylation	  cascade	  that	   results	   in	  4E-­‐BP1	   release	   from	  eIF4E	   (22).	   For	   clear	  discrimination	  of	   the	  interaction	  equilibria	  of	  hypo-­‐phosphorylated	  4E-­‐BP1	  with	  eIF4E	  we	  compared	  Nx	   versus	   Ax	   conditions,	   since	   hypo-­‐phosphorylation	   of	   4E-­‐BP1	   in	   primary	  astrocytes	  occurs	  only	  during	  severe	  Ax-­‐G	  stress	  (Fig.	  1A).	  This	  time	  astrocytes	  were	  challenged	  for	  16	  and	  36	  hours	  periods	  to	  see	  if	  i)	  16	  hour	  of	  ischemia	  (Ax-­‐G)	   corresponds	   to	   an	   optimal	   degree	   of	   4E-­‐BP1	   activation,	   and	   ii)	   extended	  periods	   of	   severe	   injury	   could	   augment	   4E-­‐BP1	   hypo-­‐phosphorylation.	   36h	  oxygen	   deprivation	   alone	   did	   not	   affect	   4E-­‐BP1	   phosphorylation	   (data	   not	  shown)	  and	  only	  marginally	  strengthened	  the	  association	  of	  eIF4E	  with	  4E-­‐BP1	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(Fig.	   1C;	   36h	  Nx+G	   versus	   Ax+G).	   In	   contrast,	   16	   and	   36h	   glucose	   deprivation	  clearly	   increased	   capture	   of	   eIF4E	   by	   non-­‐phosphorylated	   (active)	   4E-­‐BP1.	   It	  should	  be	  noted	  that	  despite	  increased	  hypo-­‐phosphorylated	  4E-­‐BP1	  at	  36h	  Ax-­‐G,	  the	  ability	  of	  4E-­‐BP1	  to	  bind	  eIF4E	  was	  not	  affected.	  The	  heightened	  capacity	  of	   dephosphorylated	   4E-­‐BP1	   to	   interact	   with	   eIF4E	   during	   ischemia	   was	   also	  reflected	  by	  reduced	  interaction	  between	  eIF4G	  and	  eIF4E	  (Fig.	  1B)	  for	  both	  16	  and	  36	  hours	  exposure.	  	  4E-­‐BP1	  knockdown	   reduces	  both	  protein	   synthesis	   and	   cell	   cycle	   rate	   in	  astrocytes	  Next	  we	  knocked	  down	  4E-­‐BP1	  using	  siRNA	  to	   investigate	   the	  effect	  of	   loss-­‐of-­‐function	   of	   the	   hyper-­‐	   (in	   Nx±G)	   or	   hypo-­‐phosphorylated	   (in	   Ax-­‐G)	   factor	   on	  overall	   PSR	   and	   cell	   cycle	   regulation	   (Fig.	   2).	   80%	   knockdown	   of	   4E-­‐BP1	   by	  siRNA	   (Fig.	   2A)	   did	   not	   affect	   cell	   viability	   in	   any	   condition	   (data	   not	   shown).	  Interestingly,	  4E-­‐BP1	  silencing	  reduced	   the	  rate	  of	  protein	  synthesis	   to	  70%	  of	  the	   control	   (Scrm)	   during	   normoxic	   conditions	   independently	   of	   glucose	  exposure	   but	   unexpectedly	   did	   not	   alter	  mRNA	   translation	   during	   near-­‐anoxic	  exposure	  (Fig.	  2B).	  These	  data	  led	  us	  to	  hypothesize	  that	  hyper-­‐phosphorylated	  4E-­‐BP1	   might	   act	   as	   potential	   stimulator	   of	   protein	   synthesis	   in	   oxygenated	  astrocytes,	   a	   notion	   further	   supported	   by	   measuring	   cell	   proliferation	   using	  BrdU	   incorporation	  (Fig.	  2C).	  Although	  oxygen	  and	  glucose	  deprivation	  did	  not	  produce	   measurable	   differences	   in	   proliferative	   activities,	   4E-­‐BP1	   knockdown	  induced	   a	   trend	   to	   decreased	   cell	   cycle	   progression	   in	   all	   conditions	   and	  significantly	  inhibited	  BrdU	  incorporation	  down	  to	  80%	  of	  control	  values	  during	  normoxia	  (Fig.	  2C).	  We	  also	  attempted	  to	  reverse	  4E-­‐BP1-­‐knockdown	  mediated	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inhibitory	   effects	   by	   overexpressing	   a	   constitutively	   active	   (dephosphorylated)	  mutant	   form	   of	   4E-­‐BP1	   (Thr-­‐37–Glu/Thr-­‐46–Glu	  4E-­‐BP1).	   However,	  overexpression	  of	  the	  double	  mutant	  4E-­‐BP1	  did	  not	  affect	  protein	  synthesis	  or	  BrdU	   incorporation	   rates	   (data	   not	   shown).	   We	   infer	   that	   the	   hyper-­‐phosphorylated	   4E-­‐BP1	   species	   plays	   a	   major	   and	   positive	   role	   in	   mRNA	  translation	   and	   cell	   cycle	   regulation	   during	   non-­‐stress	   conditions	   in	   primary	  astrocytes.	  	  4E-­‐BP1	  knockdown	  suppresses	  S6K1	  but	  not	  AKT,	  eIF2α	  or	  eIF4E	  We	   investigated	   the	   effect	   of	   4E-­‐BP1	   knockdown	   on	   players	   of	   both	   cap-­‐	   and	  TOP-­‐dependent	  translation	  (Fig.	  3),	  which	  ultimately	  regulate	  cell	  proliferation.	  Since	   normoxia	   and	   near-­‐anoxia	   minus	   glucose	   were	   sufficient	   to	   distinguish	  between	   actions	   of	   hyper-­‐	   versus	   hypo-­‐phosphorylated	   4E-­‐BP1,	   subsequent	  experiments	  were	  performed	  under	   these	   two	  conditions.	  Surprisingly,	  4E-­‐BP1	  knockdown	   significantly	   decreased	   total	   levels	   of	   S6K1	   during	   normoxia	   and,	  although	  not	  statistically	  significant,	  caused	  a	  similar	  reduction	  during	  ischemic	  conditions	  (Fig.	  3A&B).	  While	  oxygen	  deprivation	  had	  no	  effect	  on	  total	  levels	  of	  S6K1,	   the	   phosphorylation	   of	   this	   mTORC1	   effector	   was	   inhibited	   during	  ischemia.	  4E-­‐BP1	  knockdown	  seemed	  to	  reduce	  phosphorylated	  S6K1	  only	  as	  a	  consequence	   of	   decreased	   total	   S6K1	   levels	   (Fig.	   3A&C).	   Total	   AKT	   did	   not	  change	   in	   any	   of	   the	   conditions	   (Fig.	   3A),	   while	   in	   contrast	   Ax-­‐G	   significantly	  decreased	  AKT	  phosphorylation.	  Notably,	   4E-­‐BP1	   knockdown	  had	  no	   effect	   on	  AKT	  (Fig.	  3A&D).	   Initiation	   factor	  eIF4E	  and	   total	  eIF2α	  were	  also	  not	  affected	  either	   by	   oxygen	   deprivation	   or	   4E-­‐BP1	   manipulation	   (Fig.	   3A),	   although	  phosphorylated	   eIF2α	   increased	   during	   oxygen	  withdrawal	   (Fig.	   3A&E).	   These	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results	   suggest	   that	   in	   primary	   astrocytes	   4E-­‐BP1	   promotes	   expression	   and	  activity	   of	   the	   TOP-­‐protein	   synthesis	   regulator	   S6K1	   but	   not	   of	   any	   of	   the	  investigated	  cap-­‐translation	  related	  proteins.	  	  S6K1	   knockdown	  mimics	   the	   effect	   of	   4E-­‐BP1	   gene	   silencing	   on	   overall	  protein	  synthesis	  but	  not	  cell	  proliferation.	  As	  4E-­‐BP1	  knockdown	  decreased	  S6K1	  levels	  (Fig.	  3A&B),	  we	  hypothesized	  that	  phosphorylated	  4E-­‐BP1	  promotes	  PSR	  and	  cell	   growth	  via	  S6K1	  regulation.	  To	  investigate	   the	   consequence	   of	   reduced	   S6K1-­‐mediated	   TOP-­‐dependent	  translation	  on	  overall	  protein	  synthesis	  and	  cell	  proliferation,	  we	  used	  siRNA	  to	  silence	   transcription	   of	   S6K1	   alone	   and	   in	   combination	  with	   4E-­‐BP1	   (Fig.	   4A).	  While	  si4E-­‐BP1	  again	  weakened	  S6K1	  levels,	  knockdown	  of	  S6K1	  did	  not	  impact	  abundance	   of	   4E-­‐BP1	   protein.	   Interestingly,	   S6K1	   knockdown	   reduced	   protein	  synthesis	  rates	  almost	  as	  effectively	  as	  4E-­‐BP1	  depletion	  under	  Nx+G	  condition,	  although	   not	   statistically	   significant.	   However,	   genetic	   manipulation	   of	   S6K1	  neither	   affected	   the	   rate	   of	   mRNA	   translation	   during	   glucose	   withdrawal	   nor	  oxygen	  deprivation	  (Fig.	  4B).	  These	  results	  indicate	  that	  S6K1	  may	  regulate	  the	  decrease	   of	   PSR	   caused	  by	   4E-­‐BP1	   knockdown	  only	   during	   normal	   conditions.	  Unexpectedly,	  DNA	  replication	  was	  not	  affected	  by	  gene	  silencing	  of	  S6K1	  in	  any	  of	  the	  conditions	  (Fig.	  4C),	  while	  double	  knockdown	  of	  S6K1	  and	  4E-­‐BP1	  (si4E-­‐BP1/S6K1)	   reduced	   DNA	   replication	   to	   the	   same	   extent	   as	   4E-­‐BP1	   genetic	  manipulation	   alone	   (si4E-­‐BP1).	   Thus	   loss	   of	   S6K1	   does	   not	   alter	   BrdU	  incorporation	   and	   therefore	   it	   is	   not	   implicated	   as	   a	   trigger	   for	   astrocyte	   cell	  cycle	  regulation.	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The	  inhibitor	  NVP	  blunts	  the	  effect	  of	  4E-­‐BP1	  gene	  silencing	  To	   further	   assess	   the	   contribution	   of	   hyper-­‐phosphorylated	   4E-­‐BP1	   to	   mRNA	  translation	   and	   cell	   proliferation	   in	   oxygenated	   astrocytes,	   we	   fully	  dephosphorylated	   4E-­‐BP1	   by	   treating	   normoxic	   astrocytes	   with	   NVP-­‐BEZ235	  (NVP),	  a	  potent	  ATP-­‐competitive	  PI3K	  and	  mTOR	  inhibitor	  (27).	  NVP	  treatment	  inhibited	  4E-­‐BP1	  phosphorylation	   in	  a	  dose-­‐dependent	  manner,	  with	  non-­‐toxic	  250	  nM	  causing	  its	  complete	  dephosphorylation	  (α	  band	  only)	  (Fig.	  5A).	  Next	  we	  additionally	   used	   siRNA	   to	   knockdown	   4E-­‐BP1	   and	   performed	   PSR	   and	   BrdU	  incorporation	  assay.	  Surprisingly,	  250	  nM	  NVP	  reduced	  protein	  synthesis	  to	  50%	  of	   the	   control	   (Scrm	   Nx+G)	   independently	   of	   glucose	   exposure	   (Fig.	   5B).	  Furthermore,	   drug	   treatment	   completely	   blunted	   the	   effect	   of	   4E-­‐BP1	  knockdown	  on	  PSR	  during	  normoxia.	  In	  complete	  contrast,	  applying	  NVP	  to	  cells	  subjected	   to	   anoxia	   did	   not	   yield	   any	   attenuation	   in	   global	   protein	   synthesis	  activity	   (Fig.	   5C).	   NVP	   treatment	   also	   caused	   a	   50%	   decrease	   in	   BrdU	  incorporation	  during	  both	  normoxic	   and	  near-­‐anoxic	   conditions	   independently	  of	  glucose	  deprivation	  and,	  here	  again,	  completely	  blunted	  the	  effect	  of	  4E-­‐BP1	  knockdown	   (Fig.	   5D).	   Taken	   together	   these	  data	  underline	   the	  hypothesis	   that	  hyper-­‐phosphorylated	   4E-­‐BP1	   rather	   than	   the	   dephosphorylated	   protein	  stimulates	   overall	   protein	   synthesis	   and	   cell	   cycle	   progression	   in	   primary	  astrocytes	  during	  non-­‐stress	  conditions.	  	  	  
DISCUSSION	  4E-­‐BP1	   has	   been	   shown	   to	   play	   a	   pivotal	   role	   in	   the	   regulation	   of	   protein	  synthesis	  and	  cell	   survival	   in	  cancer	  cells	  during	  disease	  progression.	  However	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the	  physiological	  function	  of	  this	  important	  regulator	  in	  primary	  cells	  still	  needs	  to	  be	   elucidated.	  This	   study	   shows	   that	  during	   stress	   conditions	   astrocytic	  4E-­‐BP1	   inhibits	   cap-­‐dependent	   translation	   when	   hypo-­‐phosphorylated	   similar	   to	  the	   mechanisms	   observed	   in	   cancer	   cells.	   However,	   we	   now	   provide	   novel	  evidence	   that	   phosphorylated	   4E-­‐BP1,	   rather	   than	   being	   an	   inactive	   mTORC1	  pathway	   component,	   actively	   stimulates	   cell	   proliferation	   and	   overall	   protein	  synthesis	  under	  normal	  conditions.	  Differential	   sensitivity	   of	   4E-­‐BP1	   and	   S6K1	   to	   rapamycin-­‐induced	   mTORC1	  inhibition	  in	  cancer	  cells	  as	  well	  as	  in	  myoblasts	  was	  recently	  described	  (26,	  28,	  29).	   Similarly,	   although	   ischemia	   completely	   dephosphorylated	   4E-­‐BP1	   and	  S6K1	   in	  primary	  astrocytes,	  anoxia	  or	  rapamycin	   treatment	   inhibited	  S6K1	  but	  not	  4E-­‐BP1	  phosphorylation.	  This	  observation	  suggested	  that	  other	  rapamycin-­‐refractory	  kinases	  also	  contribute	  to	  4E-­‐BP1	  regulation.	  In	  our	  study	  the	  kinase	  AKT	   was	   activated	   by	   prolonged	   rapamycin	   treatment,	   similar	   to	   data	   from	  others	   (26)	   showing	   that	   S6K1	  dephosphorylation	  by	   rapamycin	   results	   in	   the	  loss	   of	   a	   negative	   feedback	   loop	  which	   eventually	   resulted	   in	   the	   activation	   of	  AKT	   in	   bladder	   cancer	   cells.	   Other	   groups	   have	   shown	   in	   human	   embryonic	  kidney	   cells	   as	  well	   as	   in	   cancer	   cells	   that	  AKT	   signaling	  directly	  mediates	  4E-­‐BP1	   phosphorylation	   (24,	   25).	   We	   speculate	   that	   in	   primary	   astrocytes	   S6K1	  dephosphorylation	   may	   induce	   S6K1-­‐dependent	   AKT	   activation	   and	   thereby	  sustain	  4E-­‐BP1	  phosphorylation.	  During	   severe	   stress	   conditions	   (i.e.	   ischemia)	   dephosphorylated	   (active)	   4E-­‐BP1	   inhibited	   cap-­‐dependent	   translation	   through	   interaction	   with	   eIF4E	   in	  analogy	   to	   published	   data	   obtained	   from	   both,	   transformed	   (30)	   and	   primary	  cells	   (13).	   Combining	   glucose	   with	   oxygen	   deprivation	   also	   prohibited	   the	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partnering	   between	   eIF4E	   and	   eIF4G	   within	   the	   eIF4F	   cap-­‐binding,	   which	  mirrors	  observations	  in	  anoxic	  HeLa	  cells	  (31).	  Nevertheless,	  ischemic	  inhibition	  of	   astrocytic	   cap-­‐dependent	   translation	   through	   dephosphorylated	   4E-­‐BP1	   did	  not	   further	   intensify	   inhibition	  of	  overall	  protein	  synthesis	  compared	  to	  anoxia	  (where	  hyper-­‐phosphorylated	  4E-­‐BP1	  prevails).	  These	  findings	  are	  in	  agreement	  with	  a	  previous	  study	  on	  isolated	  rat	  hepatocytes	  demonstrating	  the	  inadequacy	  of	   rapamycin-­‐dependent	   4E-­‐BP1	   dephosphorylation	   to	   cause	   a	   decrease	   in	  global	  protein	  synthesis	  (13).	  This	  contrasts	  with	  the	  observation	  that	  4E-­‐BP1	  in	  immortalized	  breast	  epithelial	  cells	  partially	  regulates	  global	  translation	  during	  hypoxia	  (32).	  Thus,	  tumor	  cells	  may	  be	  more	  susceptible	  than	  non-­‐transformed	  cells	  to	  the	   inhibitory	  role	  of	  4E-­‐BP1	  due	  to	  their	  high	  PSR.	   In	  our	  more	  slowly	  dividing	   astrocytes	   we	   failed	   to	   obtain	   any	   evidence	   implicating	  dephosphorylated	  4E-­‐BP1	   in	   the	   regulation	  of	   global	   translation	  during	   severe	  stress,	   i.e.	   under	   conditions	   when	   the	   factor	   scavenges	   eIF4E	   from	   the	   cap-­‐translation	  promoting	  eIF4F	  complex.	  While	   its	   canonical	   activities	   were	   restricted	   to	   extreme	   challenges,	   4E-­‐BP1	  surprisingly	   stimulated	   protein	   synthesis	   under	   normal	   circumstances	   when	  oxygen	   and	   substrates	  were	   abundantly	   available.	   Furthermore,	   knockdown	  of	  the	   allegedly	   inactive,	   i.e.	   hyper-­‐phosphorylated,	   species	   reduced	   overall	   PSR	  and	  decreased	  cell	  proliferation	  under	  normoxia	  but	  had	  no	  effect	  during	  near-­‐anoxia.	   These	   findings,	   support	   the	   hypothesis	   that	   hyper-­‐phosphorylated	   4E-­‐BP1	   promotes	   protein	   synthesis	   and	   cell	   cycle	   progression	   during	   non-­‐stress	  conditions.	   Indeed	   regulation	   of	   cell	   cycle	   by	   4E-­‐BP1	   could	   be	   an	   indirect	  consequence	  of	  altered	  protein	  synthesis	  or	  vice	  versa.	  In	  good	  agreement	  recent	  evidence	   showed	   phosphorylated	   4E-­‐BP1	   levels	   to	   increase	   during	   mitosis	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where	  the	  factor	  is	  believed	  to	  play	  a	  role	  in	  cell	  division	  in	  both	  primary	  retinal	  cells	   (33)	   and	   some	   transformed	   cell	   lines	   (15,	   16).	   Moreover,	   a	   recent	   study	  correlated	   4E-­‐BP1	   phosphorylation	   levels	   with	   glioblastoma	   grade	   (10).	  Phosphorylated	  4E-­‐BP1	  could	  influence	  both	  cell	  cycle	  and	  protein	  synthesis	  by	  regulating	  different	  proteins	   including	  S6K1,	  AKT,	  eIF2α	  and	  eIF4E,	  key	   factors	  in	  the	  control	  of	  mRNA	  translation	  and	  cell	  proliferation	  via	  AKT/mTOR	  pathway	  (34).	   We	   demonstrated	   that	   astrocytes	   subjected	   to	   oxygen	   and	   glucose	  deprivation	   inactivate	   S6K1	   and	   AKT	   in	   parallel	   with	   the	   induction	   of	  phosphorylated	   eIF2α.	   Interestingly,	   4E-­‐BP1	   knockdown	   diminished	   total	   and	  phosphorylated	  S6K1	  levels,	  while	  genetic	  manipulation	  of	  S6K1	  had	  no	  effect	  at	  all	  on	  4E-­‐BP1.	  S6K1’s	  role	  in	  regulating	  TOP-­‐dependent	  translation	  suggests	  that	  its	   down	   regulation	   may	   additionally	   contribute	   to	   decreased	   global	   protein	  synthesis	  when	  4E-­‐BP1	  is	  depleted.	  Indeed,	  it	  was	  already	  observed	  that	  S6K1	  is	  involved	   in	  coordinating	   the	  assembly	  of	   the	   translation	  pre-­‐initiation	  complex	  (35).	  Astrocytic	  S6K1	  knockdown	  was	  as	  effective	  as	  the	  4E-­‐BP1	  loss-­‐of-­‐function	  in	   decreasing	   PSR	   in	   normoxic/glucose-­‐proficient	   cells,	   but	   not	   in	  normoxic/glucose-­‐deficient	  cells,	  suggesting	  modulation	  of	  protein	  synthesis	  in	  a	  glucose	   and	   oxygen	   dependent	   manner.	   Hence,	   in	   oxygenated	   cells,	  phosphorylated	   4E-­‐BP1	   might	   stimulate	   protein	   synthesis	   through	   S6K1.	  Deletion	   of	   S6K1	   in	   published	   studies	   impaired	   proliferation	   of	   cultured	  hepatocytes	   and	   human	   U2OS	   osteosarcoma	   cells	   (36,	   37)	   but	   not	   skeletal	  muscle	   (38)	   or	  murine	   primary	   astrocytes	   (39).	   In	   agreement	   with	   the	   above	  studies	  of	  non-­‐cancer	  models,	   our	  data	   also	   showed	   that	   S6K1	  knockdown	  did	  not	   impact	   astrocyte	   cell	   cycle	   indicating	   that	   loss	   of	   S6K1	  may	   contribute	   to	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reduced	   protein	   synthesis	   but	   not	   decreased	   cell	   proliferation	   after	   4E-­‐BP1	  depletion.	  Importantly,	  the	  present	  study	  emphasizes	  that	  deletion	  of	  hyper-­‐phoshorylated	  4E-­‐BP1	  in	  oxygenated	  glia	  decreased	  PSR	  and	  cell	  proliferation.	  So	  far	  the	  impact	  of	   phosphorylated	   forms	   of	   4E-­‐BP1	   remains	   largely	   uninvestigated.	   Although	  some	   recent	   studies	   demonstrated	   involvement	   of	   phosphorylated	   4E-­‐BP1	   in	  regulating	   mitotic	   division	   and	   cell	   cycle	   progression	   (15,	   16,	   33),	   to	   our	  knowledge	   it	  has	  never	  been	  shown	  that	  hyper-­‐phosphorylated	  4E-­‐BP1	  can	  act	  as	   stimulator	   of	   protein	   synthesis.	   Under	   normal	   conditions	   4E-­‐BP1	   triggered	  mRNA	   translation	   and	   cell	   proliferation	   whereas	   inhibition	   of	   the	  PI3K/AKT/mTOR	   pathway	   via	   NVP	   abrogated	   4E-­‐BP1	   phosphorylation	   and	  completely	   blunted	   the	   effect	   of	   4E-­‐BP1	   knockdown	   on	   global	   translation	  regulation.	   It	   is	  worth	   noticing	   in	   this	   context,	   that	  maximal	   interference	  with	  PI3K/AKT/mTOR	  signaling	  (complete	  dephosphorylation	  of	  4E-­‐BP1)	  by	  NVP	  in	  normoxic/glucose-­‐proficient	   astrocytes	   resulted	   in	   ~50%	   reduction	   of	   PSR,	  whereas	  deficiency	  of	  phosphorylated	  4E-­‐BP1	  caused	  protein	  synthesis	  to	  drop	  by	   ~30%.	   By	   these	   measures,	   only	   half	   of	   the	   astrocytic	   capacity	   to	   generate	  polypeptides	   is	   controlled	   by	   the	   PI3K/AKT/mTOR	   pathway.	   Thus	  phosphorylated	   4E-­‐BP1	   controls	   roughly	   60%	   of	   the	   bulk	   protein	   synthesis	  pathway.	   In	   reality,	   the	  binding	  proteins’	   control	   index	   is	   likely	   to	  even	  exceed	  60%,	   given	   the	   incomplete	   efficacy	   of	   the	   knockdown.	   Thus	   4E-­‐BP1	  dephosphorylation	   inhibits	   cap-­‐dependent	   translation	   as	   expected	   whereas	  hyper-­‐phosphorylation	   actively	   stimulates	   overall	   protein	   synthesis.	   These	  results	   clearly	   indicate	   that	   hyper-­‐phosphorylated	   4E-­‐BP1	   is	   not	   inactive	   as	   is	  commonly	   thought	   but	   has	   a	   rather	   widespread	   impact	   on	   stimulating	   the	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synthesis	  of	  bulk	  protein	  and	  DNA	  during	  normal	  growth	  conditions.	   	  However,	  considering	  NVP	  treatment	  had	  a	  stronger	  effect	  than	  4E-­‐BP1	  knockdown	  alone,	  other	  players	  of	  the	  PI3K/AKT/mTOR	  pathway	  must	  also	  be	  involved.	  At	  least	  for	  primary	  astrocytes,	  4E-­‐BP1	  exists	  as	  Janus-­‐faced	  molecule,	  where	  its	  hyper-­‐	   and	   hypo-­‐phosphorylated	   forms	   exert	   opposing	   effects	   on	   protein	  synthesis	   and	   cell	   cycle	  progression.	  This	   study	  provides	  novel	   information	  on	  mechanisms	   stimulating	   astrocytic	   proliferation	   that	   will	   help	   to	   identify	   new	  targets	   to	   suppress	   exaggerated	  growth	   in	  nonmalignant	   (e.g.	   astrogliosis)	   and	  malignant	   (e.g.	   astrocytoma)	   CNS	   pathologies.	   Clearly,	   more	   detailed	  examination	   of	   how	   (hyper)phosphorylated	   4E-­‐BP1	   is	   able	   to	   trigger	   mRNA	  translation	   and	   cell	   proliferation	   in	   non-­‐stressed	   backgrounds	   and	   in	   different	  cells	  is	  needed.	  The	  current	  prevailing	  doctrine	  that	  ascribes	  activity	  only	  to	  the	  hypo-­‐/dephosphorylated	  form	  of	  4E-­‐BP1	  clearly	  needs	  to	  be	  revisited.	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FIGURE	  LEGENDS	  
Fig.	   1	   Astrocytic	   4E-­‐BP1	   and	   S6K1	   have	   differential	   sensitivity	   to	  
rapamycin	  A)	  Western	  blot	  of	  total	  and	  phosphorylated	  S6K1,	  AKT	  and	  4E-­‐BP1	  in	  astrocytes	  exposed	  to	  room	  air	  (Nx),	  1%	  O2	  (Hx)	  and	  0.2%	  O2	  (Ax),	  with	  (+)	  and	  without	  	  (-­‐)	  glucose,	  with	  (+)	  and	  without	  (-­‐)	  rapamycin	  treatment	  (10	  nM)	  for	  16	  hours.	  β-­‐actin	   was	   used	   as	   loading	   control.	   4E-­‐BP1	   γ/β	   bands:	   hyper-­‐phosphorylated	  protein;	  4E-­‐BP1	  α	  band:	  hypo-­‐phosphorylated	  protein;	  B)	  Protein	  synthesis	  rate	  was	   measured	   as	   percentage	   of	   incorporation	   of	   [35S]-­‐methionine	   and	   [35S]-­‐cysteine	  into	  cellular	  proteins.	  Following	  16h	  incubation	  cells	  were	  exposed	  for	  30	   minutes	   to	   radiolabeled	   media,	   then	   proteins	   were	   precipitated	   with	   cold	  10%	  trichloroacetic	  acid	  and	  incorporation	  of	  [35S]	  was	  measured	  by	  counts	  per	  minute	   (CPM).	   Graph	   represents	   percentage	   CPM	   of	   total	   counts	   compared	   to	  Nx+G.	  Values	  are	  means	  ±	  SD	  (n=3).	  *p<0.05,	  **p<0.01,	  ****p<0.0001.	  C)	  In	  vitro	  assessment	  of	  eIF4F	  complex	  integrity	  employing	  a	  cap-­‐affinity	  pull-­‐down	  assay.	  Cells	  were	  exposed	  to	  Nx	  and	  Ax,	  +G	  and	  –G	  for	  16	  and	  36	  hours,	  protein	  extracts	  were	  subjected	   to	  pull-­‐down	  assay	  with	  7-­‐Methyl	  GTP	  sepharose	  beads	   (7-­‐Met	  GTP)	  before	  immunoblot	  analysis	  of	  eIF4E,	  eIF4G	  and	  non-­‐phospho	  (Thr46)	  4E-­‐BP1.	   Whole	   cell	   extract	   (Input)	   was	   used	   as	   positive	   control	   for	   protein	  extraction,	  7-­‐Met	  GTP	  was	  used	  as	  negative	  control	  and	  β-­‐actin	  to	  monitor	  pull	  down	  efficiency.	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Fig.	   2	   4E-­‐BP1	   knockdown	   reduces	   both	   protein	   synthesis	   and	   cell	  
cycle	  rate	  in	  astrocytes.	  Astrocytes	   were	   transfected	   with	   4E-­‐BP1	   siRNA	   (si4E-­‐BP1)	   or	   non-­‐targeting	  scrambled	  (Scrm)	  siRNA	  and	  then	  exposed	  to	  16	  hours	  of	  room	  air	  (Nx)	  or	  0.2%	  O2	   (Ax),	   with	   (+G)	   or	   without	   glucose	   (-­‐G).	   A)	   Knockdown	   efficiency	   was	  evaluated	   by	  Western	   blot	   of	   4E-­‐BP1.	   All	   samples	  were	   run	   on	   the	   same	   blot,	  however	   image	   was	   cropped	   due	   to	   sample	   redundancy.	   B)	   Protein	   synthesis	  rate	   measurement.	   Details	   as	   in	   Fig.	   1.	   C)	   Cell	   proliferation	   was	   measured	   by	  BrdU	   incorporation.	  BrdU	  was	   incorporated	   for	  16	  hours,	  measured	  by	  optical	  density	  (OD)	  at	  450	  nm	  (reference	  of	  620	  nm)	  and	  plotted	  as	  percentage	  versus	  Scrm	  Nx+G.	  Values	  are	  means	  ±	  SD	  (n≥3).	  *p<0.05,	  **p<0.01,	  ***p<0.001.	  	  
Fig.	   3	   4E-­‐BP1	   knockdown	   suppresses	   S6K1	   but	   not	   AKT,	   eIF2α	   or	  
eIF4E	  Astrocytes	   were	   transfected	   with	   4E-­‐BP1	   siRNA	   (si4E-­‐BP1)	   or	   non-­‐targeting	  scrambled	  (Scrm)	  siRNA	  and	  then	  exposed	  to	  16	  hours	  room	  air	  (Nx)	  or	  0.2%	  O2	  (Ax)	   without	   glucose	   (-­‐G).	   A)	   Whole	   cell	   lysates	   were	   subjected	   to	   Western	  blotting	   with	   antibodies	   specific	   to	   total	   and	   phosphorylated	   (p)	   S6K1,	   AKT,	  eIF2α.	  All	  samples	  were	  run	  on	  the	  same	  blot,	  however	  image	  was	  cropped	  due	  to	   sample	   redundancy.	   Protein	   levels	   were	   quantified	   by	   densitometry	   using	  ImageJ	  software,	  graphs	  represent	  ratio	  of	  B)	  S6K1	  to	  β-­‐Act	   ,	  C)	  p-­‐S6K1	  to	  total	  S6K1	  ,	  D)	  p-­‐AKT	  to	  total	  AKT	  and	  E)	  p-­‐eIF2α	  to	  total	  eIF2α	  .	  Values	  are	  means	  ±	  SD	  (n=3).	  *p<0.05,	  **p<0.01,	  ***p<0.001,	  ****p<0.0001.	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Fig.	  4	  S6K1	  knockdown	  mimics	  the	  effect	  of	  4E-­‐BP1	  gene	  silencing	  on	  
overall	  protein	  synthesis	  but	  not	  cell	  proliferation	  Astrocytes	  were	  transfected	  with	  S6K1	  siRNA	  (siS6K1)	  or	  4E-­‐BP1	  siRNA	  (si4E-­‐BP1)	  or	  combination	  of	  both	  siRNAs	  (si4E-­‐BP1/siS6K1)	  prior	  to	  exposure	  to	  16	  hours	  of	  room	  air	  (Nx)	  or	  0.2%	  O2	  (Ax),	  with	  (+G)	  or	  without	  glucose	  (-­‐G).	  Non-­‐targeting	  scrambled	  (Scrm)	  siRNA	  was	  used	  as	  control.	  A)	  Western	  blot	  assessed	  efficiency	   of	   S6K1	   and	   4E-­‐BP1	   knockdown.	   B)	   Protein	   synthesis	   rate	  measurements.	  Details	  as	  in	  Fig.	  1.	   	  C)	  Cell	  proliferation	  was	  measured	  by	  BrdU	  incorporation	  for	  16	  hours	  in	  the	  different	  conditions.	  Details	  as	  in	  Fig.	  2.	  	  Values	  are	  means	  ±	  SD	  (n=3).	  *p<0.05,	  **p<0.01,	  ****p<0.0001.	  	  
Fig.	  5	  The	  inhibitor	  NVP	  blunts	  the	  effect	  of	  4E-­‐BP1	  gene	  silencing	  A)	  Western	   blot	   of	   4E-­‐BP1	   in	   astrocytes	   exposed	   to	   room	  air	   (Nx)	   or	   0.2%	  O2	  (Ax),	   with	   increasing	   concentrations	   of	   NVP-­‐BEZ235	   hydrochloride	   (NVP),	   a	  potent	  ATP-­‐competitive	  PI3K	  and	  mTOR	  inhibitor,	  for	  16	  hours.	  β-­‐actin	  was	  used	  as	   loading	  control.	  All	   samples	  were	  run	  on	   the	  same	  blot,	  however	   image	  was	  cropped	   due	   to	   sample	   redundancy.	   B)	   Protein	   synthesis	   rate	   (PSR)	   of	   cells	  transfected	  with	   4E-­‐BP1	   siRNA	   (si4E-­‐BP1)	   or	   non-­‐targeting	   scrambled	   (Scrm)	  RNA	  and	  subsequent	  exposure	  (16	  hours)	  to	  room	  air	  (Nx)	  with	  (+G)	  or	  without	  glucose	  (-­‐G),	  with	  or	  without	  250	  nM	  NVP.	  PSR	  measurements	  as	  in	  Fig.	  1.	  C)	  PSR	  after	  16	  hours	  exposure	  to	  0.2%	  O2	  (Ax)	  +G	  or	  –G,	  with	  or	  without	  250	  nM	  NVP.	  PSR	   measurements	   as	   in	   Fig.	   1.	   Graphs	   in	   (B)	   and	   (C)	   show	   percentage	   of	  radiolabel	  incorporation	  compared	  to	  Scrm	  Nx+G	  (B)	  and	  Ax+G	  (C),	  respectively.	  D)	  Cell	  proliferation.	  16	  hours	  BrdU	  incorporation	  was	  measured	  as	  detailed	  in	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Fig.	  2.	  In	  all	  graphs	  values	  are	  means	  ±	  SD	  (n=3).	  *p<0.05,	  **p<0.01,	  ***p<0.001,	  ****p<0.0001.	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